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Abstract 
Lineage specific expansion of hematopoietic stem and progenitor cells (HSPCs) from 
human umbilical cord blood (UCB) is desirable because of their several applications in 
translational medicine e.g. treatment of various cancers, bone marrow (BM) failure and in 
management of immunodeficiencies. The current methods for HSPC expansion use either 
cellular feeder layers and/or soluble growth factors and selected matrix components coated on 
different surfaces. The use of decellularized extracellular matrices (ECM) from stromal cells 
for this purpose has not been previously reported.  
This thesis, proposes that a model surface which is prepared by using the ECM of BM 
stromal cells and possesses the properties of hematopoietic stem cell niches in vivo would be 
most suited for the ex vivo expansion of HSPCs. To test this hypothesis, insoluble, cell free 
matrices were prepared from a murine BM stromal cell line (MS-5), grown under low or high 
O2 concentrations, with or without osteogenic medium (OGM). Thus generated four types of 
acellular matrices respectively: MX1 (cells grown in 5% O2 + OGM), MX2 (cells grown in 
20% O2 + OGM), MX3 (cells grown in 5% O2 – OGM) and MX4 (cells grown in 20% O2 – 
OGM). These matrices were used as biological scaffolds for the growth and lineage specific 
expansion of magnetically sorted CD34+ cells from UCB for period of eight days. The UCB 
cells were characterized by flow cytometry and colony forming assays, before and after 
expansion.  
The results indicated that MX2 matrices, which were closer to vascular niche like 
conditions, were best suited for expanding more committed hematopoietic progenitors (by 
upto 80 fold), whereas, MX3 matrices, that mimic endosteal niche like conditions were best 
suited for expanding more primitive progenitors (by upto 32 fold). Ablation of 
glycosaminoglycans (GAGs) from the matrices significantly decreased their expansion 
capacity. A comparative proteomic analysis of the matrices indicated the up regulation of 
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markers such as Aldh1a1 and Gsn in MX2 matrix, which have previously been identified as 
playing a role in HSPC maintenance and expansion.  
The molecular profile of these matrix producing cells, identified differentially 
expressed genes like Wnt4, Angpt2, Vcam and Cxcl12 that are like the signature molecules 
of stem cell supportive microenvironment. The process also found the down regulation of 
several ECM related pathways and up regulation of Ang-Tie2 and Wnt signaling pathways in 
MX2 condition in comparison to MX3 condition. These pathways are known to play roles in 
regulation of HSC niche and a balance of which would have supported the lineage specific 
expansion of HSPCs on their matrices. Thus, these findings could be helpful in understanding 
the biochemical organization of hematopoietic niches and may also suggest the possible 
design of bioactive and biomimetic scaffolds that could be used for hematopoietic stem-cell 
based tissue engineering there by increasing the availability of more transplantable HSPCs.  
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1.1 STEM CELLS - GENERAL CONCEPTS 
Stem cells are functionally defined as cells that have the unique capacity of self-
renewal as well as to give rise to differentiated cells throughout the lifetime of a multicellular 
organism (Till and McCulloch, 1961; Wasnik et al., 2012; Weissman, 2000). At variance 
with the large majority of cells that otherwise constitute the adult body and are committed to 
a specific function, stem cells are uncommitted and remain as such, until they receive signals 
from the environment to generate specialized cells (Lemoli et al., 2005). The following three 
features of stem cells are significant: 
Stem cells are unspecialized. A fundamental property of stem cells is that they are 
devoid of tissue-specific genes which are involved in specialized functions. These 
unspecialized stem cells can then give rise to other specialized cells, including heart muscle 
cells, blood cells, or nerve cells (Basics, 2009). 
Stem cells are capable of dividing and renewing themselves for long periods. Unlike 
the differentiated muscle, blood, or nerve cells which do not undergo replication, stem cells 
may replicate many times. Daughter cells that remain unspecialized serve to maintain the 
stem cell population, a process called self-renewal (Basics, 2009).  
Stem cells can give rise to specialized cells. The process by which unspecialized stem 
cells give rise to specialized cells is called differentiation (Basics, 2009). The supply of 
differentiated cells is maintained by stem cells, which undergo replication followed by 
differentiation into the specialized cells that are needed to continuously replenish 
homeostasis. 
The potency of a stem cell reflects the options of commitment available to it (Fig 1.1) 
which can be further classified as follows: Totipotent cells are sufficient to form entire 
organism, including extra-embryonic tissues e.g. fertilized ovum. Pluripotent cells can give 
rise to all the cell lineages, including germ cells, but not extra-embryonic tissues e.g. 
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embryonic stem cells (ESCs). Multipotent cells can form multiple lineages that constitute an 
entire tissue or tissues e.g. hematopoietic stem cells (HSCs) (Smith, 2006). 
 
Figure 1.1: Stem Cell Potency and Hematopoiesis. The totipotent morula gives rise to the 
pluripotent inner cell mass which can form all the body's cell lineages including germ cells. 
Mesoderm further differentiates to form multipotent HSCs. 
1.2. STEM CELLS IN HEMATOPOIETIC TISSUES   
HSCs are responsible for maintenance and production of functional blood cells. Each 
day the human body produces billions of new white blood cells, red blood cells, and platelets 
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to replace blood cells lost to normal cell turnover processes as well as to illness or trauma. A 
variety of homeostatic mechanisms allow blood cell production to respond quickly to stresses 
such as bleeding or infection and then return to normal levels when the stress is resolved. The 
highly orchestrated process of blood cell production and homeostasis is termed hematopoiesis 
(Smith, 2003).  
During embryonic and fetal development of hematopoiesis in mammals, sequential 
sites have been established. The first site is the yolk sac (first 2 weeks), an area surrounding 
the dorsal aorta termed the aorta-gonad mesonephros (AGM) region (weeks 3 and 4); the next 
hematopoietic area is the fetal liver and spleen (1st to 9 months), and finally the bone marrow 
(BM) (from 3 months onward). Recently, the placenta has been recognized as an additional 
site that participates during the AGM to fetal liver period (Galloway and Zon, 2003). The 
properties of HSCs in each site differ, presumably reflecting diverse niches that support HSC 
expansion and/or differentiation and intrinsic characteristics of HSCs at each stage. For 
instance, HSCs present in the fetal liver are in cycle, whereas adult BM HSCs are largely 
quiescent (Orkin and Zon, 2008). 
In adult mammals, the hematopoiesis occurs in the BM. During the hematopoietic 
developmental hierarchy, as shown in Fig 1.2,  HSCs differentiate to form more committed 
lineages such as the common lymphoid progenitors (CLPs) and the common myeloid 
progenitors (CMPs), where CMP further differentiates to form megakaryocyte /erythroid 
progenitors (MEPs) and granulocyte/monocyte progenitors (GMPs) (Orkin and Zon, 2008). 
CMP give rise to myeloid cell lineages, including monocytes, granulocytes, megakaryocytes 
and erythrocytes, while CLP produce cells of lymphoid lineages, such as B cells, T cells and 
natural killer (NK) cells, thus ultimately producing terminally differentiated cells (Park et al., 
2012). 
Introduction 
5 
 
1.2.1. Characterization of HSCs  
HSCs can be characterized in two ways: morphological and functional. 
Morphologically, HSCs are medium-sized mononuclear cells with a high nuclear-cytoplasmic 
ratio, basophilic cytoplasm with no granules, and prominent nucleoli; they cannot, however, 
be classified based on the appearance under a light microscope (Orkin and Nathan, 2009). 
Functional studies show that there are two kinds of HSCs:  long-term repopulating 
HSCs (LTR HSC) and short-term repopulating HSCs (STR HSC) (Atkinson, 2000). When 
regenerated cells from an irradiated transplanted mouse are injected into another lethally 
irradiated mouse and are able to restore its hematopoietic system over a period of few 
months, these cells are considered to be LTR HSCs. On the other hand, cells from the 
BM/bloodstream that can immediately regenerate all the different blood cells but cannot 
regenerate themselves for a long period of time (3-4 months) are considered STR HSCs 
(Marshak, June 2002). Progenitor cells are immature cells that are precursors to fully 
differentiated cells of the same tissue e.g. hematopoietic progenitor cells (HPCs). Unlike 
HSCs, they can proliferate, but have a limited capacity to differentiate into more than one cell 
type as HSCs are able to do. For clinical uses, the long-term stem cells seem to have the self-
replicating advantage for efficient and long-term HSC therapy (Marshak, June 2002) (Fig 
1.2). 
1.2.1.1 Immunophenotypic Markers 
Fluorescence-activated cell sorting (FACS) is used to sort stem cells populations 
based on the expression of surface markers. Some of the most accepted surface markers for 
HSCs are CD34, Thy-1, CD133, Flk-1, Sca-1 and c-kit (Basics, 2009). HSCs are also 
characterized as being negative for lineage-specific antigens (lin-) (Brehm et al., 2002). A 
standard phenotype for murine HSCs is considered to be LSK (Lin
- 
Sca-1
+ 
c-Kit
+
), which 
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represents 0.08 % of the nucleated cell population in the BM (Morrison and Weissman, 
1994). 
 
Figure 1.2: Hematopoietic cell hierarchy. The model recapitulates hematopoietic 
developmental hierarchy and cell-surface markers expressed by HSCs (Bryder et al., 2006). 
The CD34+ surface marker includes stem cells, multipotent progenitor (MPP) and committed 
progenitor cells (CPC), and the CD34+CD133+ surface marker includes HSC to early CPC. 
Stem cells identified by CD34+CD38- are among the most primitive type of cells in the 
hematopoietic system hierarchy (Larsson and Karlsson, 2005). 
Although many surface markers for HSCs and progenitor cells have been identified, 
there is no clear consensus on universally acceptable HSC surface markers. However, the 
study from John Dick’s lab has recently proposed a standard classification system based on 
surface markers expression on human hematopoietic progenitors (Doulatov et al., 2010) 
(Table 1.1). 
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Table 1.1: The proposed scheme of surface markers for human hematopoiesis (Doulatov 
et al., 2010) 
Hematopoieitic 
stem cell 
(HSC) 
Multilymphoid 
Progenitor 
(MLP) 
Common 
Myeloid 
Progenitor 
(CMP) 
Megakaryocyte/ 
Erythroid 
Progenitor 
(MEP) 
Granulocyte/ 
Monocyte 
Progenitor 
(GMP) 
CD34+ CD34+ CD34+ CD34+ CD34+ 
CD38- CD38- CD38- CD38+ CD38+ 
CD90+ CD90- CD133+ CD133+ CD133+ 
CD45RA- CD45RA- CD45RA- CD45RA+ CD45RA+ 
  Flt3+ Flt3+ Flt3- 
 
    
  
1.2.1.2 Functional Assays 
Functional assays for HSC characterization can be performed either in vivo or in vitro. 
CFU-s (colony forming unit-spleen) is the original in vivo assay used to measure the number 
of injected stem and progenitor cells in a BM suspension, as measured by the formation of 
hematopoietic colonies in the spleen of the lethally irradiated mice (Till and McCulloch, 
1961). The transplantation is based on the ability of the donor hematopoietic cell population 
to reconstitute the hematopoietic system of the irradiated subject (Harrison, 1980). In vivo 
SCID repopulating cell assays are performed to assess the degree of engraftment at various 
time points post transplantation into non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice (Danet et al., 2003). Serial NOD/SCID transplants are frequently 
performed to demonstrate the presence of long term repopulating HSC. 
In vitro functional assays can be used to determine if the cells obtained from the 
subject have the potential to reconstitute all blood lineages, although in vitro assays do not 
always correlate with in vivo repopulation assays (Harrison, 1980). The CFU-c (colony 
forming unit in culture) assay is used to identify progenitor cells by evaluating their ability to 
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differentiate into different cell lineages in semi solid medium. Different versions of the CFU-
c are known, each one aimed to identify the presence of specific progenitors (Dexter et al., 
1977; Humphries et al., 1979). CAFC (cobblestone area forming cells) form colonies on a 
supportive irradiated stromal layer (Morrison and Weissman, 1994). The LTC-IC (long-term 
colony-initiating cells) and ELTC-IC (extended long-term colony-initiating cells) are used to 
study the ability of human HSPCs to survive for long periods of time in culture and to later 
differentiate (Hao et al., 1996; Sutherland et al., 1990). The cells are grown on a stromal 
feeder layer between 35 to 60 days for LTC-IC, and aliquots are transferred at many periods 
to CF-U medium to count the colonies of differentiated cells that will be generated. The cells 
are grown for a longer time period (60 to 100 days) for the ELTC-IC, which allows for the 
detection of even more primitive cellular populations (Sutherland et al., 1990).  
1.2.2. Asymmetric Self-Renewing Division in Stem Cells 
Asymmetric cell division is a conserved mechanism required for partitioning 
information during mitosis. Despite the fact that stem cells undergo proliferation, their total 
population in a particular organ remains relatively constant under homeostatic conditions as 
they undergo both self-renewal and differentiation. Therefore, an individual stem cell can 
give rise to two non-identical daughter cells, one maintaining stem-cell identity and the other 
becoming a differentiated cell. There are two mechanisms by which this asymmetry in 
daughter cells can be achieved, depending on whether it occurs “while” (divisional 
asymmetry), or “post” (environmental asymmetry) cell division  (Wilson and Trumpp, 2006). 
1.2.2.1 Divisional Asymmetry 
 In divisional asymmetry, specific cell-fate determinants in the cytoplasm of the 
mother cell (mRNA and/or proteins) redistribute unequally before the onset of cell division. 
During cell division, the cleavage plane is oriented such that only one daughter cell receives 
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the determinants (Wilson and Trumpp, 2006). Therefore, two non-identical daughter cells are 
produced, one retaining the stem-cell fate while the other initiates differentiation (Fig 1.3A). 
Hence this type of asymmetry occurs “within the mother cell” to give two different daughter 
cells. 
1.2.2.2 Environmental Asymmetry and the Stem-Cell Niche Concept 
An alternative to asymmetric cell division is environmental asymmetry. The stem cell 
is in close contact with the stem cell niche and depends on this contact for maintaining the 
potential to self-renew (Li and Xie, 2005) (Fig 1.3B). Therefore, a stem cell would first 
undergo a symmetric self-renewing division, producing two identical daughter cells. By 
orienting its mitotic spindle perpendicularly to the niche surface, it ensures that only one 
daughter cell can maintain contact with the stem cell niche and retain the ability to self-
renew. Therefore, the final product would be two non-identical daughter cells but achieved 
post-cell-division due to the microenvironment “around the cell”. Environmental asymmetry 
is more common in adult stem cells, whereas divisional asymmetry predominates during 
development (Ho and Wagner, 2007).  
It is interesting that the balance between symmetric and asymmetric divisions depends 
on the environment: When cultured on an osteoblastic cell line, HSCs undergo mostly 
asymmetric divisions whereas a generic stromal cell line induces mostly symmetric divisions. 
Thus, HSCs may control self renewal through a stem cell niche that regulates the balance 
between symmetric and asymmetric stem cell divisions (Yamashita et al., 2003). 
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Figure 1.3: A model of asymmetric cell division. (A) In divisional asymmetry, cell-fate 
determinants are asymmetrically localized to only one of the two daughter cells, thereby 
producing two non-identical daughter cells. (B) In environmental asymmetry, after division, 
one of two identical daughter cells remains in the self-renewing microenvironment while the 
other relocates outside the niche to a different, differentiation-promoting microenvironment.         
1.3. HEMATOPOIETIC NICHE IN THE BM 
The BM consists of the hematopoietic cells and the non-hematopoietic (stromal) cells. 
Forty four years ago, studies performed in the laboratory of Dr John Trentin demonstrated 
that stromal cells had an active role in the regulation of the differentiation of hematopoietic 
stem cells (HSCs) into all blood cell lineage types. Trentin proposed that this was an 
inductive event involving the interaction of stromal cells and HSCs, and the hematopoietic 
organ stroma were thereby termed hematopoietic inductive microenvironments (Trentin, 
1971; Wolf and Trentin, 1968). However the first evidence that hematopoietic cells may 
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develop within specific microenvironments in the BM came in 1975 when Lord and Testa 
found an unequal distribution of HSCs in the BM (Lord et al., 1975). BM samples taken from 
the endosteal surface of mouse femurs had greater spleen repopulating ability than those from 
the center of the marrow. Soon after, Schofield first proposed the concept of a HSC niche, 
wherein cell-cell interactions allow stem cell self-renewal but prohibit differentiation 
(Schofield, 1978).  
Anatomically long bones have three regions: epiphysis, metaphysis and diaphysis 
(Fig 1.4A). Diaphysis surrounds the shaft of the bone, metaphysis is adjacent to the diaphysis 
and ends of the round bone are called as epiphysis. The epiphyseal region is composed of 
trabecular bone within the bone cavities that contains the BM and cortical bone on the outer 
shell, which forms compact layers around. The networks of trabeculae create multiple spaces 
thereby increasing the surface area where HSCs can come in intimate contact with osteoblasts 
and provide life-long hematopoiesis (Singbrant et al., 2011) (Fig 1.4B). The diaphyseal 
region also contains trabeculae in humans and other large mammals, but forms a cavity in 
mice. 
The stroma of the BM is directly involved in the primary function of hematopoiesis. 
In hemopoietically inactive marrow the stroma consists largely of adipose cells, and is termed 
“yellow BM”. Active (red) marrow is located centrally in large adult mammals (vertebrae, 
pelvis, proximal ends of the limbs), though all of the marrow is active in the newborn and 
early childhood. Stroma is indirectly involved in hematopoiesis, since it provides the 
hematopoietic microenvironment that facilitates hematopoiesis (Bianco, 2011). Cells that 
constitute the BM stroma are: fibroblasts (reticular connective tissue), macrophages, 
adipocytes, osteoblasts, osteoclasts and endothelial cells, which form the sinusoids (Wasnik 
et al., 2012).  
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Figure 1.4: Hematopoietic Niches in the BM. The HSCs specifically home to the trabeculae 
in the epiphysis and the spongy part of the trabecular bone contains hollow cavities which are 
sites containing the HSCs and other cell types. These neighboring cells are all able to regulate 
HSC behavior. HSC niches are comprised of two specialized sub-compartments: endosteal 
niche, responsible for maintaining dormant HSCs and vascular niche for active HSCs (A) 
Long bone with Trabeculae (B) Trebacular bone with marrow cavities (C) HSC niche. 
Abbreviations: CAR, Cxcl-12 abundant reticular cells; ECM, Extracellular matrix; FGF, 
fibroblast growth factor; MPP, multipotent progenitor; MSC, mesenchymal stem cell. 
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Studies of stem cell niche in model organisms such as Drosophila melanogaster and 
Caenorhabditis elegans have revealed several features important for regulating stem cell 
behavior.  
• soluble signals that are released in the niche, regulate HSC self-renewal, survival and 
maintenance (Kiger et al., 2001; Tran et al., 2000; Xie and Spradling, 2000);  
• the particular spacio-temporal communication  between HSCs and niche cells can 
polarize HSCs within the niche for  asymmetric stem cell divisions (Bianco et al., 
2001; Yamashita et al., 2003);  
• adhesion between HSCs and supporting stromal cells and/or the extracellular matrix 
(ECM) anchors them within the niche in close proximity to self-renewal, maintenance 
and survival signals (Song and Xie, 2002; Song et al., 2002); and  
• physicochemical factors such as nutrients and O2 levels (Wilson and Trumpp, 2006).  
Thus, components of a stem cell niche provide not only the structural, trophic and 
mechanical support to the niche, but they also deliver specific 3D topographical information 
and physiological cues to the cells regarding the availability of mobilized and immobilized 
growth factors (GFs) that are vital to stem cell functions (Morrison and Spradling, 2008).  
Table 1.2 shows a list of secreted, ECM, cell adhesion molecules and signaling pathways 
involved in the crosstalk between HSCs and their niches (Lane et al., 2009; Lo Celso and 
Scadden, 2011). Utilizing different phenotypic markers for HSCs, many groups have 
attempted to define the location of the HSC niche based on its cellular constituents. Two 
types of HSC niches have thus been described - the endosteal or osteoblastic niche and the 
vascular niche (Dellatore et al., 2008; Mohyeldin et al., 2010) (Fig 1.4C). 
Table 1.2: Molecular interactions involved between HSCs and their niches 
Secreted Ligands and their Receptors References 
Angiopoietin-Tie2 interactions  (Arai, 2004) 
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Thrombopoietin, Mpl receptor  (Yoshihara et al., 2007) 
stem cell factor (SCF), cKit receptor  (Barker, 1997) 
Stromal derived factor (SDF-1/CXCL12), CXCR-4  (Xie et al., 2009) 
Transforming growth factor beta (TGF-β), TGF-β R  (Yamazaki et al., 2009) 
Fibroblast growth Factor (FGF), FGFR1-4  (Rizo et al., 2006) 
Placental growth factor (PIGF), VEGFR-1  (Li and Li, 2006) 
Insulin growth factor, IGF-I/IIR  (Garrett and Emerson, 2008) 
Parathyroid hormone (PTH) (Garrett and Emerson, 2008) 
Signaling Pathways   
Canonical Wnt-frizzled signaling  (Malhotra and Kincade, 2009) 
Notch signaling   (Kunisato et al., 2003) 
Jak-Stat signaling  (Steelman et al., 2004) 
Hedgehog (Hh) signaling pathway  (Hofmann et al., 2009) 
Bone morphogenic protein (BMP) signaling    (Goldman et al., 2009) 
ECM   
Osteopontin, β1-Integrin  (Nilsson, 2005) 
Hyaluronic, CD44 interactions  (Haylock and Nilsson, 2006) 
S100A4, S100A4R/HSPG/annexin II  (Jung et al., 2011) 
Matrix Metalloprotease (MMP)-1,2,3,9,11,14  (Hattori and Tashiro, 2010; Rizo et 
al., 2006) 
Adhesion molecules   
VLA-4  (Priestley et al., 2006) 
VLA-5  (Nilsson, 2005) 
VCAM-1  (Jiang et al., 2009) 
N-cadherin  (Zhang, 2003) 
Connexin-43  (Foss et al., 2009) 
Chemical gradients   
HIF-1α  (Levesque et al., 2007)  
Ca2+ ions, calcium-sensing receptor  (Levesque et al., 2010) 
1.3.1 Osteoblastic/Endosteal Niche 
The endosteal niche mainly comprises endosteal cells, osteoblasts and osteoclasts, 
located either on the endosteal surface of the diaphysis (in mice) or on the surface of bony 
trabeculae (Bianco, 2011). Reticular and mesenchymal cells are also present (Wilson and 
Trumpp, 2006). Endosteal niches have a different physical and chemical environment 
compared to the central BM. In the endosteum, where most HSC reside, soluble Ca2+ ions are 
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released by osteoclasts. HSC are equipped with Ca2+ receptors sensing this gradient and 
enabling them to home to endosteal niches. The second characteristic of HSC niches are their 
very low O2 tension, with less than 2% O2 (Levesque et al., 2010) (Fig 1.5). 
 
Figure 1.5: Endosteal niche and the interactions between osteoblast and HSCs.  
Several cellular components have been suggested to comprise the endosteal niches including 
niche osteoblasts, CXC-chemokine ligand 12 (Cxcl-12)-abundant reticular (CAR) cells, and 
osteoclasts. Dormant HSCs are tightly anchored in quiescent endosteal niches through a 
number of adhesion molecules expressed by both HSCs and support cells. These include N-
cadherin, CD44 and various integrins, including very late antigen 4 (VLA-4) that, together 
with secreted ECM components like osteopontin and hyaluronic acid and Ca2+-mediated 
signaling, keep HSCs in close proximity to niche cells so that efficient ligand–receptor 
signaling can occur in the HSC–niche synapse. Several receptors binding soluble and 
membrane-bound ligands produced by support cells are crucial for the maintenance of 
dormant HSCs. These include c-KIT, FGF-R, Tie-2 and CXC-chemokine receptor 4 
(CXCR4). Endosteal niche has low O2 and FGF-4 but high Ca2+.  
Introduction 
16 
 
More recently, two independent approaches have provided evidence for an interaction 
between HSCs and the osteoblasts that line the endosteal surface. Genetically increasing the 
number of osteoblasts by expressing a constitutively active form of parathyroid hormone 
(PTH) or the PTH/PTH-related protein receptor, both positive regulators of osteogenesis, 
resulted in a concomitant increase in the number of HSCs (Kiel et al., 2005).  
A second group arrived at the same result by knocking down expression of bone 
morphogenetic protein receptor 1A (BMP-R1A), a negative regulator of osteogenesis which 
is normally expressed on endosteal osteoblasts. In addition, both studies provide evidence for 
a direct, physical interaction between HSCs and osteoblasts (Mohyeldin et al., 2010) (Table 
1.2). 
1.3.2 Vascular/Endothelial niche 
Despite the landmark work in identifying osteoblastic niches for HSCs, the fact that 
hematopoiesis can also take place in extramedullary sites with no osteoblasts, implies the 
presence of other supportive HSC niches. The derivation of HSCs and endothelial cells from 
a common progenitor, the hemangioblast, suggests the existence of an endothelial HSC niche. 
The physiological environment of hematopoietic niches in the BM is often hypoxic (Dellatore 
et al., 2008; Mohyeldin et al., 2010), with the vascular niche having comparatively higher O2 
concentration (4%) than endosteal niche. Osteogenic signals generated by osteoblasts are also 
very low in vascular niches (Kiel and Morrison, 2008) (Fig 1.6). 
Recent advances in HSPC purification have enabled in situ imaging of HSPCs and 
revealed possible endothelial niches (Kiel et al., 2005). In the BM, 60% of these cells that 
were imaged were in contact with sinusoidal endothelium. Consistent with this, endothelial 
cells isolated from heart and liver were able to maintain HSPC activity in vitro (Li et al., 
2004). Together, these data provide strong evidence for a vascular niche for HSPCs in the 
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BM and other hematopoietic tissues. One prominent model linking the endosteal and vascular 
niches proposes that the endosteal niche provides a microenvironment suited to quiescence 
and HSPC maintenance, while the vascular niche promotes proliferation and differentiation 
(Kopp et al., 2005).   
 
Figure 1.6: Vascular niche and the interactions between the niche cells and HSCs. 
Cellular components comprising the vascular niche include CXC-chemokine ligand 12 (Cxcl-
12)-abundant reticular (CAR) cells, mesenchymal stem cells (MSCs), sympathetic neurons 
and sinusoidal endothelial cells (SECs). The neighboring cells supply HSC maintenance 
factors including Cxcl-12, stem cell factor (SCF), Ang-1, Vcam-1, Wnt, and hyaluronan. 
HSCs located close to the sinusoid endothelium have reduced self-renewal capacity and are 
cycling more rapidly, due to higher O2 levels and FGF-4 and lower Ca2+.   
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1.3.3 Components of HSC Niche 
The study of stem cell niches, including those that support blood and germline stem 
cells, have revealed several physical and functional characteristics as their hallmarks. By 
combining data from different systems, a probable “part list” can be generated for these 
niches, including: the stem cell itself; supporting stromal cells that interact directly with the 
stem cell and with each other through cell-surface receptors, soluble factors and gap 
junctions; ECM proteins that provide structural organization and mechanical signals; 
physiological factors like pH, O2 and Ca2+; and neural inputs that might help in 
communicating distant physiological cues in these niches. In summary, the niche represents a 
complex and dynamic entity in which the integration of multiple inputs accomplishes 
exquisite control of stem cell number and function (Jones and Wagers, 2008).  
1.3.3.1 Secreted Factors  
Communication within the niche is essential for self-renewal and differentiation of the 
stem cells.  Secreted factors may act locally or may diffuse throughout the niche to direct 
stem cell fate decisions (Kaur-Bollinger et al., 2012). Earlier studies have indicated that 
support cells, located adjacent to stem cells, secrete factors that are required for stem cell 
functions (Crittenden et al., 2006; Tulina and Matunis, 2001). Secreted growth factors have 
also been shown to regulate stem cell behavior in mammalian stem cell systems. In addition 
to secreted protein factors, small molecules and ions can provide important signals in stem 
cell niches. As seen in Fig 1.5, high local concentrations of Ca2+ in the BM, appear to 
facilitate the localization of HSCs adjacent to osteoblasts at the endosteum (Adams, 2006). 
Thus, a cocktail of several soluble factors and small molecules regulate stem cell function 
their activities can be integrated with additional inputs to determine appropriate stem cell 
responses to physiological stimulus as shown in Fig 1.5 and Fig 1.6.  
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1.3.3.2 Cell-Cell Interactions  
Physical attachment to supporting stromal cells or to a basal lamina is also important 
for regulating stem cell behavior and helps to maintain stem cells within the niche, in close 
proximity to self-renewal signals (Park et al., 2012). Adherens junctions are cell–cell contacts 
that are formed by homotypic interactions between transmembrane proteins called cadherins. 
Based on expression studies, cadherin-mediated cell adhesion has also been suggested to 
facilitate HSC association with osteoblasts (through N-cadherin) (Zhang, 2003). Within adult 
mammalian tissues, high levels of integrin expression can be used as a marker for tissue stem 
cells, suggesting that attachment to a basal lamina may also be important for holding stem 
cells within the niche. Other adhesion receptors in the blood system include membrane-bound 
stem cell factor (SCF), c-kit (receptor for SCF) and CXCR4, appear to mediate HSC retention 
in the niche (Gu et al., 2003; Sugiyama et al., 2006) (Fig 1.5 and Fig 1.6 and Table 1.2). 
1.3.3.3 Cell- ECM Interactions 
The stromal cells within the stem cell niche also secrete ECM that is crucial for HSCs. 
The major structural protein of the ECM is collagen, specifically type I or type IV for the 
basal lamina (Vakonakis and Campbell, 2007). Glycoproteins contribute to the organization 
of the matrix and help in cell attachment by binding tightly to collagen, elastin and 
proteoglycans (Jones and De Clerck, 1982). Proteoglycans are specialized glycoproteins that 
usually carry glycosaminoglycans (GAGs). GAGs are important in cell signaling due to their 
unique location on the cell membrane and in the ECM (Kumarasuriyar et al., 2009; Cooper, 
2000). Matrix metalloproteinases (MMPs) represent a family of 20+ members of zinc 
dependant proteolytic endopeptidases involved in the degradation of number of ECM 
proteins. Different types of MMPs participate in the BM ECM remodeling and regulate 
release of bound cytokines and HSCs from BM into the circulation. Tissue inhibitors of 
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metalloproteinases (TIMPs) are natural inhibitors of MMPs found in most tissues and also 
active regulators of  ECM remodeling where as ADAM (a disintegrin and metalloprotease) 
proteins are cell surface proteins that possess both an adhesion domain as well as a protease 
domain (Hattori and Tashiro, 2010).  
ECM provides a natural scaffold, a physical frame for the HSCs to grow within but at 
the same time it is also a dynamic environment that offers molecular signaling, whether it is 
by way of soluble growth factors like SCF and FGF-4, insoluble ECM and growth substrates 
like BMP and Vcam-1, or by way of environmental stress, physical cues or cell-cell 
interactions. In particular, stem cell differentiation decisions can be directly regulated by the 
relative elasticity or stiffness of the ECM (Philp et al., 2005). Polarized attachment of the 
HSCs to support cells, ECM or asymmetrically localized soluble factors within the niche, can 
provide cues to determine different cell fates for stem cell progeny (Chen et al., 2007) (Fig 
1.5, Fig 1.6 and Table 1.2).   
1.4. METHODS FOR EX-VIVO HSPC EXPANSION 
Successful BM transplantations for several decades have demonstrated the therapeutic 
importance of HSCs. The use of non invasively accessible umbilical cord blood  (UCB) 
derived HSPCs are limited by their low cell numbers and hence ex vivo expansion is one of 
the best ways to get more of these cells (Csaszar et al., 2012). Optimization of the conditions 
for HSPC ex vivo expansion requires understanding of their in vivo environment and factors 
which influence the balance between HSPC maintenance, self-renewal and differentiation 
(Chou et al., 2010). Investigation of the natural environment of HSPC within the BM niche 
has provided important clues of influencing factors (Mishima et al., 2010). The complexity of 
the stem cell niche is challenging to reproduce. However, in order to mimic these niches, 
researchers have focused on four main factors namely; the expansion media and additives 
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that includes the use of cocktails of cytokines and growth factors, co-culture with stromal and 
osteoblastic cells, oxygen levels and the use of ECM proteins as cell binding surfaces (Chou 
et al., 2010). 
1.4.1 HSPC Expansion on Stromal Cells 
The importance of stromal cells in the maintenance and expansion of primitive 
progenitors including transplantable stem cells have been repeatedly demonstrated (Breems et 
al., 1998). BM stromal cells have been the first choice of the researchers for coculture with 
the HSPCs as they mimic the closest association between the HSCs and their niches (Jing et 
al., 2010; Wagner et al., 2008). However, a number of stromal cell lines have also been 
reported to support the proliferation of human primitive progenitors. MS-5 is one such cell 
line, derived from Dexter-type murine long-term marrow culture, which supports CFU-S 
maintenance (Dexter et al., 1977) and acts synergistically with human growth factors to 
stimulate the formation of blast colonies and macroscopic colonies from CD34+CD38- 
primitive progenitors in short-term methylcellulose assays (Breems et al., 1998; Issaad et al., 
1993). Furthermore, a recent study has demonstrated that, in the presence of multiple 
cytokines, MS-5 cells promote a net increase of LTC-IC through self-renewal divisions 
(Issaad et al., 1993). Another cell line, AFT024, provides an environment that supports a 
balanced state of commitment and of self-renewal while at the same time generating mature 
components of the stem cell and progenitor cell hierarchy. Contact with AFT024 seems 
sufficient to support stem cells without acting through other micro-environment elements; the 
mechanisms maintaining the balance are conserved between mouse and man (Hackney et al., 
2002). 
 Since the HSC niche mainly comprises of osteoblastic cells, HSPCs were also 
expanded on osteosarcoma monolayers like UMR, HOS, CAL72 and Saos-2 and came out 
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with very controversial results. Some researchers observed that none of the human 
osteosarcoma cell lines investigated supported hematopoietic colony formation under 
permissive conditions for colony formation (Hackney et al., 2002), whereas, other groups 
have contradicted their theory (Rochet et al., 2003; Taichman et al., 1997). Rochet et al. have 
shown in their study that CAL72 cells, in contrast to MG-63 or SaOS-2 osteosarcoma cell 
lines, do not inhibit hematopoietic colony formation and sustain the limited expansion of 
hematopoietic progenitors.  
Other clonal stromal cell lines that have been established from the Dexture culture of 
murine BM cells are SR4987 (Pessina et al., 1992), PA6 (Nishikawa et al., 1988), ST2 
(Hardy et al., 1987), M2-10B4 (Lemoine et al., 1990), S-17 (Rawlings et al., 1997) and 
HESS5 (Nakamura et al., 1999). Each cell line was characterized by the cytokines produced 
by the cells and the hematopoietic cell lineage supported by them (Takagi, 2005). Wineman’s 
group compared the hematopoietic supporting activity of several cell lines and suggested that 
the positive HSC effects of these cell lines were not only related to the expression or 
secretion of haematopoietic cytokines and that matrix or some other unknown molecules play 
a crucial role in the regulation of stem cells (Wineman et al., 1996). 
1.4.2 ECM proteins as Cell Binding Surfaces 
The HSPC niche is a complex 3D structure, composed of potentially many different 
cell types. Adding to that complexity of structure are the numerous ECM molecules found in 
the stem cell niche region. Elegant studies have shown that concentrated in the endosteal 
region of the BM are ECM molecules such as collagen type I, fibronectin and, to a lesser 
degree, collagen type IV (Adams, 2008). These molecules presumably play a role in 
maintenance of the structure of the niche, or potentially in stem cell homing and retention in 
the correct microenvironment although, no specific studies have linked the biology of the 
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HSPCs in their niche to these molecules (Gordon, 1988). In the niche, the ECM serves an 
anchorage function and allows for communication between the niche and stem cells. The 
matrix components of the ECM anchor the cells in the niche environment and could exert 
influences on the stem cell population that either stimulate or inhibit behaviors (Nurcombe 
and Cool, 2007).  
To mimic the complexity of in vivo HSC niche, the use of single or mixture of ECM 
proteins as a coating material for HSPC expansion has also been common in last decade. 
Celebi et al. investigated the effect of coating of culture surfaces with ECM proteins 
normally present in the marrow microenvironment like collagen types I and IV (Col I and 
IV), laminin (LM) and fibronectin (FN) also known as retronectin (RN) and two types of 
ECM mixes on the ex vivo expansion of HSPCs (Celebi et al., 2011). The individual effect of 
some ECM proteins favoured the differentiation of some lineages over that of others (e.g. FN 
for erythroids and LM for megakaryocyte (MK) progenitor). Removal of Col I from the 
mixture of the above four ECMs led to strong reductions in cell growth and HSPCs 
expansion suggesting that optimization of BM ECM protein complexes could provide a better 
environment for the ex vivo expansion of HSPCs than individual ECM protein.  Table 1.3 
below shows the list of single and mixture of ECMs used in different studies for ex vivo 
expansion of HSPCs. 
Table 1.3: List of single and mixture of ECM proteins used for HSPC expansion 
Cell 
source 
ECM 
molecules 
used 
Cytokines Test Days in 
culture 
Fold 
increase  
References 
BM Angptl2 Heparin,TPO,SCF, 
IGF-2,FGF-1  
LTCIC 10 24 (Zhang, 
2006) 
BM Angptl3 Heparin,TPO,SCF, 
IGF-2,FGF-1 
LTCIC 10 30 (Zhang, 
2006) 
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1.4.3 O2 Levels in the Stem Cells Niche 
O2 is one of the most important and most studied “non-biological” factors which 
affect HSPC behavior. Many studies have shown that O2 levels have an effect on the HSPC 
proliferation. In vivo, the O2 tension in the BM is about 2%-7%, with a gradient from higher 
O2 close to the sinusoids to very low O2 at the endosteal surface (Chow et al., 2001). In vitro, 
it has been demonstrated that cultures maintained in atmospheric O2 (20%) have poorer 
growth compared to cultures grown in O2 tensions ranging from 1%-10%. A 5% O2 tension 
has been demonstrated to enhance the size and numbers of HSPCs in semisolid media (Dao et 
al., 2007; Zhao et al., 2008). HSPCs located closure to sinusoids are exposed to higher O2 
levels and various factors carried in the blood, and are more likely to undergo differentiation 
(Nodwell et al., 2005). Studies have demonstrated that CD34+CD38- cells show enhanced 
expansion in low (1.5%) O2, and SCID-repopulating cell frequency in NOD/SCID mice was 
also higher when cells were expanded in low or hypoxic O2 in comparison to “standard” 
(atmospheric) O2 (Sullivan et al., 2006). 
BM RN, LM FL, SCF,IL-6 CFU-C 10 800 (Sagar et al., 
2006) 
UCB Col-I, Col-
IV, LM, FN 
SCF,FL,TPO,IL-6,    
IL-9 
CFU-C 6 20-22 (Celebi et al., 
2011) 
UCB Col-IV, 
LM, FN 
SCF,FL,TPO,IL-6,   
IL-9 
CFU-C 6 38-40 (Celebi et al., 
2011) 
UCB FN (RN) TPO, ARP CFU-C 10 8.5 (Deutsch et 
al., 2010) 
UCB FN (RN) TPO, β–FGF CFU-C 10 6.4 (Deutsch et 
al., 2010) 
UCB FN (RN) TPO, SCF CFU-C 10 6.5 (Deutsch et 
al., 2010) 
UCB FN IL-3, IL-6, SCF, 
MGDF 
CFU-C 8 2.4 (Han et al., 
2002) 
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The physiological approach suggests that an environment combining both MSCs and 
low O2 concentration would be most favorable for the maintenance of HSPCs in course of ex 
vivo expansion. Hammoud et al. demonstrated that association of co-culture and low O2 
concentration induces sufficient expansion of committed progenitors and also ensures a better 
maintenance/expansion of HSPCs, pointing that oxygenation is not only an important 
physiological regulatory factor, but also a cell engineering tool (Hammoud et al., 2011). 
1.4.4 Expansion Media and Additives 
Approaches to the ex vivo expansion HSPCs have generally involved culture 
techniques that include growth factors or cytokine additives with the media (Rogers et al., 
2008; Yao and Hwang, 2007). The cultures were traditionally performed in a medium 
containing fetal calf serum (FCS) but to utilize expanded cells in clinical practice, ‘good 
manufacturing practice’ standards and serum-free conditions are required. In particular, FCS 
must be excluded from the medium because it may contain allergenic substances and 
transmissible infections (Rogers et al., 2008). The growth factors can act in an autocrine, 
paracrine, juxtacrine or retrocrine way (Atkinson, 2000). In numerous cases, the term ‘growth 
factor’ is used as an equivalent for cytokines. The term cytokine is used in a generic way for 
a heterogenous group of soluble molecules (proteins and peptides) that can act as humoral 
regulators and, under either normal or pathological states regulate the functional activities of 
individual tissues and cells (Dao et al., 2007; Madkaikar et al., 2007).  
Four growth factors have been identified and found to significantly enhance ex vivo 
HSC expansion: thrombopoietin (TPO), stem cell factor (SCF), FMS-like tyrosine kinase 3 
ligand (Flt3L), and interleukin-6 (IL-6) (Hasumura et al., 2003; Horst., 2009). These factors 
have little effect on HSPC expansion individually, but interact synergistically to increase 
STR and LTR HSCs. In combination, they induce a dramatic surge in CFU-GEMM and 
LTC-IC numbers (Heike and Nakahata, 2002; Madkaikar et al., 2007). Pineault et al., 
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investigated the individual and synergistic cytokine effects controlling the expansion of cord 
blood CD34+ cells in culture using a cocktail of six cytokines: SCF, Flt-3L, IL-3, IL-6, IL-9 
and IL-11 (Pineault et al., 2011). Results from several other studies including one from our 
group have shown that TPO, SCF, Flt3L and IL-6 when used in combination, gives 
maximum expansion of CFUs (Flores-Guzman et al., 2009; Heike and Nakahata, 2002; 
Madkaikar et al., 2007; Tursky et al., 2012). Table 1.3 also shows the synergistic effect of 
the cocktails of cytokines and growth factors when used in combination with ECM proteins. 
1.5. APPLICATIONS OF EXPANDED HSPCS  
The lifelong regulated production of mature blood cells by HSPCs drives great 
interest in adapting them for cell therapy applications, such as advanced HSPC 
transplantation (HSCT) and gene therapy (Atkinson, 2000; Basics, 2009). HSCT is the 
transplantation of multipotent HSCs, usually derived from BM, peripheral blood (PB) stem 
cells, or umbilical cord blood (UCB). Historically, HSPCs were primarily obtained from the 
BM, usually by puncturing a bone (hip) and drawing out the BM cells with a syringe 
(Atkinson, 2000). In the last few years, a more convenient and widely used source for HSPC 
transplantation is the peripheral blood  as some mobilized stem cells and progenitor cells are 
known to be present in circulation in the blood (Atkinson, 2000). Currently, tens of thousands 
of HSPC transplants are performed every year throughout the world (Hofmeister et al., 2007). 
In the 1990s, UCB became widely accepted as a source of stem cells for allogeneic 
hematopoietic reconstitution in children, and lately also for adult patients. UCB has a number 
of advantages over other sources of HSPC, including a lower incidence and severity of “Graft 
versus Host disease” (GvHD). This allows HSCT to be performed safely even when there is 
an HLA mismatch between donor and recipient, and as a result cord blood banks have been 
established around the world to provide a source of UCB for transplant. (Broxmeyer et al., 
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2009; Cai et al., 2004) The results of transplantation of UCB HSPC have indicated 
engraftment in approximately 80–90% of recipients proving its potential clinical application 
(Brunstein and Wagner, 2006; van den Oudenrijn et al., 2000). The transplantation of UCB 
cells has two major disadvantages: (i) the low number of HSPCs in each UCB unit limits its 
application to children only (usually less than 20 kg body weight) and (ii) neutrophil and 
platelets in UCB-transplanted patients need a longer recovery time than in BM or mobilized 
PB following transplantation (Hofmeister et al., 2007; Laughlin et al., 2004). Hence, ability 
to expand human HSPCs ex vivo is clearly an enormous boost to all current and future 
medical uses (Yao et al., 2004).  
In cell culture, UCB-derived CD34+ cells significantly increase their proliferation 
when exposed to external cytokines and growth factors and are easier to culture in vitro than 
BM CD34+ cells (Lewis and Verfaillie, 2000; van den Oudenrijn et al., 2000). The greater 
success in culturing UCB HSPCs may also be augmented by the fact that UCB HSPCs have 
markedly longer telomeres than in BM or PB HSPCs (Allsopp et al., 2001), suggesting that 
UCB HSPCs are able to go through more cell duplications than BM HSPCs.  
Initial efforts to expand UCB HSPCs were largely unsuccessful because mature rather 
than immature cells were expanded, however, with increased knowledge of the hematopoietic 
niche and new methods to promote progenitor cell expansion without differentiation, UCB 
transplantation in adults have now become more widely available (Koestenbauer et al., 
2009). These expanded cells can be used for the treatment of various non-hematopoietic (e.g. 
breast cancer) and hematopoietic cancers and disorders. Autologous HSCT is the type of 
transplantation that can be carried out using cells from the same person being treated; 
examples being multiple myeloma, neuroblastoma and several other autoimmune disorders 
(Sorrentino, 2004). Allogeneic HSCT instead uses cells from a related donor and is used for 
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treatment of several diseases including acute lymphoblastic leukemia, Hodgkin’s disease, 
sickle cell anemia and severe combined immunodeficiency (Zheng et al., 2011).  
1.6 CHALLENGES IN EX-VIVO HSPC EXPANSION 
The ex vivo expansion of HSPCs is an area of active interest in the field of stem cell 
transplantation, hematopoietic stem cell gene therapy and transfusion medicine. Many 
investigators have already shown that it is possible to expand sub-populations of HSPCs, 
including colony-forming cells, by the addition of cytokines. However, expansion of the cells 
responsible for long-term reconstitution has not met with similar success (Bodine et al., 1991; 
Peters et al., 1995). The addition of high doses of cytokines to HSPC cultures promotes the 
proliferation and differentiation of early pre-progenitors by terminal differentiation, thereby 
amplifying the progenitor and precursor pools (Banu et al., 2001). Unfortunately, as this 
happens, the number of CD34+ cells and primitive long-term culture initiating cells (LTC-IC) 
in these cultures decreased. As a result of longer incubation periods with cytokines, the 
cultures become depleted in pre-progenitors cells (Brugger et al., 1993; Srour et al., 1993). 
Thus, such cultures may not show any evidence of true stem cell expansion, but rather of in 
vitro differentiation. Earlier attempts to expand HSPC ex vivo have been largely thwarted 
because of the loss of their stem cell properties during culture as they undergo senescence or 
“spontaneously” commit to a particular cell lineage (McCulloch et al., 1991; Morrison and 
Spradling, 2008).  
The loss of HSPC properties in vitro strongly suggests that critical features of the 
marrow environment responsible for the maintenance of HSPC stemness are missing in 
standard culture systems (Philp et al., 2005). Celebi et al., demonstrated that the mixtures of 
ECMs were better in expanding the HSPCs as compared to the coating of single ECM 
proteins (Celebi et al., 2011). This calls for further studies to use a mixture of ECM proteins 
that represent the complexity of HSC niches in vivo considering two most important factors 
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involved with quiescence and proliferation of HSCs in BM; O2 and osteogenic signal. A 
better model mimicking the niche would probably be a mixture of ECMs produced by the 
BM stromal cells cultured at different O2 concentrations and with varying levels of 
osteogenecity.  
1.7. THESIS PROPOSAL 
1.7.1 Research Hypothesis 
The BM in which HSCs reside contains stromal cells, adipocytes, vascular elements, 
and sympathetic nerve cells (Bianco et al., 2001; Katayama, 2006). All these cells are arrayed 
within a complex ECM composed of fine reticular fibers thought to be made by the stromal 
cells (Campbell et al., 1985; Campbell, 1987; Hamilton and Campbell, 1991; Klein, 1995). 
Analysis of BM, as well as the ECM made by cultured marrow stromal cells, has shown the 
presence of collagens I, III, IV, V, and VI, fibronectin, laminin, and other adhesive proteins, 
as well as large molecular weight proteoglycans such as syndecan, perlecan, biglycan, 
decorin and hyaluronan (Gordon, 1988). Adhesion of HSPCs to the marrow ECM inhibits 
cellular proliferation and prevents apoptosis, both of which would lead to long term survival 
of quiescent HSCs (Adams, 2008). 
An important fact to keep in mind is that the BM is vascularized, thus allowing some 
circulating agents in the peripheral blood to enter in contact with HSCs within their niche, 
then to trigger their release and their latter fixation in another location followed by their 
diapesis through the endothelial cells. The complexity of the niche exemplified by the various 
natural materials present within the niche may be part of the explanation as to why, so far, 
few artificial materials are in routine use to culture HSPCs or to help in the maintenance of 
HSPC in vitro (Philp et al., 2005; Williams and Nilsson, 2009). Different cells, structural 
proteins, soluble and linked agents together create an environment that gives a 3D structure to 
provide physical and chemical interactions in a dynamic fashion allowing the cells to respond 
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to the many stimuli of a living organism.  
Based on the above, this thesis hypothesizes that the ECM is an important component 
of the HSPC niche in BM. As a corollary, lack of an appropriate ECM is responsible for loss 
of stem cell properties when HSPCs are maintained on a standard tissue culture plastic 
surface. The loss of stemness during growth of HSPCs using current culture methods reflects 
the production of more differentiated progeny with diminished self-renewal capacity, rather 
than the production of identical daughter stem cells. 
The current study uses cell free matrices from MS-5 cells that mimic the endosteal 
and/or vascular niche-like conditions in biological scaffolds to support the ex vivo expansion  
of HSPCs. MS-5 cells were grown under varying conditions of osteogenic induction and O2 
tension and cell free matrices were prepared by a standardized protocol. The growth and 
differentiation of human UCB derived CD34+ cells were analyzed on these matrices for a 
period of 8 days. The results showed optimal expansion of HSPCs on matrices of stromal 
cells that were grown at 20% O2 in the presence of osteogenic medium (OGM). Comparison 
of the protein profiles of the cell free matrices of MS-5 cells, grown under different 
conditions, by 2D gel electrophoresis and MALDI-TOF/MS analysis identified some 
candidate proteins that may be involved in the regulation of HSPC proliferation and 
differentiation. Further research was conducted to study the gene expression profiles of the 
matrix producing cells to understand the mechanism behind HSPC expansion.  
The results of this research provide a new methodology for the ex vivo expansion of 
human CD34+ cells on heterologous cell free biological scaffolds. They also provide a model 
for investigating the role of O2 tension and osteogenic signals in regulating HSPC 
differentiation through indirect effects on the niche stromal cells and ECM. The proteomic 
and the transcriptomic studies helped in picking up few candidate proteins which were 
differentially expressed in the matrices. These candidate proteins can further be studied by 
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using them as single protein supplements during HSPC expansion or by binding them to 
scaffolds. Thus, these findings could be helpful in understanding the biochemical 
organization of hematopoietic niches and may also suggest the possible design of bioactive 
and biomimetic scaffolds that could be used for hematopoietic stem cell based tissue 
engineering, thereby increasing the availability of more transplantable HSPCs. 
1.7.2 Thesis Outline 
This project aims at efficiently replicating the ECM components of the hematopoietic 
niche in vitro so that expansion of HSPCs can be done such that their maximum possible in 
vivo properties are retained. Based on the findings of other research groups, this thesis 
hypothesizes that lack of an appropriate ECM is responsible for loss of stem cell properties 
when HSPCs are maintained on a standard tissue culture plastic surface, and the presence of 
ECM molecules which normally bind the soluble factors and present them to the cell in the 
correct conformation should enhance the HSPC expansion in vitro (Guilak et al., 2009). In 
this study, I aim to mimic the functions of the endosteal and vascular niches by preparing cell 
free matrices from MS-5 cells grown under different O2 concentrations and with/without 
osteogenic signals. Such approach has significant advantages over the other traditional 
method of using single ECM protein, as it captures the true complexity of ECM mix surfaces 
(Galan et al., 2007). 
Chapter 1 provides an overview of the literature review, the gaps and unanswered 
questions and the hypothesis and aims of the thesis.  
Chapter 2 lists all the materials and the general overview of the methods used to 
carry out the work. 
Chapter 3 focuses on preparation and characterization of cell free matrices from 
stromal cells. MS-5 cells were cultured under different conditions and were treated with 
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NH4OH to make acellular matrices. Matrices thus prepared were qualitatively characterized 
by phase contrast microscopy, SEM, biochemical staining and immunoflourescence. These 
matrices were also characterized using proteomic tools. All the matrices were extracted and 
were subjected to quantitative MALDI-TOF MS analysis. The proteins were run on a 2D 
SDS gel to find the differentially expressed proteins which were then excised, digested and 
identified using MALDI-TOF /MS. 
Chapter 4 assesses the ability of cell free matrices to support HSPC expansion. 
CD34+ HSPCs were isolated from human UCB and those characterized CD34+ cells were 
cultured on the decellularized matrices along with positive and negative controls. Functional 
and biomarker characterization of both pre and post expanded cells were done by flow 
cytometry and colony forming assays to calculate the fold change of the expanded cells. This 
chapter also focuses to figure out the components from the decellularized matrices that might 
have played role in HSPC expansion. Mixing and recoating experiments were performed to 
find if the coated matrices helped in HSPC expansion. In another batch of experiment, few 
components were ablated from the matrices like GAGs and the residual cellular proteins to 
see if they were the candidates helping with HSPC expansion. Further, solubelized and 
dialyzed matrix proteins were added to check if it was just the constituents or also the 
morphological properties of the matrices that helped in HSPC expansion.  
In Chapter 5, gene expression analysis for MS-5 cells were performed under 
different conditions of matrix preparation to find the candidate genes that made these 
matrices suitable for ex vivo expansion. The microarray results were validated using RT-PCR 
for 8 random genes. The data thus acquired was analyzed using MetaCore software to find 
the pathways that were maximally affected by differentially affected genes in this study. 
Chapter 6 concludes the findings of the work and gives some future directions to this 
project.  
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2.1. MATERIALS USED 
2.1.1. Source of Chemicals 
Stemline II serum free media, ethylenediamine tetra acetic acid (EDTA), Trypan 
Blue, dexamethosone, ascorbate -2-phosphate, Type I collagen, mouse Monoclonal antibody 
anti-collagen type-1, anti mouse HRP linked, , anti-fibronectin, anti laminin, isotype IgG-
FITC, Alcian blue, protease inhibitor cocktail, Trichloro acetic acid (TCA), Thiourea, 
CHAPS, proteomics grade trypsin, agarose, β-mercaptoethanol, BSA, TEMED, ethidium 
bromide, formamide, Tris base, tricine, Proteinase K, TritonX-100, SDS, HEPES, Dimethyl 
sulfoxide (DMSO), Acrylamide, Bis-acrylamide and Actinomycin D were all purchased from 
Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com.  
 Sodium dodecyl sulphate (SDS), Urea, Dithiothreitol (DTT), Bio-lyte, IPG strips, 
Protean IEF Cell system, iodoacetamide (IAA), Fast Coomassie brilliant blue R-250, 
PDQuest version 7.2, were from Bio Rad Laboratories, Inc. Hercules, CA. http://www3.bio-
rad.com. Glycerol, acetone, acetonitrile (ACN), Ammonium Bicarbonate (NH4HCO3) were 
from Merck Limited, Mumbai, India. Trifluoroacetic acid (TFA) and α-cyano-4-
hydroxycinnamic acid (CHCA) were from Applied Biosystems, Framingham, MA. RNeasy 
Plus Mini Kit- Qiagen, Valencia, CA, USA. 
2.1.2. Instruments Used 
FACS Calibur flow cytometer and CellQuest software were sourced from Becton 
Dickinson Biosciences, San Jose, CA, USA. AutoMACS was from Miltenyi Biotec Inc., 
Bergisch-Gladbach, Germany. 4800 Proteomics Analyzer MALDI-TOF/TOF mass 
spectrometer, global proteomic solutions (GPS) software was from Applied Biosystems, 
Framingham, MA. Scanning Electron Microscope (SEM)-3400N Hitachi, Japan. Axioplan-2 
and Live cell 200M were purchased from Carl Zeiss, Germany. Forma series II, Hepa class 
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100 incubator were from Thermo Fisher Scientific Inc. Rockford, IL. 
http://www.piercenet.com. Thermanox cover slips and 24 well plates from NUNC, Thermo 
Fisher Scientific, Rochester, NY. Hemocytometer was from Hausser Scientific, Horsham, 
PA, USA. NanoDrop® ND-1000- was from NanoDrop Technologies, Wilmington, Delaware 
USA. 
BioRad power pack, BioRad vertical (PAGE) and Broviga horizontal (AGE) 
electrophoresis apparatus, Applied Biosystems 4800 MALDI TOF/TOF analyzer (Applied 
Biosystems), MALDI plate spotter (Probot, LC Packings), Ion-trap, Thermo Finnigan LTQ, 
2D-High Performance Liquid Chromatography (2D-HPLC) (Agilent Technologies 1100 
Series), Micro and Nano HPLC. Gel Scanners and Gel docs-BioRad-VersaDoc, Flour-S 
imagers, Syngene-Dyversity, GE-Amersham Biosciences-Typhoon.WS-400-6NPP, Laurell 
Technologies, North Wales, PA. 
MouseWG-6 v2.0 Expression BeadChip Kit was from Illumina, Inc., San Diego, CA. 
2.1.3. Software Programs  
AxioVision, Version release 4.4.0.0 (Carl Zeiss) Axiovert 200M (Carl Zeiss, Inverted 
fluorescent microscope), Axioplan 2 Imaging (Carl Zeiss, Upright fluorescent microscopy), 
for Immunofluorescence assays. PDQuest Ver.6.2.1 & PDQuest Basic Ver.8.0, (Flour-STM-
MultiImager, Bio-Rad), Dymension Ver.2.0.5.11, Gene Snap Ver.6.08, Gene Tools Ver.3.06 
(Dyversity, Syngene), Typhoon Scanner Control Ver.5.0 (Typhoon Trio, Amersham 
Biosciences) for 2D-gel image analyses. ChemStation, for 2D-LC Rev 10.02 (Agilent 
Technologies), uCarrier, Ver. 2.0 Probot control software for LC-MALDI plate spotting, 
4000 series explorer Ver.3.5, Global proteome server (GPS) ExplorerTM Ver.3.6, Xcalibur 
Ver.2.0 SR2, Bioworks Browser Ver.3.2 EF2 (Thermo) for mass spectral data acquisition and 
analysis.  
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2.2. MEDIA AND SOLUTIONS USED 
Penicillin/streptomycin (Pen/Strp), Dulbecco’s Phosphate buffered saline without 
magnesium and calcium, pH 7.2 (PBS), alpha-minimum essential media (α-MEM), fetal calf 
serum (FCS), 0.25% trypsin/EDTA, Cell dissociation buffer solution, Rhodamine-phalloidin 
(Molecular Probes), DTT, dNTPs, Reverse Transcriptase, RNAse OUT and PCR components 
were all obtained from Invitrogen, Carlsbad, CA, http://www.invitrogen.com. 
CD45-FITC, CD34-PE, CD38-FITC, CD34-FITC and 7AAD (catalogue numbers 
347463, 348057, 555459, 348053 and 559925 respectively) were supplied by Becton 
Dickinson Biosciences, San Jose, CA, USA. IgG-FITC (ab6854) and IgG-PE (ab7006) were 
from Abcam. 
Thrombopoietin (TPO), stem cell factor (SCF,), interleukin-6 (IL-6), Flt3 Ligand 
(Flt3L) growth factors were from Millipore, Bedford, MA, USA.  
Ficoll–Paque plus was from GE Healthcare Bio-sciences AB, Uppsala, Sweden; 
MACS CD34 Microbead Kit and , CD133-PE from Miltenyi Biotec Inc., Bergisch-Gladbach, 
Germany; b-glycerol phosphate from Calbiochem EMD Biosciences San Diego, CA; PMSF, 
NH4OH from SRL, Mumbai, India; (2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-
diammonium salt) (ABTS), was from Thermo Fisher Scientific Inc. Rockford, IL. 
http://www.piercenet.com. Vectashield mounting medium from Vector labs, Burlingame, 
CA; RetroNectin from TAKARA BIO INC. Shiga, Japan; Methocult  media-H4434 from 
Stem Cell Technologies, Vancouver, BC, Canada; and Tris-HCl, pH 6.8 from Qualigens, 
Mumbai, India. 
2.2.1. Media Compositions 
• MS-5 Complete Media: Α-Minimum Essential Media (αMEM) with 10% FCS, 
Penicillin (100U/ml) Streptomycin (100µg/ml) (1X Pen/Strp) and 1X glutamax 
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• Osteogenic Media: MS-5 complete media with 100nM Dexamethosone, 100mM 
Ascorbate Phosphate and 10mM β-Glycerophosphate. 
• HSPC expansion Media: Stemline II with Pen/Strep and thrombopoietin (TPO)-
25ng/ml, stem cell factor (SCF)-25ng/ml, interleukin-6 (IL-6)-50ng/ml and Flt3 Ligand 
(Flt3L)-40ng/ml.  
2.2.2. Solutions for Proteomics  
• Protein extraction buffer: 125 mM Tris-HCl, pH 6.8, 0.1% SDS, 10% glycerol, 1% 
DTT, 0.05mM PMSF and protease inhibitor cocktail. 
• Nuclease inhibitor solutions: 400 μg/mL DNase (10X) and 100 μg/mL RNase (10X).  
• Rehydration buffer: 40 mM Tris-HCl, pH 8.0, 6.0 M Urea, 2 M Thiourea, 2% CHAPS 
(w/v) and 50 mM DTT.  
• Trichloro acetic acid: 10% tri-chloro-acetic acid (TCA) in acetone.  
• Acrylamide/Bisacrylamide stock (30%): 87.6 g acrylamide and 2.4 g N,N-methylene 
bisacrylamide, dissolved and made up the volume to 300 mL with milli Q (MQ) 
water, filtered through 0.4μ membrane filter and stored at 4 °C.  
• Tris pH 8.8: 1.5 M Tris HCl: 27.5 g Tris Base (121.14 g/mol) dissolved in about 80 
mL MQ water. The pH was adjusted to 8.8 with conc. HCl or 6 N HCl. Made up the 
volume to 150 mL with MQ water and stored at 4 °C.  
• Tris pH 6.8: 0.5 M Tris HCl, 6.057 g Tris Base dissolved in 60 mL MQ water. The pH 
was adjusted to 6.8 with conc. HCl. Made up the volume to 100 mL with MQ water 
and stored at 4 °C.  
• SDS 10%: 10 g SDS dissolved in 100 mL MQ water.  
• TEMED: Tetra methyl ethylene diamine, 100%.  
• APS 10%: 100 mg Ammonium per sulfate dissolved in 1.0 mL of MQ water.  
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• Water saturated butanol: 40 mL butanol + 60 mL water or 1:1.  
• Tris-Glycine-SDS-Electrode/Running Buffer (TGS): 10X  
          30.3 g (250mM) Tris Base (121.14 g/mol), 140g (2500mM) glycine (75.07 g/mol),          
10g (1% SDS)  
• Agarose (sealing): 1.5% agarose in TGS buffer.  
• 4 – 15% Gradient gel: 
Table 2.1: Components of 4-15% gradient gel 
Components 4% 15% 
Distilled water 4.7mL 2.7mL 
30% Acrylamide Mixture 1.112mL 3.2mL 
Tris HCl, pH 8.8 2mL 2mL 
10% SDS 80µL 80µL 
10% APS 80µL 80µL 
TEMED 3.3µL 3.3µL 
 
• Bradford-Working solution: Bio-Rad Protein Assay Dye Reagent Concentrate (2.5X) 
reconstituted to 1X. 
• 3X  Loading Dye (10mL): 6% SDS (0.6g), 0.94mL 1M Tris, pH 6.8, 30% Glycerol 
(3.4mL from 87% stock) and 15% β-Mercaptoethanol (1.5mL). 
• Running Buffer (1L): 3.02g Tris, 18.8g Glycine, 1g SDS. 
• Amido Black solution: 500mg Amido Black, 50mL Acetic Acid (stock), 225mL 
Methanol, 225mL distilled water. 
• Destaining solution (Amido Black Estimation): 90% Methanol, 2% Glacial Acetic Acid, 
8% distilled water. 
• Protein stain: Coomassie Brilliant Blue R-250: 0.25 mg in 250 mL of 45% methanol + 
10% acetic acid solution.  
• Protein destaining solution: 45% methanol, 10% acetic acid, 45 % water  
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• Protein gel storage solution: 7% glycerol containing 2% acetic acid.  
• Trypsin buffer: 25 mM ammonium bicarbonate (79.056 g/mol) solution. 19.764 mg 
ammonium bicarbonate in 10 mL MQ water.  
• Protein gel slice destaining solution: 50% acetonitrile (ACN) and 25mM ammonium bi 
carbonate.  
• Trypsin (MS-grade) solution: 10 ng trypsin (MS-grade) per μL solution with 25mM 
ammonium bicarbonate.  
• Peptide extraction solution: 50% ACN and 0.1% tri fluoro acetic acid (TFA) in MQ. 
• Peptide reconstitution: 5% acetonitrile and 0.2% formic acid in MQ water.  
• HPLC-Solution A: 5% ACN, 0.2% Formic acid in MQ water, filtered through 0.4μ filter.  
• HPLC-Solution B: 95% ACN, 0.2% Formic acid in MQ water, filtered through 0.4μ 
filter.  
2.2.3. Solutions and reagents for Transcriptomics and RT-PCR  
• RNA template: 10 ng mRNA per reaction of MS-5 cells.  
• cDNA Primers: 0.3 μg per 20 μL reaction, Hexanucleotide Primers or Random Primers 
and oligo-dT primers (0.1 μg/μL stock).  
• Gene specific primers: 100 ng per 20 μL reaction, gene specific primers (300 μM or 300 
μg stock). 
• Mixture of dNTPs: 25 mM per 20 μL reaction, dNTPs (100 mM stock).  
• RNase free water: Diethyl pyrocarbonate (DEPC)-treated MQ water.  
• Reverse transcriptase enzyme: 50 U per 20 μL reaction, RT, (50 U/μL, 2500 U stock). 
• DNA polymerase enzyme: 1 U per 20 μL reaction, Taq DNA polymerase, (5 U/μL, 2000 
U stock).  
• PCR buffer: 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, pH 8.3. 
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• Taq MasterMix (1X): 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, 5 
% Glycerol, 0.08 % NP-40, 0.05 % Tween-20, 50 U/mL Taq DNA Polymerase, pH 8.6 
at 25°C. 
• Gel-loading Buffer (Type III): 0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% 
glycerol in sterile water, stored at 4°C.  
• Ethidium bromide (1%): 1g of ethidium bromide to 100 mL of MQ water.  
• TAE buffer (1X): 0.04 M Tris-acetate, 0.001 M EDTA.  
• EDTA (0.5 M) (pH8.0): 186.1g of disodium ethylenediaminetetra-acetate.2 H2O in 800 
mL of MQ water, adjusted pH to 8.0 by NaOH, adjusted volume to 1 L and sterilized by 
autoclaving.  
• MgCl2 (1.0 M): Dissolved 203.3g of MgCl2.6H2O in 800 mL of MQ water, adjusted the 
volume to 1 liter with MQ water and sterilized by autoclaving.  
• NaCl (5 M): Dissolved 292.2 g of NaCl in 800 mL of MQ water, adjusted the volume to 
1 L with MQ water and sterilized by autoclaving.  
• Tris (1.0 M): Dissolved 121.1 g of Tris base in 800 mL of MQ water, adjusted pH to the 
desired value by adding concentrated HCl (for pH 7.4, 7.6, and 8.0, respectively, ~ 70 
mL, 60 mL, and 42 mL of concentrated HCl was added), adjusted the volume to 1 liter 
with MQ water and sterilized by autoclaving.  
• RNase inhibitor: 20 U per 20 μL reaction, RNase Block (40 U/μL, 4000 U stock) or 
RNasin (40 U/μL, 2500 U stock) (40 U per reaction mixture). 
2.2.4. Sterilization  
All glassware and plastic ware were sterilized by autoclaving at a steam pressure of 
15 psi at 120°C for 20 min. Solutions were prepared in MQ water and generally sterilized by 
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autoclaving. Heat-sensitive solutions were sterilized by filtering through a sterile 0.2 μm 
nitrocellulose filter. 
2.3. OVERVIEW OF THE METHODS USED 
2.3.1. Cord Blood Isolation, Matrix Preparation and HSPC Expansion on Acellular 
Matrices 
 For expansion of UCB derived HSPCs, acellular matrices were prepared from one of 
the cell lines which are already known to support HSPC expansion in co-culture, MS-5. As 
shown in Fig 2.1, this flow chart consists of three main methods:  
Fig 2.1A: The details of this section in described in Chapter 4. As shown in the 
flowchart, human UCB was used as the cell source for HSPCs. Freshly collected UCB (40-55 
ml) was diluted with PBS and the MNCs were collected from the buffy coat following 
Ficoll–PaquePLUS density gradient centrifugation. CD34+ cells were isolated from MNCs 
by magnetic sorting on AutoMACS cell sorter using MACS CD34 MicroBead Kit, according 
to the manufacturer’s instructions. The percentage of the purified CD34+ cells after MACS 
isolation was assayed by flow cytometry and colony assays. 
Fig 2.1B: The details of this section in described in Chapter 3. Early passage MS-5 
cells were maintained at 5% O2, 5% CO2 and 37ºC; conditions were standardized in the lab 
for expansion of UCB cells on MS-5 cultures. For matrix preparation, MS-5 cells were grown 
under low O2 (5% O2) and normal O2 (20% O2) conditions for 10 days with media change 
after every 72 hours to allow them to prepare ECM. For osteogenic induction CM was 
replaced with osteogenic medium (OGM) for the last 2 days. For decellularization, confluent 
cells were treated with 0.02 M NH4OH for 1-2 minutes at room temperature for cell lysis 
which was observed carefully under inverted microscope and NH4OH were removed by 
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gently inverting the culture plates. The matrices thus prepared were dried overnight in the 
laminar flow cabinet, washed and stored in PBS with Pen/Strep at 4°C. 
 
Figure 2.1: Experimental flow chart for ex vivo HSPC expansion on acellular MS-5 
matrices. (A) Isolation of CD34+ HSPCs from UCB, (B) Matrix preparation and (C) HSPC 
expansion on acellular matrices. Abbreviations: HSPC, hematopoietic stem/progenitor cells; 
UCB, umbilical cord blood; CFU, colony forming unit; RN, retronectin; OGM, osteogenic 
medium (Tiwari et al., 2012). 
Fig 2.1C: The details of this section in described in Chapter 4. Magnetically sorted 
UCB CD34+ cells, were resuspended in Stemline II serum free media supplemented with GF 
cocktails and seeded on the acellular matrices. The positive control, C3, was prepared by 
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incubating wells RetroNectin (RN) whereas, negative control surfaces C1 was prepared by 
incubating the wells (without cells) with only CM for 10 days followed by only OGM for 
next 2 days and C2, was prepared by incubating them with CM only for 12 days. All cultures 
were placed in the hypoxic incubator (5% O2, 5% CO2, 37oC, humidified) for 8 days. The 
cells were then characterized by flow cytometry and CFU assays and finally, the fold 
expansion was calculated by comparing pre and post culture numbers. 
2.3.2. Proteomic Analysis of Acellular Matrix Components 
There have been extensive studies to isolate the ECMs from cell lines (Dorothy A. 
Beacham, 2006; Grunert et al., 2007) and the BM (Chen et al., 2007) and further 
characterizing them for their proteomic components. Proteome analysis has traditionally been 
accomplished using a combination of 2D gel electrophoresis to separate proteins and MS for 
protein identification. The proteins are separated according to their iso-electric point (pI) in 
the first dimension and molecular weight (MW) in the second dimension (Gorg, 2000) which 
are then visualized and compared. After in-gel enzymatic digestion of the proteins, the tryptic 
products can be analyzed by MALDI-TOF-MS, resulting in the mass fingerprint of the 
proteins, or the sequences of the resulted peptides can be mapped with the help of 
electrospray ionization-MS analysis. The identification can be performed by databank search. 
There are three main steps in this flow chart; sample preparation, 2D gel separation and 
MALDI-TOF-MS analysis for protein identification (Fig 2.2), details of which are given in 
Chapter 3. 
Step A: In this step, the decellularized matrices were prepared from MS-5 cells as 
mentioned in Fig 2.1B. In this method, cells were lysed in the presence of NH4OH that leaves 
the ECM largely intact (Grunert et al., 2007). The culture dishes were incubated with 
extraction buffer for 1 hour and the matrix proteins were scrapped off with a scrapper. The 
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protein extracts were sonicated, centrifuged and the supernatant was TCA precipitated. The 
protein thus obtained were dissolved in rehydration buffer and estimated. 
 
Figure 2.2: Proteomic analysis of acellular matrix components. (A) Sample preparation 
and protein extraction, (B) 2D gel separation and image analysis and (C) MALDI-TOF/MS 
analysis for protein identification.   
In step B, proteins were separated in first dimension on IPG strip according to their 
isoelectric points (11cm, pI range 4-7) and in second dimension by SDS-PAGE (4-15% 
gradient) on BioRad Criterion pre-cast gels according to their masses. The 2D gel was 
subsequently stained for visualisation, and PDQuest version 7.2 was used for identification of 
the differential spots expressed in MX1, MX2 and MX4 taking MX3 as the standard culture 
condition, as determined with a Student’s t -test, considering p ≤ 0.05. Selected protein spots 
were excised manually and destained.  
Step C: The dehydrated gel pieces were proteolytically in-gel digested by cold 
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trypsin. Peptides were extracted, desalted and the resulting peptides analysed by MS. Peptide 
mass fingerprint (PMF) was performed with reconstituted extract on 384-well MALDI plate. 
The samples were analyzed with a 4800 Proteomics Analyzer MALDI-TOF/TOF mass 
spectrometer working in positive ion reflector mode. PMF data was then interrogated for 
protein identification with IPIMouse database using Mascot search engine and analysis was 
done on global proteomic solutions software automatically. Protein identifications were done 
on the basis of multiple variables such as score, number of peptides matched and percent 
sequence coverage of the matched protein. 
2.3.3. Matrix Modification Experiments 
In chapter 3 and 4, it has been shown that the decellularized matrices help in UCB 
derived HSPC expansion. But there were many unanswered questions like: 
a. As evident from proteomics analysis that the matrices still have cellular proteins, will 
the functionality of the matrices change if further treated with TritonX-100 to remove 
cellular components? 
b. Will GAGs ablated matrices help in HSPC expansion? 
c. Is it the molecular composition or the ultrastructure of the matrices that plays greater 
role in expansion?  
d. Can these matrices be recoated and will they still retain their functionality? 
e. What will happen if the two matrices are mixed while recoating? 
To answer these, two sets of experiments were set up as shown in Fig 2.3, details of which 
are given in Chapter 4.  
Fig 2.3A:  In ablation and add back experiments, the best matrix MX2 was ablated for 
glycosaminoglycans (GAGS) with Heparinase I, II, III and Chondroitinase A, B, C (MX2 
GAGS), whereas TritonX-100 was used to further remove cellular components from the 
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matrix (MX2 TX). For add back, MX2 matrix was collected while decellularization and 
dialyzed against PBS to remove residual ammonia for 48 hours. This solubilised MX2 matrix 
(MX2 sol) was then added to the HSPC expansion media for this condition.  
 
Figure 2.3: Matrix modification experiments. (A) Ablation and add back experiments (B) 
Mixing and recoating of decellularized matrices. 
Fig 2.3B: This part of matrix modification can be called as Mixing and recoating 
experiments.  Since MX1 and MX2 were better matrices for primitive HSPCs and committed 
HSPCs respectively, matrices were prepared for these two conditions only. While 
decellularization, when the matrices were still viscous and sticky, they were scrapped and 
collected in tubes. To check the effect of recoated matrices, two of the tubes were kept in 
pure MX1 and MX2 forms, while two more tubes were prepared by mixing MX1: MX2 in 
the ration of 4:1 (MX5) and MX1: MX2 in the ration of 1:4 (MX6). 100µl of each matrix was 
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then added in the centre of the wells in 24 well plates and were spin coated for 1 minute. The 
coated plates, now called MX1c, MX2c, MX5c and MX6c, were then dried overnight in the 
laminar flow cabinet, washed in PBS with Pen/Strep and used for HSPC expansion. 
2.3.4. Gene Expression Profiling of Matrix Producing Cells 
Microarray analysis is one of the advance methods for analysing the RNA profile and 
also for fishing out the candidate or novel genes which could play important role in 
regulation or the maintenance of stem cells (Forsberg et al., 2005; Ng et al., 2004). Moore’s 
group have earlier studied the gene expression profiles of HSC supportive and non-supportive 
cell lines to understand the mechanism behind HSC niche (Charbord and Moore, 2005; 
Hackney et al., 2002). As shown in Fig 2.4, the transcriptomic study of the matrix producing 
cells was performed in order to understand the molecules involved with HSPC expansion by 
analyzing the RNA profile and differential gene expression of the cells. The flow chart 
mainly consists of 5 steps, details of which are shown in Chapter 5.  
Step 1: This step involves the culture of MS-5 cells in different culture conditions of 
varying O2 gradient and osteogenecity. Then total RNA extraction and purification was 
performed from 3 samples MX2, MX3, MX4. Purified RNA was quantified by NanoDrop 
and finally its integrity was checked by Bioanalyser.   
Step 2: In this step, the RNA was hybridized to the Illumina MouseWG-6 v2.0 
expression beadchip. The basic principal of this process is to confine a number of genes in a 
small area where each gene represents its complementary genes or atleast any part of the 
gene. Once the platform is designed, the mRNA labelled with appropriate probes is 
hybridized; the labeling is specifically done by fluorescent dyes so that hybridization to the 
probe spot can be detected when scanned with a laser. 
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Figure 2.4: Gene expression profiling of matrix producing cells.  Total RNA extraction 
and purification was performed from MX2, MX3 and MX4 cells and were hybridized to 
Illumina MouseWG-6 v2.0 expression beadchip. The hybridized arrays were scanned and 
subjected to data extraction, analysis and biostatistics to understand the involvement of the 
differentially expressed genes in different pathways and their interaction with other signaling 
molecules. 
Step 3: The hybridized arrays were scanned using Illumina BeadArray reader. The 
analysis is based on the principle that the transcripts expression level can be deduced by the 
correct measurement of the amount of hybridization of RNA to its corresponding probe by 
scanning. The signal intensity increases with higher number of transcripts hybridized and 
decreases with lesser number of transcripts hybridized. Any particular genes off or on status 
can be deduced if the gene is observed in one sample but absent in other. Un-normalized 
summary probe profiles, with associated probe annotation, were output from BeadStudio. 
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Step 4: For data extraction, analysis of the array data was performed in R environment 
(RTeam, 2008) with Bioconductor packages (Gentleman et al., 2004). The differential signals 
produced  after the hybridization were converted in to the raw data which were normalized to 
a level and statistically checked for getting significant expression profile. A number of tests 
were applied to extract the most significant data.  
Step 5:
 
 This final step includes data analysis and biostatistics. Analysis of the 
enrichment of GO (Harris et al., 2004) and KEGG (Kanehisa et al., 2008) terms was 
performed in R environment (RTeam, 2008) with Bioconductor packages (Gentleman et al., 
2004). Annotation of the Entrez gene IDs to GO and KEGG terms was obtained from 
“illuminaMousev2.db” library, available via the Bioconductor website. The annotation tools 
can annotate the particular gene’s biological function, molecular function, its cellular 
localization etc. The annotated genes of similar features are clustered together which 
represents their enrichment in a population. Gene expression profile was observed in a 
manner in which a cut off value was set as threshold and expression level above that was 
considered as up-regulated and expression level below it is considered as down-regulated. 
For understanding the involvement of the particular gene in any signaling pathway of 
its interaction with other signaling molecules, a number of tools can be applied (MetaCore, 
Pathway Express). These tools enable us to visualize the gene’s presence in a pathway, its 
role and also interaction with other signaling molecules in graphical method which can easily 
be analyzed and understood. Venn diagrams were created using VENNY (Oliveros, 2007). 
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3.1 OVERVIEW 
The BM in which HSCs reside contains stromal cells, adventitial reticular cells, 
macrophages, and adipocytes (Bianco, 2011; Katayama, 2006). These stroma cells synthesize 
growth factors, and ECM components that form 3D scaffold creating an intricate 
hematopoietic inductive microenvironment upon which the HSCs lodge (Campbell et al., 
1985; Klein, 1995). This ECM provides structural as well as biological support for cells in 
vivo (Hamilton and Campbell, 1991) and also act as a molecular filter, a boundary, a storage 
depot of growth factors and cytokines and can block cryptic sites (Kleinman et al., 2003).  
Biologically, the ECM functions in cell polarity, cell adhesion, morphogenesis and 
differentiation, migration, proliferation and prevention of apoptosis which are regulated by 
cell-surface receptors that allows for communication between the niche and HSCs 
(Nurcombe and Cool, 2007). The components of the ECM are in a combination that promotes 
specific biological functions and loss of one ECM component can be life threatening and 
disrupt phenotypes (Chen et al., 2007). Collagens make up the frame of the ECM and may 
anchor stem cells or supportive cells to the niche to allow interaction between the cells and 
extrinsic factors (Philp et al., 2005). Many of these extrinsic factors have been shown to play 
a role in HSC self-renewal and differentiation including hedgehog, Wnts, BMPs, FGFs, and 
Notch (Li and Neaves, 2006; Liu, 2006). The spatial arrangement of HSCs and support cells 
within the niche organizes the timing and secretion levels of signals that HSCs receive which 
in turn directs the fate of the cell (Avecilla, 2004; Peerani et al., 2007).   
Keeping all this in mind, researchers have been using single or mixtures of ECM 
proteins as a coating material along with high doses of cytokines and growth factors for 
HSPC expansion over the last three decades (Celebi et al., 2011) (Table 1.3). The addition of 
large amounts of cytokines to the culture of HSPCs enabled their expansion, but is too 
expensive. The two dimensional liquid culture systems used in these studies, however, do not 
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replicate the in vivo 3D stem cell environment in which HSCs normally reside. Hence, 
elucidating the biology of the HSC niche requires understanding of how all of the systems 
interact to form a complex combination of signaling pathways. Many different factors must 
be presented in the correct arrangement and orientation within a well-defined 3D construction 
in the presence of pO2 and growth factor gradients in order to mimic the complexity of the 
stem cell niche. Although it probably is not necessary to mimic all aspects of the niche to 
greatly increase stem cell self-renewal, it is certainly necessary to simultaneously mimic 
multiple components of the niche.  
Hence, recreating artificial niche for stem cell expansion, have been an important 
issue for the researchers these days (Adams, 2008; Banu et al., 2001; Bottaro et al., 2002; 
Dellatore et al., 2008; Franke et al., 2007; Guilak et al., 2009). The concept of stem cell 
niches has been used in the tissue engineering field to prepare bioengineered 3D scaffolds for 
the purpose of ex vivo stem and progenitor cell expansion (Adams, 2008; Guilak et al., 2009). 
Many inorganic biomaterials have also been used for this application (Banu et al., 2001; 
Bottaro et al., 2002; Dellatore et al., 2008; Franke et al., 2007).  
There is substantial evidence that the ECM plays an important role in the in vitro 
proliferation and differentiation of HSPCs. The generation of extracellular environment 
secreted by cells carries with it proteomic and glycomic consequences that are responsible for 
the cell-fate determination of progenitor cells (Chen XD, 2007; Dellatore et al., 2008; Guilak 
et al., 2009; Klein, 1995). Hence, culture models that utilize co-culture of HSPCs with 
decellularized matrices from stromal cells could certainly be considered to better mimic the 
complexity of in vivo hematopoietic environment concept. Examples of cells that have been 
expanded on acellular matrices include mesenchymal stem cells (MSCs) (Chen et al., 2007), 
neuronal cells (Aizman et al., 2009), chondrogenic cells (You et al., 2011) and osteogenic 
cells derived from murine embryonic stem cells (Evans et al., 2010). 
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BM stromal cells have been the first choice of the researchers for co-culture with the 
HSPCs as they mimic the closest association between the HSCs and their niches (Jing et al., 
2010; Wagner et al., 2008). However, a number of stromal cell lines have also been reported 
to support the proliferation of human primitive progenitors. The murine MS-5 stromal cell 
line was established by Itoh et al, 1989 (Itoh et al., 1989) after irradiation of the adherent 
cells in long-term BM culture. MS-5 cells produce ECM proteins such as fibronectin, 
laminin, and collagen type-1. The cells also produce GM-CSF, and high quantities of IL-6, 
SCF, HGF and act synergistically with human GFs to stimulate the formation of macroscopic 
colonies from CD34+CD38- primitive progenitors in short-term methylcellulose assays 
(Breems et al., 1998; Issaad et al., 1993). MS-5 cells with or without exogenous cytokines 
have been shown to support human HSPC expansion as feeder layers (Kanai et al., 2000; 
Keller et al., 2002).  
Hence to mimic this interplay between cells and their cytokine rich, tissue-specific 
environments, acellular matrices were prepared from one of the cell lines which are already 
known to support HSPC expansion in co-culture, MS-5. In order to replicate the endosteal 
and/or vascular niche-like conditions, the role of osteogenic signals and O2 gradient were 
examined on the ECM generated by MS-5 cells (Fig 2.1B). It has been shown that O2 
tensions also influence stem cell biology (Eliasson and Jonsson, 2010; Mohyeldin et al., 
2010; Sullivan et al., 2006; Zhao et al., 2008). The matrices thus prepared were characterized 
using different biochemical and proteomics approaches.  
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3.2 METHODS 
3.2.1 Preparation of Decellularized Matrices 
3.2.1.1 Cell Line Used 
MS-5 cell line was established by Dr. Katsuhiko Itoh, Department of Clinical Medical 
Biology, Kyoto University, Japan (Itoh et al., 1989). MS-5 cells were kindly provided by Dr. 
Stewart Fabb, Monash Institute of Pharmaceutical Sciences, Australia. 
3.2.1.2 Cell Maintenance and Passaging 
MS-5 cells were maintained in conditions standardized in the lab for expansion of 
UCB cells on MS-5 cultures. The cells were grown in complete medium (CM) at 5% O2, 5% 
CO2 and 37ºC. For passaging, cells were rinsed once in PBS and 0.025% Trypsin/EDTA was 
added at room temperature (RT) while visualizing them under microscope.  The dissociated 
cells were then neutralized in complete media with triple the volume of trypsin.  The cells 
were pelleted and then counted using Trypan Blue, before re-seeding at the appropriate 
concentration. 
3.2.1.3 Cell Counting and Viability 
Cell number and viability was measured by counting both viable and non-viable cells 
in 4 squares of a hemocytometer that had been filled with 10µl of a cell suspension made up 
of an equal volume of Trypan Blue and dilution of cells in media. Non-viable cells were 
assessed as any whole cell that had taken up the blue dye.  The total cell density was 
calculated according to the equation: cell number X dilution factor (2) X 104 per ml.  The 
percentage of viable cells was then calculated by dividing the viable cells by the total of the 
viable and the non-viable cells. 
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3.2.1.4 Freezing and Revival of Cell Lines  
Cells were washed in PBS and resuspended in MS-5 complete media (CM) containing 
20% DMSO on ice, aliquoted in cryotubes and frozen immediately at -80°C. After 24 hours, 
the tubes were transferred to liquid N2 for long-term storage. For reviving cells from the 
frozen stock, cells were thawed in water bath set at 37°C for 2 minutes and transferred to 5 
ml of complete media in T-25 which were then transferred to the incubator.  
3.2.1.5 Different Growth Conditions for Matrix Preparation 
For matrix preparation, MS-5 cells were seeded at 1 X 104 cells/cm2 in CM and grown 
under low O2 (5% O2) and normal O2 (20% O2) conditions for 10 days with media change 
after every 72 hours. For osteogenic induction CM was replaced with OGM (CM containing 
10 mM b-glycerol phosphate, 100 nM dexamethosone and 100 mM ascorbate-2-phosphate) 
for 48 hours. 
3.2.1.6 Preparation of Decellularized Biological Scaffolds 
Cell free matrices which acted as biological scaffolds were prepared from all cell 
types by the following protocol. Confluent cells were rinsed in PBS and incubated with Milli-
Q deionized water (MQ) for 2-3 minutes to loosen the cell attachment with the plastic 
surface. After removing MQ, 0.02 M NH4OH was applied on the cells for 1-2 minutes at RT 
for cell lysis which was observed carefully under inverted microscope and NH4OH was 
removed by gently inverting the culture plates. The fragile matrices were allowed to dry 
overnight in the laminar flow cabinet, washed three times with PBS and stored in PBS with 
Pen/Strep at 4°C. Thus at the end of the procedure, the following four types of decellularized 
matrices (MX1-4) were obtained from MS-5 cells (Fig. 2.1B):  
MX1= Cells grown in 5% O2 + OGM  
MX2 = Cells grown in 20% O2 + OGM  
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MX3 = Cells grown in 5% O2 -OGM   
MX4= Cells grown in 20% O2 -OGM. 
3.2.2 Morphological and Biochemical Characterization of Cells and Matrices 
3.2.2.1 Phase Contrast and Scanning Electron Microscopy (SEM) 
Matrices before and after decellularization were examined by phase contrast and 
SEM. Further, live cell microscopy was done using 10X magnification. For SEM analysis, 
MS-5 cells were seeded at 1X104 cells/cm2 on 12mm diameter thermanox cover slips and 
grown as described earlier. Cultures were rinsed in PBS, fixed in 2.5% glutaraldehyde, 
washed and dehydrated in acetone. Samples were then subjected to critical point drying and 
mounted on aluminium stubs before being sputter coated with a thin layer of gold and 
examined at 5 kV. 
3.2.2.2 Alcian Blue Staining 
Alcian blue staining for ECM-bound glycosaminoglycans (GAGs) before and after 
decellularization was done as follows. Cultures were fixed in 4% formaldehyde and 
permeabilized with 0.5% Triton-X100 for 30 minutes. They were washed twice with PBS and 
rinsed in 3% acetic acid (pH 2.5) for five minutes to equilibrate the pH. Samples were then 
incubated with 1% alcian blue for 2 hours, washed in 3% acetic acid, then by 3% acetic 
acid/50% ethanol followed by two washes with water. Presence of GAGs was verified by the 
accumulation of blue stain as observed under phase microscope with 10X magnification. 
3.2.2.3 Light Green Staining 
The retention of a collagenous matrix following the NH4OH treatment was verified by 
positive staining for collagen by light green. Briefly, samples were washed three times in 
PBS and fixed in ice cold 75% ethanol for 10 minutes, incubated with light green stain at 
25°C for 30 minutes on orbital shaker before being washed with ddH2O until no leaching was 
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detected. This was followed by 75% ethanol wash to remove non-specific dye, dried at 25°C 
and then examined for the presence of greenish-blue stain under phase microscope with 10X 
magnification. 
3.2.2.4 Immunoflorescence 
DAPI staining for the nucleus was done by fixing both cells and the decellularized 
matrices in chilled 70% ethanol for 20 minutes followed by incubation in 1 mg/ml solution of 
DAPI for 10 minutes at 250C in the absence of light. Samples were washed, examined by 
fluorescence microscopy with 10X magnification. The digital images were analyzed with 
Axiovision software. 
Immunostaining of the cells and matrix was done with the standard protocol. After 
fixing both the cells and matrices with 4% formaldehyde and permeabilizing with chilled 
acetone the samples were blocked with 3% BSA. The fixed samples were incubated with the 
appropriate dilution of Rhodamine-phalloidin in 1% BSA in PBS (1:200 dilution of a 200 
units/ml stock) for 45 mintes in dark. Primary antibodies against Collagen type I (1:500), 
fibronectin (1:200), and laminin (1:100) were added to the samples. After an hour of 
incubation, samples were washed and incubated with appropriate isotype IgG-FITC (1:200) 
secondary antibody. Nonspecific isotype IgG-FITC (1:200) was used as a negative control. 
The samples were washed and mounted with Vectashield mounting medium and images were 
taken using Axioplan-2 microscope with 20X magnification. 
3.2.3 Proteomic Characterization of the Matrices 
 3.2.3.1. Protein Extraction from the Matrices 
The matrix plates were incubated with extraction buffer containing 125 mM Tris-HCl, 
pH 6.8, 0.1% SDS, 10% glycerol, 1% DTT, 0.05 mM PMSF and protease inhibitor cocktail at 
37°C for 1 hour and the matrix proteins were scrapped off with a scrapper. The protein 
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extracts were pooled and sonicated three times, 60 seconds each with 30 seconds gap and 
centrifuged at 14000 rpm at 4°C for 30 minutes. Supernatant was kept for overnight TCA 
precipitation. The precipitates were recovered by centrifugation at 15,000 rpm at 4°C, for 30 
minutes. Protein pellets were washed with cold 100% acetone to remove excess of SDS and 
TCA and vacuum-dried. The protein was dissolved in rehydration buffer containing 6M Urea, 
2M Thiourea, 2% (w/v) CHAPS and 50mM DTT, estimated by amido black method and 
stored at -70°C for further analysis. 
3.2.3.2. Protein Estimation 
The concentration of the extracted protein is estimated using Bradford Estimation and 
Amido Black Estimation. A standard curve is plotted using BSA as standard and the 
concentration of the sample is calculated. Thus the volume of the sample that should be 
loaded onto the gel is estimated. 
• Bradford Estimation: 
 BSA was used as the standard and standards of concentration 5µg/µl, 2.5µg/µl, 
1.25µg/µl, 0.625µg/µl and 0.3125µg/µl were prepared through dilution of the1mg/ml stock. 
This was used to obtain a standard OD curve from an ELISA reader. The measurements were 
made at 595nm. A curve was plotted using the known concentration samples, and the protein 
concentration of the unknown sample was estimated using this standard curve. 
• Amido Black Estimation: 
On a sheet of Hybond-C 0.5µl, 1µl, 2µl, 3µl, 4µl, 5µl and 10µl of BSA standard of 
concentration 1mg/ml were spotted.1µl each of the unknown samples were also spotted. The 
sheet was dried for an hour. The sheet is then diped in Amido Black solution for 30 minutes. 
It is decanted and destaining solution was added with change of solution 3-4 times to prevent 
background and the membrane was then dried. It is then cut into small strips and kept in 
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different eppendorfs. To each eppendorf, 2mL of elution buffer was added and vortexed at 
RT for an hour. OD was measured at 630nm using elution buffer as the blank. 
3.2.3.3. Two Dimensional SDS Polyacrylamide Gel Electrophoresis (2-D PAGE) 
2-DE of matrix proteins was performed as described by O’Farrell et al (O'Farrell, 
1975). 300µg of protein was loaded on gel by rehydration method onto immobilized pH 
gradient (IPG) strips (11cm pI range 4-7). The first dimension was carried out on a Protean 
IEF Cell system by active rehydration at 20˚C for 5 h ours followed by isoelectric focusing 
(IEF) using the following conditions: 250 V for 30 minutes, 6000 V for 2 hours and 30 
minutes and 6000 V for additional 40000 Vh. After equilibration, the second-dimensional 
separation was carried out on a gradient gel of 4-15% SDS-PAGE (11×11 cm2). 
3.2.3.4. Staining and Destaining of the Gel 
• Coomassie Staining 
Gel plates were disassembled and the gel was put into a tray with 0.2% Coomassie 
solution and kept on shaker for 5 hours. The dye was then replaced with destaining solution 
well enough to dip the gel. Gel was kept on a shaker with occasional changing of the 
destaining solution until the bands were well stained with little or no background with final 
storage in distilled water for digitized using Flour-S gel scanner. 
• Silver Staining 
The gel was fixed in the fixer for a minimum of 1.5 hours, washed twice with MQ water 
for 5 minutes each. It was then immersed in 0.02% hypo (Sodium Thiosulphate) for a minute, 
rinsed twice with water for 20 seconds. Stored in 0.1% siver nitate solution for 10 minutes 
(Take care to cover the box from light), rinsed with water and added developing solution for 
3 to 5 minutes. Once the bands were well stained, the solution was discarded and stop 
solution was added. 
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3.2.3.5. Spot Excision and In-Gel Digestion 
PDQuest version 7.2 was used for identification of the differential spots expressed in 
MX1, MX2 and MX4 taking MX3 as the standard culture condition. Experimental molecular 
mass and pI were calculated from digitized 2-DE images using standard molecular mass 
marker proteins. Differentially expressed protein spots were excised manually and destained 
with 50% acetonitrile, ACN (v/v)/ 25 mM Ammonium Bicarbonate, NH4HCO3, pH 8.0 for 
30 minutes. The gel pieces were dehydrated in 100% ACN for 5 minutes followed by 
vacuum-drying. The dried gel pieces were rehydrated with 30µL of cold trypsin in 25mM 
ammonium bicarbonate at 37˚ C for a minimum of 16 h ours.  Peptides were extracted by 100 
µl of 50% ACN/0.3% TFA, for 30 minutes with gentle agitation and the supernatant was 
vacuum-dried. Reconstitution of the peptides was done by adding 5 µl of 50% ACN/ 0.1% 
TFA for MALDI analysis. 
3.2.3.6. MALDI-TOF/MS 
Peptide mass fingerprint (PMF) was performed with 0.6 µl of reconstituted extract with 
0.6 µl of fresh CHCA matrix on 384-well MALDI plate. The samples were analyzed with a 
4800 Proteomics Analyzer MALDI-TOF/TOF mass spectrometer working in positive ion 
reflector mode. PMF data was then interrogated for protein identification with IPIMouse 
database using Mascot search engine and analysis was done on global proteomic solutions 
(GPS) software automatically. Protein identifications were done on the basis of multiple 
variables such as score, number of peptides matched and percent sequence coverage of the 
matched protein. 
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3.3 RESULTS 
3.3.1. Characterization of the Cells and Matrices 
3.3.1.1. Morphological Characterization 
In order to examine the role of decellularized matrices in expansion of CD34+ HSPCs, 
preparation of the matrices was done as described in Section 3.2.1.6 and Fig 2.1B. Phase 
contrast microscopy of the cells and matrices was done to confirm the presence of an intact 
layer of matrix after decellularization (Fig. 3.1A subpanels a and b). Phase contrast 
microscopy of the matrices before and after decellularization showed the absence of intact 
cells (Fig. 3.1A subpanels a and b).  This was confirmed by SEM analysis (Fig. 3.1A 
subpanels c-f) where matrix bound cells were seen before NH4OH treatment (subpanels c 
and e) but only an intact 3D matrix could be seen after cell removal (subpanels d and f). 
3.3.1.2. Cytochemical Characterization  
Cell and matrices were examined via cytochemical staining with light green 
(collagen) and alcian blue (ECM bound GAGs). To assess the efficiency of the 
decellualrization protocol, the absence of cells in the matrices was also confirmed by DAPI 
staining for nuclei (Fig. 3.1B subpanels a and b). Presence of collagen and GAGs in the 
cells and matrix was assessed by cytochemical staining with light green and alcian blue 
respectively. Deep staining for both collagen and GAGs could be seen in both conditions 
(Fig. 3.1B subpanels c-f) indicating that the decellularization process did not extract these 
molecules from the matrix.  
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Figure 3.1: Characterization of the cells and matrices before and after decellularization. 
 (A) The figure shows the morphological properties of the cells and decellularized matrices 
generated under MX2 conditions. Phase-contrast microscopy of a. the cells and b. the 
matrices show the removal of cells after NH4OH treatment (scale bar = 100 µm). Scanning 
Electron Microscopy (SEM) analysis of c. the cells and d. matrix at lower magnification 
(scale bar = 50 µm) and e. and f. at higher magnification for the same (scale bar = 10 µm) 
shows the cells attached to the ECM produced by them and subsequently, the rough, 3D 
structure of the matrix after decellularization. (B) Cytochemical properties of the MX2 cells 
and their decellularized matrices. a, c and e show matrices with cells and b, d and f show 
them after decellularization. a and b. fluorescence microscopy for DAPI illustrates that the 
nucleus is removed by NH4OH treatment. c and d. light green staining for collagen shows 
that NH4OH removes cells without adversely affecting the collagenous ECM on the culture 
surface e and f. alcian blue staining for proteoglycans also prove the integrity of ECM bound 
GAGs upon decellularization. Similar analysis was done for the cells grown under all other 
conditions also (scale bar = 100 µm) (Tiwari et al., 2012). 
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3.3.1.3. Immunoflourescence 
Specific immunostaining for fibronectin, laminin and collagen type-1 was 
demonstrated in both cellular and acellular conditions (Fig. 3.2 panels A, B and C 
respectively). The absence of co-localized actin, after removal of cells (compare subpanels a 
and d or c and f in Fig. 3.2), indicated that most of the cellular actin was removed during the 
decellularization process. Similar results were obtained for all matrices. 
  
Figure 3.2: Immunostaining for actin and ECM proteins on MX2 matrices. 
Panels A-C show dual fluorescence staining with actin-rhodamin and fibronectin-FITC, 
laminin-FITC and collagen type 1-FITC respectively. Sub panels a-c show staining of the 
cells with actin-rhodamin, FITC tagged antibodies and the combination of both stains 
respectively.  Sub panels d-f show staining of the decellularized matrices with actin-
rhodamin, FITC tagged antibodies and the combination of both stains. Yellow color in sub 
panel c and f show the co localization of two proteins. Notice the absence of actin staining in 
sub panels d and f indicating that most of cellular actin was removed during decellularization. 
(Scale bar = 100 µm) (Tiwari et al., 2012). 
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3.3.2 Proteomic analysis of the scaffold proteins 
 3.3.3.1. 2D gel comparisons 
Proteins from all the scaffolds, (MX1-4) were analyzed using standard 2D gel 
electrophoresis followed by MALDI-TOF/MS protocols as described in Section 3.2.3. 
Protein identities of approximately 300 spots, taken from all the four gels, with triplicates of 
each gel, were established using the PDQuest software and comparison of protein expression 
in MX1, MX2 and MX4 scaffolds was done using MX3 proteins as the reference scaffold. 
A total of 64 differential spots could be identified in MX1, MX2 and MX4 whose 
levels differed significantly from the MX3 gels, as determined with a Student’s t -test, 
considering p < 0.05. Positions of these spots have been indicated in the gel pictures of the 
respective matrices (Fig. 3.3). The differential proteins identified belong to several different 
classes including cytoskeletal, mitochondrial, plasma membrane, endoplasmic reticulum 
(ER), cytoplasmic, extracellular, intermediate filaments and proteins belonging to other 
groups. Some of the identified spots were also found in a different position in 2-D gels 
indicating post-translational modifications or different isoforms of such proteins. MX1 and 
MX4 showed 19 unique spots each whereas MX2 showed 29 differential proteins. The 
MALDI-TOF/MS identities of 52 spots from all matrices, along with their functional 
category have been shown in Annexure Table 3.1. 
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Figure 3.3: Four representative 2-DE images of the decellularized matrices grown under different culture conditions (MX1-4). Proteins 
were separated in first dimension on IPG strip (11cm, pI range 4-7) and in second dimension by SDS-PAGE (4-15% gradient) on BioRad 
Criterion pre-cast gels. Rectangles indicate upregulated/present and ovals indicate downregulated/absent protein spots as compared to the 
standard condition- MX3 (Tiwari et al., 2012).  
Preparation and Characterization of Cell Free Matrices from Stromal Cells 
66 
 
3.3.2.2 Identities of MX2 Specific Proteins 
The protein spots of MX2 scaffolds were studied in more detail because MX2 had 
shown the most significant expansion of clonogenic progenitors (see Chapter 4). These 29 
spots represented 23 unique protein identities whose comparative expression details are 
shown in Table 3.1. Out of the 10 proteins that were uniquely regulated in the MX2 scaffold 
(see S.No.1-10 in Table 3.1) only one protein (α-centractin) was upregulated whereas the rest 
were down regulated in comparison to other scaffolds.  
Among other proteins, 4 were commonly affected in MX2 and MX4 (S. No. 11-14) 
and 7 were commonly affected in MX2 and MX1 (S. No. 15-21). It is noticeable that among 
23 proteins identified in MX2, 18 were down regulated in comparison to other matrices 
indicating that their presence could be inhibitory for HSPC expansion.  
The identities of the 23 MX2 related proteins (Table 3.1) indicate several proteins 
that are linked with stem cell differentiation functions are present in the stromal matrices. For 
example Aldh and Gelsolins are involved in the regulation of stem cell signaling and they are 
also upregulated in the matrices of stromal cells.  
Table 3.1: Differentially expressed proteins in the MX2 scaffold, relative to MX1 and 
MX4 scaffolds (Tiwari et al., 2012). 
S. 
No 
Protein Name MX1 MX2 MX3 MX4 Functions 
Uniquely Affected in MX2 
1 α-centractin  + ↑ + + Involved in vesicle motility.  
2 Peroxiredoxin-6 + - + + Anti-oxidant.  
3 Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein K 
(hnRNPs) 
+ - + + Downregulation helps in 
osteogenic differentiation.  
4 Annexin A5 + ↓ + + Mediate vesicle/matrix 
interactions for bone 
mineralization. Also used as 5 Annexin A7 + ↓ + + 
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apoptotic marker.  
6 78 kDa glucose-
regulated protein 
(HSPA5) 
+ ↓ + + Hypoxia induced stress 
protein.  
7 Actin, cytoplasmic 1 + - + + Cell motility   
8 Dynactin subunit 2 + ↓ + + Motor activity, protein 
binding  
9 Actin, cytoplasmic 2 + ↓ + + Cell motility   
10 T-complex protein 1 
subunit epsilon 
+ ↓ + + Chaperone, ATP binding.  
Commonly affected in MX2 and MX1 and/or MX4 
11 Aldehyde 
dehydrogenase (Aldh) 
+ ↑ + ↑ Highly expressed in 
primitive HSCs.  
12 ATP synthase subunit β, 
mitochondrial 
+ ↑ + ↑ Cellular energy provision.  
13 Nucleophosmin 1 + ↓ + ↓ Enhances HSC proliferation.  
14 Isoform 1 of 
Tropomyosin α-1 chain 
+ ↓ + ↓ IFP; involved in stroma-
dependent hematopoiesis.  
15 Annexin A1 ↑ ↑ + + MSC differentiation into 
osteoblasts.   
16 L-lactate dehydrogenase 
B chain (LDH) 
- + - + Related to hypoxia induced 
factor. Levels reduce in 
hypoxic condition.  
17 Protein disulfide-
isomerase A3 
↓ ↓ + + Calcium binding antioxidant 
protein.   
18 Calreticulin ↓ ↓ + + Regulates production of 
ECM.  
19 Vimentin  ↓ ↓ + + MSC marker.  
20 Ferritin light chain 1 ↓ ↓ + + Ferric ion binding, 
oxidoreductase.  
21 Guanine deaminase  ↓ ↓ + + Guanine deaminase activity.  
22 Isoform 2 of Gelsolin  ↑ ↑ + ↑ Homing functions of MSCs.  
23 Endoplasmin  ↓ ↓ + ↓ Stress protein.  
 
3.4 DISCUSSION 
In recent years, a great deal of attention has been focused on ECM proteins. The interest 
was stimulated by active studies on mammalian stem-cell proliferation and differentiation, as 
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well as by the development of new techniques of stem-cell expansion required for their 
therapeutic and scientific use. Despite having ample knowledge about the in vivo BM HSC 
niche, one of the most challenging tasks for researchers today is to recreate in vitro niche like 
conditions and hence provide more favorable ex-vivo HSC expansion. In general, materials 
from natural sources (e.g. collagen, laminin or fibronectin) are advantageous for expansion, 
because of the presence of cell-recognizable receptors (Table 1.3). However, issues 
associated with natural materials, including complex structural composition, purification, and 
immunogenicity have driven the development of synthetic biomaterials for use as 2D or 3D 
extracellular microenvironments to mimic the regulatory characteristics of natural ECMs and 
ECM-bound growth factors. The use of coated or uncoated inorganic substrates and ECM 
components for ex vivo expansion of HSPCs has been reported and reviewed in the literature; 
for example, scaffolds developed from synthetic biodegradable polymers such as 
polyhydroxyalkanoate (PHA) (You et al., 2011). However, the synthetic polymers are limited 
by their biological inertness and the acidic moieties, residual catalysts, and micro-scale 
particulates that accompany degradation (Lu et al., 2011). Since the structural and chemical 
characteristics of 3D matrices offer opportunities for lineage-specific biochemical and 
biophysical cues to enhance selective differentiation of HSPCs, the choice of material for the 
3D scaffold is very crucial (Lund et al., 2009; Miyoshi et al., 2011).  
To obtain scaffolds mimicking native ECM, cells are specifically removed by a 
decellularization treatment and the intricate mixture of structural and functional proteins and 
glycosaminoglycans remains (Discher et al., 2009). Many methods have been developed for 
decellularization (Brown et al., 2011; Hoshiba et al., 2010). The results discussed in this 
chapter have, for the first time, shown that it is possible to prepare functional decellularized 
biological scaffolds from a BM-derived stromal cell line, MS-5. It has been shown that 
stromal cells can significantly change the constitution of their matrix and their ability to 
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support HSPC expansion in response to O2 levels and osteogenic induction. Further, 
preliminary analysis of the stroma has been undertaken to identify matrix components that 
may contribute to this functional difference. 
This study aimed to mimic the functions of the endosteal and vascular niches by 
preparing cell free matrices from MS-5 cells that were grown under different O2 
concentrations and with/without osteogenic signals. Such an approach has significant 
advantages over the other traditional method of using single ECM protein, as it captures the 
true complexity of ECM mix surfaces (Galan et al., 2007). As these matrices were intended 
for ex vivo HSPC expansion, the isolation procedure called for a balance between complete 
removal of cells, and the preservation of ECM protein activity (Grunert et al., 2007), and 
therefore differed significantly from other methods (Brown et al., 2011). The matrices were 
characterized using different biochemical and immunostaining methods and the results 
showed that the decellularization procedure removed almost all the cells  but  ECM 
components such as collagen and ECM bound GAGs, which are both important for 
haematopoiesis (Rodgers et al., 2008), were retained in the residual matrices. 
The limitations of scaffolds prepared from MS-5 matrices to support human HSPC must 
be taken into consideration. MS-5 is an immortalised cell line habituated to growth under 
non-physiological conditions, and the HSPC expansion itself occurs in the presence of supra-
physiological growth factor concentrations. Nevertheless, these scaffolds allow the direct 
comparison of the effects of ECM generated from a single homogeneous cell type under 
different conditions, which could enable us to identify key factors involved in control of 
HSPC growth and differentiation. Therefore, proteomics analysis of the matrices generated 
under different conditions was undertaken. MS-5 cells were originally maintained at 5% O2 
as it represents the niche like conditions and expansion of CD34+ cells is greater at a lower 
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O2 concentration (Tursky et al., 2012). MX3 (low O2, no OGM) was taken as the “baseline” 
to identify the differentially expressed proteins in ECM grown under other conditions. 
The proteins differentially expressed under different O2 conditions (MX2/MX4 vs 
MX1/MX3) may indicate their possible role in O2 metabolism in stromal cells. Proteins like β 
chain of β subunit of mitochondrial ATP synthase, L-lactate dehydrogenase-B (LDH-B), and 
aldehyde dehydrogenase (ALDH) that protect cells from reactive O2 species (ROS) caused by 
higher O2 levels as well as other processes relevant to stem cell regulation (Levi et al., 2009; 
Rossignol et al., 2003; Satyavani R, 2009), are upregulated under high O2 conditions (MX2 
and MX4). It should be noted that many of these proteins are intracellular, yet being detected 
in an acellular matrix – presumably indicating that the decellularization process does not 
remove all intracellular proteins and also, it is unlikely to be impacting directly on the growth 
of HSPCs on that matrix. Gelsolin, which has a potential impact on the homing functions of 
stem cells (Forsberg et al., 2005) was also upregulated in MX2. Some hypoxia induced stress 
proteins such as HSPA5 were downregulated in MX2 as expected. Upregulation of annexin 
A1 in stroma grown in the presence of OGM (MX1 and MX2) is consistent with its role in 
regulation of osteoblastic differentiation (Park et al., 2007; Zhang et al., 2007).  
Calreticulin, an ECM protein which interacts with thrombospondin and regulates the 
ECM production, and vimentin which is a marker for MSCs and its expression decreases with 
the differentiation of the MSCs into osteogenic lineage, are downregulated in both MX1 and 
MX2 (Kim et al., 2005; Satyavani R, 2009). Yi et al., have shown that the expression of 
Prx6, an oxidoreductase (Ye et al., 2006) and hnRNPs is downregulated in differentiating 
MSCs, consistent with their absence in MX2 matrices. It is also to be noted that 17 out of 23 
proteins were downregulated in the MX2 matrix, indicating that osteogenic induction and 
higher O2 levels reduce the expression of proteins that could be inhibitory for HSPC 
expansion.  
Preparation and Characterization of Cell Free Matrices from Stromal Cells 
71 
 
In summary, an acellular biological scaffold was prepared by modulating O2 tension and 
osteogenic induction of mouse stromal cells that approaches to mimic the complexity of a 
stem cell niche. This preliminary proteomic analysis has therefore identified a number of 
proteins that are differentially regulated and that could be linked to the observed differences 
in the ability of these matrices to support HSPC expansion. It is believed that this therefore 
serves to validate the experimental model and justifies more detailed proteomic and gene 
expression analysis to identify additional factors that may be involved. 
  
Assessment of the Ability of Cell Free Matrices to Support HSPC Expansion 
72 
 
 
 
 
 
 
Chapter 4: Assessment of the Ability 
of Cell Free Matrices to Support 
HSPC Expansion 
 
 
 
 
 
 
 
 
Assessment of the Ability of Cell Free Matrices to Support HSPC Expansion 
73 
 
4.1 OVERVIEW 
Ex vivo expansion of HSPCs has been actively investigated for over 35 years (Dexter 
et al., 1977; Pineault et al., 2011). In adults, HSCs self renew in BM, and the hematopoietic 
microenvironment in BM is mainly composed of HSCs, stromal cells and secretory 
components from these cells, such as cytokines and ECM proteins (Park et al., 2012). Self 
renewal is therefore maintained by signals from surrounding cells, such as osteoblasts, 
stromal mesenchymal progenitors, adipocytes, vascular endothelial cells and maybe some 
others, which are organized into a specific niche for the HSC. Understanding these signals 
may allow us to culture, multiply and maintain undifferentiated HSCs in feeder-free 
conditions, which could be more scalable for clinical applications.  
Almost all research on HSPC expansion has focused on the effects of exogenous 
cytokines, single or mixed ECM coatings and/or co-cultures of HSPCs with stromal cells, and 
the beneficial effects of these culture techniques on cell expansion have been clearly 
demonstrated (Hackney et al., 2002; Jing et al., 2010; Sagar et al., 2006; Wagner et al., 2008; 
Zhang, 2006) (Table 1.3). In contrast, the haematopoietic microenvironment in BM is three-
dimensional (3D) with changes in O2 gradients and osteogenecity, and mimicry of these 
characteristics seems a possible way to achieve efficient ex vivo expansion of HSPCs.  
The concept of stem cell niches has been used in the tissue engineering field to 
prepare bioengineered 3D scaffolds for the purpose of ex vivo stem and progenitor cell 
expansion (Adams, 2008; Guilak et al., 2009). Although many inorganic biomaterials have 
been used for this application, (Banu et al., 2001; Dellatore et al., 2008; Franke et al., 2007) 
the use of cell free ECMs as biological scaffolds for tissue engineering has been less common 
(Hoshiba et al., 2010). Examples of cells that have been expanded on cell free matrices 
include mesenchymal stem cells (MSCs) (Chen et al., 2007), neuronal cells (Aizman et al., 
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2009) and osteogenic cells (Evans et al., 2010) and hepatic cells (Shiraki et al., 2011) derived 
from murine embryonic stem cells (ESCs). 
In order to mimic the complexity of the HSC niche, acellular matrices were prepared 
from one of the cell lines which are already known to support HSPC expansion in co-culture 
(Breems et al., 1998; Issaad et al., 1993). MS-5 is a mouse stromal cell line derived from the 
BM and secretes abundant ECMs (Breems et al., 1998; Issaad et al., 1993). Attempts have 
been made to replicate the niche like conditions, taking into account two important variables 
in the HSPC niche – O2 and osteogenecity (Chapter 3).  
The growth and differentiation of human UCB derived CD34+ cells were analyzed on 
these matrices for a period of 8 days with a cytokine growth factor cocktail and in serum free 
media. HSPC expansion on different matrices was assessed phenotypically by flow cytometry 
and functionally by CFU-GEMM assays which assess the presence of multi-potent and 
committed progenitors (BFU-E, CFU-GM and CFU-GEMM). Flow cytometry detection of 
surface markers is an indirect measure of HSPCs which correlates with but does not 
necessarily indicate functionality. CFU-GEMM assays, however, measure the functional 
clonogenic potential of HSPCs in vitro with a high degree of reproducibility. Fold expansion 
of the HSPCs were calculated to determine which matrix supported the maximum HSPC 
expansion. The specific lineages supported by each matrix were also calculated based on 
FACS and CFU assays. 
4.2 METHODS 
4.2.1 Cord Blood Processing and CD34+ Cell Isolation 
4.2.1.1 Ethics Approval 
Umbilical cord blood was donated in accordance with approved institutional 
guidelines, and with appropriate ethics approval as shown in Annexure Figure 3.1 and 3.2. 
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Cord blood samples were obtained from full-term delivering mother donors at Sridevi 
Nursing Home, Warasiguda, Hyderabad with signed consent. Each cord blood was collected 
by midwives directly into blood collection bags containing 30 ml of citrate phosphate 
dextrose anticoagulant, and stored at room temperature. 
4.2.1.2 Preparation of Mononuclear Cells 
Target cell isolation was initiated within 24 hours of collection. Blood samples were 
diluted 1:4 with phosphate buffered saline lacking magnesium chloride and calcium chloride 
(PBS) containing 2mM ethylenediamine tetra acetic acid (EDTA). Ficoll-Paque Plus™ 
density gradient was used to isolate mononuclear cells by overlaying 20ml of diluted cord 
blood onto 16ml of Ficoll-Paque Plus aqueous media, and centrifugation at 19ºC 400rcf/g, for 
30 minutes. The mononuclear cell buffy coat layer was collected, diluted 1:2.5 with PBS 
2mM EDTA and centrifuged (19ºC, 400rcf, 10 minutes). This wash step was repeated and the 
cells were then diluted 1:1 with PBS 2mM EDTA, centrifuged (19ºC, 400rcf, 10 minutes) 
and resuspended in PBS 2mM EDTA for cell count and viability determination with 0.4% 
trypan blue solution (Fig 2.1A).  
4.2.1.3 Immuno-Magnetic Separation of CD 34+ Cells 
CD34 processing was performed using a Direct CD34 Progenitor Cell Isolation Kit as 
per manufacturer’s recommendations. Briefly, pelleted mononuclear cells were resuspended 
in 300μl of cold degassed PBS 2mM EDTA containing 0.5% bovine serum albumin (BSA) 
per 1 x 108 total cells. 100μl Fc antibody receptor blocking reagent was added per 1 x 108 
total cells and incubated for 5 minutes at 6-12ºC, followed by addition of 100μl CD34-
microbeads per 1 x 108 total cells and incubation for 30 minutes (6-12ºC). Excess antibodies 
were removed through the addition of 5ml cold degassed PBS 2mM EDTA 0.5% bovine 
serum albumin and centrifugation (6ºC, 200rcf/g, 10 minutes). Labeled cells were isolated 
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from MNCs by magnetic sorting on AutoMACS cell sorter using the “double positive 
selection program” provided by the manufacturers, according to the manufacturer’s 
instructions. CD34+ enriched cells were centrifuged (6ºC, 200rcf/g, 10 minutes) and 
resuspended in PBS for cell counts and viability determination (Fig 2.1A).   
4.2.2 HSPC Ex Vivo Expansion  
4.2.2.1 Seeding on Different Matrices and Culture Conditions 
Biological scaffolds (MX1-4) were prepared in 24 well plates as described in 
Chapter 3. Negative control surface C1 was prepared by incubating the wells (without cells) 
with only CM for 10 days followed by only OGM for next 2 days. Negative control surface, 
C2, was prepared by incubating them with CM only for 12 days. C3, was prepared by 
incubating wells with 10μg/ml RetroNectin for 30 minutes at RT;  RetroNectin was used as a 
standard  substrate for HSPC expansion as reported earlier (Uchida et al., 2011). Following 
these incubations, all control surfaces were treated with the same decellularization protocol as 
has been described for the cell matrices. 
Magnetically sorted UCB CD34+ cells, as primary source of HSPC, were resuspended 
in Stemline II serum free media supplemented with 1X Pen/Strep and GFs as indicated: 
thrombopoietin (TPO)-25ng/ml, stem cell factor (SCF)-25ng/ml, interleukin-6 (IL-6) 50ng/ml 
and Flt3 Ligand (Flt3L)-40ng/ml and seeded at 1 X 104 viable cells/ml in the coated wells. 
For each category MX1-4 and C1-3, triplicate cultures were prepared. All cultures were 
placed in the hypoxic incubator (5% O2, 5% CO2, 37oC, humidified) for 8 days (Fig 2.1C).   
4.2.2.2 Cell Harvesting 
Photos of each condition were taken for comparison before harvesting the cells (Fig 
4.1 A-B). Following pipetting to resuspend cells, the contents of each well were collected 
into separate 15ml collection tubes. 1ml PBS wash was added to each well and transferred 
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into the same collection tubes. To mobilize remaining attached cells, 1ml cell dissociation 
buffer solution was added per well and incubated for 30 minutes at 37ºC. After incubation, 
the well contents were transferred into collection tubes, followed by a 1ml PBS wash. 
Collection tubes were centrifuged (20ºC, 480g, 10 minutes) followed by resuspension of the 
cell pellet in 200μl of PBS. Collection tubes were stored at 4ºC while manual cell counts and 
viability determination with 1% trypan blue were preformed for each tube. Cells were then 
aliquoted for post-culture flow cytometry and CFU assays (Fig 2.1C).  
                       
Figure 4.1: UCB derived CD34+ HSPCs pre and post expansion and the Colonies 
formed after CFU assay. Panels A and B shows pre and post expanded HSPCs on MS-5 
matrices respectively. Panels C-F shows the morphology of Burst Forming Unit–Erythroid 
(BFU-E), Colony Forming Unit–Granulocyte, Macrophage (CFU-GM), BFU-E and CFU-
GM together and Colony Forming Unit–Granulocyte, Erythrocyte, Macrophage, 
Megakaryocyte (CFU-GEMM) respectively. 
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4.2.2.3 Flow Cytometry  
Flow cytometry for surface markers and cell viability were performed on pre-culture and 
post-culture samples to allow calculations of fold change in target cell population numbers. 
For each experiment, compensation controls were included to confirm correct flow cytometer 
instrument settings, and three stains were used for each sample to assess HSC phenotype. A 
minimum of 2 x 104 viable cells for each stain were resuspended in 100μl of PBS 2% FCS, 
and 5μl of the appropriate antibodies and viability stain were added for the following stains: 
compensation-FITC (CD45-FITC, IgG-PE), compensation-PE (IgG-FITC, CD45-PE), 
compensation 7AAD (IgG-FITC, IgG-PE, 7AAD), stain 1: viable CD34+ (CD45-FITC, 
CD34-PE, 7AAD), stain 2: primitive HSPC (CD38-FITC, CD34-PE, 7AAD), stain 3: CD34+ 
CD133+ HSPC (CD34-FITC, CD133-PE, 7AAD). 7-AAD (7-amino-actinomycin D) was 
added to measure the cell viability. Cells were incubated for 15 minutes at RT in the dark, 
and excess antibodies were removed through the addition of 1ml PBS 2% FCS and 
centrifugation (20ºC, 480g, 10 minutes). The cell pellets were resuspended in 300μl fixative 
solution (PBS 2% FCS 1% formaldehyde 2μg/ml actinomycin D), and stored at 4ºC in the 
dark. Data acquisition and analysis was performed within three days. 
Flow cytometry data was acquired using a FACSCalibur flow cytometer where 3,000 – 
10,000 total events per sample were collected according to ISHAGE Guidelines for CD34+ 
Cell Determination by Flow Cytometry (Sutherland et al., 1996). The events acquired were 
then analyzed with CellQuest Pro software for both pre-culture and post-culture samples in 
order to calculate the fold expansion of target cell population numbers. Events were first 
gated for small side scatter and medium forward scatter, and then analyzed on the basis of 
fluorescence in the FITC, PE and 7-AAD channels. For determining the mean and standard 
error values, data from three experiments, with triplicate samples in every experiment, was 
used. Fold increase in total cell number and lineage specific cells was calculated as follows:   
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a. For total cells    
Count of total viable cells after expansion 
Count of total viable cells before expansion 
 
b. For lineage specific cells  
(Lineage specific cell percentage × Count of total viable cells) after expansion  
(Lineage specific cell percentage × Count of total viable cells) before expansion 
 
c. For percentage of HSPC subpopulations    
Fold expansion of HSPC subpopulation    × 100 
Fold expansion of total viable cells 
4.2.2.4 Colony Forming Assays  
Colony forming assays were preformed with pre-culture and post-culture samples to 
allow calculation of fold change in total colony forming units. Cell aliquots were resuspended 
to appropriate concentrations in Stemline II, Pen/Strep and 2% FCS. Cells were diluted 1:10 
in Methocult® media and plated in triplicate in 12 well plates. Cells were plated at 0.3 X 103 
and 0.6 X 103, viable cells per ml. All CFU-GEMM cultures were incubated for 14 days in 
standard tissue culture incubators (5% CO2, 20% O2, 37ºC). Colony Forming Unit–
Granulocyte, Erythrocyte, Macrophage, Megakaryocyte (CFU-GEMM), Colony Forming 
Unit–Granulocyte, Macrophage (CFU-GM), and Burst Forming Unit–Erythroid (BFU-E) 
colonies were manually counted following the 14 day incubation, as per manufacturer’s 
instructions (Fig 4.1 C-F). 
4.2.3 Matrix Modification Experiments 
The matrices were modified for two different sets of experiments- ablation and add 
back experiments and mixing and recoating of decellularized matrices. 
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4.2.3.1 Ablation and Add-back Experiments 
For ablation and add back experiments, MX2 matrices were prepared as shown in Fig. 
2.3A. For ablation of glycosaminoglycans (GAGS), 0.3 mU heparinase I, 0.3 mU heparinase 
II, 0.3 mU heparinase III and 0.3 mU chondroitinase ABC was added to dried MX2 for 30 
minutes at 37oC (MX2-GAGS). Removal of GAGs were also confirmed by alcian blue 
staining as mentioned in Section 3.2.2.2 and the result is shown in Fig 4.5 C and D. For 
further remove cellular components, MX2 was treated with 0.5% TritonX-100 for 30 minutes 
(MX2 TX). For add back, we collected sticky MX2 matrix following decellularization and 
dialyzed it (6-8 kDa membrane) against PBS for 48 hours to remove residual ammonia. 
25µg/ml of this solubilised MX2 matrix (MX2 sol) was then directly added to the HSPC 
expansion medium.  
4.2.3.2 Mixing and Recoating of Acellular Matrices  
MX1 and MX2 matrices were prepared as shown in Fig 2.3B. Following 
decellularization, the viscous and sticky matrices were scrapped and collected in tubes. To 
check the effect of recoated matrices, two of the tubes were kept in pure MX1 and MX2 
forms, while two more tubes were prepared by mixing MX1: MX2 in the ration of 4:1 (MX5) 
and MX1: MX2 in the ration of 1:4 (MX6). 100µl of each matrix condition was then added at 
the centre of the wells in 24 well plates and were spin coated first for 30 seconds at 500rpm 
and final speed was at 1000 rpm for 60 seconds using a spin coater. The coated plates, now 
called MX1c, MX2c, MX5c and MX6c, were then dried overnight in the laminar flow 
cabinet, washed in PBS with Pen/Strep and used for HSPC expansion. These matrices were 
morphologically characterized by SEM as mentioned in Section 3.2.2.1 and the result is 
shown in Fig 4.5 A and B.  
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4.2.4 Statistical Analysis  
Statistical relevance of the mean change in cell percentage and colony numbers during 
each experiment was determined via one way ANOVA using Minitab software. Pair wise 
comparison of inter-experiment variation was done with general linear model ANOVA to see 
the individual and combined effect of the conditions on HSPC expansion. Standard errors in 
the data points were determined at the 95% confidence interval and values with p≤0.05 
within each experiment were considered as significant. 
4.3 RESULTS 
4.3.1 Isolation of Target Stem Cells - CD34+ HSPCs 
The volume of the CB samples collected (n = 5) for CD34+ isolation was 45.3 ± 14.8 
ml. The percentage of CD34+ cells before and after MACS isolation as assayed by flow 
cytometry was 0.65 ± 0.24% and 75.63 ± 1.1 % respectively. The purity of the magnetically 
sorted viable CD34+CD45lo cells was 72.49 ± 1.9% (Fig. 4.2A), CD34+ CD38- cells were 
4.51 ± 0.2% (Fig. 4.2B) and CD34+CD133+ cells were 52.49± 1.02% (Fig. 4.2C) with 
74.85±1.63% viability. Every expansion experiment is done by using single CB samples.  
4.3.2 Ex vivo expansion of the characterized CD34+ cells on the decellularized matrices 
Expansion was investigated by seeding cells on controls and matrices generated in 
different conditions as mentioned in Fig. 2.1C and incubated in 5% O2 for 8 days. Cells were 
assessed pre- and post-culture by flow cytometry and CFU-GEMM assays. Three target cell 
populations were analyzed by flow cytometry being viable cells (all 7AAD- cells), viable 
CD34+CD45lo cells (Fig 4.2A and D) (includes HSCs multipotent and committed progenitor 
cells), viable CD34+CD38- cells (Fig 4.2B and E) (the most primitive HSC population 
assessed) and viable CD34+CD133+ cells (Fig 4.2C and F) (including HSCs, multi potential 
progenitors, and some early committed progenitor cells) as illustrated in Fig 1.2. 
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Figure 4.2: Dot plot analysis of HSPCs with lineage specific surface markers 
(comparison of pre and post culture cells). A, B and C represent pre culture and D, E and F 
represent post culture CD34+ cells respectively. A and D represent staining of the cells with 
CD34 PE+ CD45 FITC+ 7AAD- (which includes HSPCs, multipotent and committed 
progenitor cells), B and E represent CD34 PE+  CD38 FITC- 7AAD- (primitive HSPCs)  and 
C and F represent CD133 PE+ CD34 FITC+ 7AAD- (including HSPCs, multi potential 
progenitors, and some early committed progenitor cells) respectively. Cell target populations 
are gated according to size, granularity and fluorescence. All three HSPC specific stains show 
an increased proportion of differentiated CD34- cells and a continued presence of CD45+ 
CD34+ CD38- and CD133+ viable (7AAD-) HSPCs (Tiwari et al., 2012). 
Average fold expansion of these populations (represented by mean ± S.E. of three 
replicates)  by flow cytometry and CFU-GEMM assay for three independent experiments 
with individual experiments having triplicates for each condition is shown in Annexure 
Assessment of the Ability of Cell Free Matrices to Support HSPC Expansion 
83 
 
Table 4.1 and Annexure Table 4.2 respectively. Statistical analysis was done using One-
way ANOVA. 
4.3.3 Fold Expansion of HSPCs by Immunophenotype Analysis 
Flow cytometric analysis of three UCB samples was performed in each batch of cord 
blood following CD34 selection but prior to HSPC expansion. Dot plot analysis of one 
representative sample is shown in Fig. 4.2. Based upon the data of three experiments, the 
distribution of viable cell percentages for CD34+CD45lo, CD34+CD38- and CD34+CD133+ 
lineages were calculated at 72.49 ± 1.9%, 4.51 ± 0.2% and 52.49 ± 1.02% respectively (Fig. 
4.2 A-C). These cells were used for HSPC expansion experiments as described in the 
experimental flow chart (Fig. 2.1C) and their fold expansion was calculated as described in 
Section 4.2.3. A representative dot plot from one expansion experiment on MX2 matrix is 
shown in Fig. 4.2 D-F.  The corresponding percentages of cells after expansion were 29.52 ± 
3.54%, 0.77 ± 0.08% and 24.35 ± 2.39% respectively. 
The average fold increases in total and lineage specific cells from three experiments 
are shown in Fig. 4.3 A-C, and in Annexure Table 4.1. Total and lineage specific cell 
expansion on control surfaces (C1 and C2) was significantly less than their corresponding 
matrices (Fig. 4.3A and B). Overall, MX3 and MX1 matrices showed better expansion and 
higher purity of CD34+CD38- cells (p ≤ 0.01), representing 36% and 28% of total viable cells 
respectively (Fig. 4.3B).  Conversely, purity of CD34+CD45lo (p ≤ 0.001) and CD34+CD133+ 
(p ≤ 0.001) lineage cells was greater on MX2 matrices, representing 23% and 25% of the 
total viable cells respectively (Fig. 4.3B), and this was reflected in greater fold expansion in 
these populations (Fig 4.3A).  
The specific roles of O2 and OGM on the ability of the scaffold to support total and 
lineage specific cell expansion are represented in Fig. 4.3C. Matrices grown at higher O2 
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concentration (MX2 and MX4) expanded CD34+CD45lo and CD34+CD133+ cells more than 
matrices prepared at low O2 (MX1 and MX3) irrespective of the presence of OGM.  
 
Figure 4.3: Fold expansion of HSPCs based on surface markers.  
(A) Represents the fold expansion of the HSPC subpopulation compared to the fold 
expansion for total cells. Statistical analysis was done using One-way ANOVA (* p ≤ 0.05; 
** p ≤ 0.01; *** p ≤ 0.005). (B) Represents the percentage of the three HSPCs sub-
populations as compared to total cell expansion. (C) General linear model ANOVA with 95% 
confidence and p ≤ 0.05 was done to compare O2 group, OGM group and the combined effect 
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of O2*OGM groups on HSPC expansion (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.005). a. total 
viable cells. There was no significant effect of either of two conditions on the expansion of 
total cell population. b. viable CD34+CD45lo cells. There was a combined effect of both 
O2*OGM groups on MX2 condition (# p ≤ 0.05) for expansion of these cells. c. viable 
CD34+ CD38- cells and d. viable CD34+CD133+ cells which also  shows a combined effect 
of both O2*OGM groups on MX2 condition (# p ≤ 0.05). The individual role of O 2 is quite 
prominent for CD34+CD45lo and CD34+CD133+ cells as the fold expansion on matrices at 
20% O2 (MX2 and MX4) was statistically better than that on 5% O2 (MX1 and MX3). The 
individual role of OGM could not be determined in this analysis as OGM alone did not show 
statistically significant change in data. Results are based on an average of three individual 
experiments with triplicates of each condition within an experiment (Tiwari et al., 2012).  
Matrices laid down by cells grown at low O2 appeared to support greater expansion of 
CD34+CD38- cells (Fig. 4.3C, panel C) but these differences were not statistically 
significant. A role of OGM alone was not seen in this analysis, with p values >0.05 for all 
analyses. However, in combination with higher O2 concentration (MX2), cells grown in 
OGM supported greater expansion of CD34+CD45lo (p≤0.05) and CD34+CD133+ cells 
(p≤0.05).  
4.3.4 Fold Expansion of HSPCs by CFU Assay 
Functional properties of the expanded cells were assessed by colony forming assays in 
semi-solid media. This directly measured the in vitro potential of HSPC differentiation into 
various hematopoietic lineages.  The fold expansion of HSPCs based on CFU assays was 
higher than that seen in the flow cytometry assays. The counts of BFU-E, CFU-GM and 
CFU-GEMM progenitors, before and after three expansion experiments, were used to 
calculate the fold expansion of the respective progenitors. Detailed analysis of this data is 
shown in Annexture Table 4.2. 
The expansion of all colony forming cell units was significantly higher using MX2, in 
comparison to other experimental matrices and controls (Fig. 4.4A). In particular it was 
observed that on MX2 matrix, the fold increase of erythroid progenitors was equivalent to the 
fold increase in total viable cell number. The fold increase of CFU-GMs and CFU-GEMMs 
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was also significantly greater on MX2 than on other matrices. For all other matrices, the 
expansion of CFU largely mirrored the comparative level of expansion of total viable cells.  
 
Figure 4.4: Fold expansion of different cell populations by colony forming assay.  
(A) Represents the fold expansion of the CFUs compared to the fold expansion for total cells. 
Statistical analysis was done using One-way ANOVA (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 
0.005). (B) General linear model ANOVA with 95% confidence and p<0.05 was done to 
compare O2 group, OGM group and the combined effect of O2*OGM groups (* p ≤ 0.05; ** 
Assessment of the Ability of Cell Free Matrices to Support HSPC Expansion 
87 
 
p ≤ 0.01; *** p ≤ 0.005). The presence of progenitor colonies were analysed by colony 
forming assays in semi-solid media after 14 days and the colonies were manually counted for 
both pre and post expanded cells to calculate fold expansion of those colonies. a. BFU-E, b. 
CFU-GM and c. CFU-GEMM d. shows total colony numbers, which is represented by the 
mean of all the colonies. The individual role of O2 is seen for all the types of colonies as the 
fold expansion on matrices at 20% O2 (MX2 and MX4) was statistically better than that on 
5% O2 (MX1 and MX3).  Individual role of OGM on BFU-E, CFU-GEMM and total 
colonies was also seen as the matrices with OGM (MX1 and MX2) showed significantly 
higher fold expansion compared to matrices without OGM (MX3 and MX4). All the four 
type of colonies had the combined effect of both O2*OGM groups on MX2 condition (# p ≤ 
0.05 and ## p ≤ 0.01). Results are based on an average of three individual experiments with 
triplicates of each condition within an experiment. 
The individual and combined roles of O2 and OGM are represented in Fig. 4.4B and 
multivariate analysis indicated a significant synergistic effect of high O2 and OGM for all 
colony types - BFU-Es (p≤0.01), CFU-GMs (p≤0.05) and CFU-GEMMs (p≤0.05). 
4.3.5 Characterization of Modified Matrices  
Since MX1 and MX2 were better matrices for primitive and committed HSPCs, 
matrices were prepared for these two conditions for coating and mixing experiments. As 
shown in Fig 4.5 A and B, the matrices were coated uniformly forming a rough surface. At 
higher magnification, it can be observed that the morphology of the coated matrices was not 
very different from those of the naturally prepared matrices. The untreated matrix with alcian 
blue staining for GAGs is shown in Fig 4.5C whereas the fact that treatment with heparinase 
I, II, III and chondroitinase ABC has removed the secreted GAGs can be seen in Fig 4.5D. 
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Figure 4.5: Characterization of modified matrices. (A-B) SEM analysis of the coated 
matrices at lower (scale bar = 50µm) and higher (scale bar = 10µm) magnifications 
respectively (C-D) Alcian blue staining of untreated and GAGs ablated matrices respectively. 
(Scale bar = 100µm). 
4.3.6 Fold Expansion for Ablation and Add-back Experiments  
Since MX2 was the best matrix, they were further modified to find out the component 
mainly responsible for HSPC expansion. As shown in Fig. 4.6A-C, the untreated MX2 
showed the best fold increases for total and lineage specific cells and any type of 
modification decreased their efficiency. However, MX2 TX was the second best matrix for 
CD34+CD45lo (p ≤ 0.001) and CD34+CD133+ (p ≤ 0.01) lineages representing 20% and 17% 
of total viable cells respectively (Fig. 4.6B). 
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Figure 4.6: Fold expansion of HSPCs for ablation and add-back experiments.  
(A) Represents the fold expansion of the HSPC subpopulation based on surface markers. (B) 
Represents the percentage of the three HSPCs sub-populations by surface markers as 
compared to total cell expansion. (C) Represents the fold expansion of the CFUs compared to 
the fold expansion for total cells. Statistical analysis was done using One-way ANOVA (* p 
≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.005). Results are based on an average of three individual 
experiments with triplicates of each condition within an experiment. 
The expansion of all HSPC sub-populations was significantly decreased in both MX2-
GAGs and MX2 Sol conditions. As expected, the expansion of all CFUs was significantly 
higher in untreated MX2 (p ≤ 0.001)  (Fig. 4.6C) followed by MX2 TX. Surprisingly, MX2-
GAGs showed better expansion of CFU-GMs (p ≤ 0.001) in contrast to the fact that fold 
increase of CFU-GEMMs (p ≤ 0.01) and BFU -Es (p ≤ 0.001) was significantly higher on 
MX2 TX matrices. The solubelized matrix, MX2 Sol was the least efficient in expanding 
HSPCs. 
4.3.7 Fold Expansion for Mixing and Recoating Experiments 
Fig. 4.7A-C shows the average fold increases in total and lineage specific cells from 
three recoated experiments. Negative control, C1 shows significantly less expansion of all the 
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lineages. Pure MX1c matrix still showed better expansion of CD34+CD38- cells (p ≤ 0.01) 
followed by the mixed MX5c matrix representing 24% and 22% of total viable cells 
respectively (Fig. 4.7B). The fold increase and purity of CD34+CD45lo (p ≤ 0.001) and 
CD34+CD133+ (p ≤ 0.001) lineage cells was greater on pure MX2c matrices, representing 
18% and 16% of the total viable cells respectively (Fig. 4.7B), showing similar patterns 
compared to the naturally formed matrices (Fig. 4.3B). Following the earlier trend, (Fig. 
4.4A) the expansion of all CFUs was significantly higher in MX2c (p ≤ 0.001) (Fig. 4.7C).  
MX2c showed the most significant expansion of CFU-GEMMs (p ≤ 0.001), however, 
the fold increase of CFU-GMs (p ≤ 0.01) and  BFU-Es (p ≤ 0.001) was also significantly 
greater on MX2 than on other matrices. Mixed MX6c matrix was second best condition for 
expansion of all CFUs, however, the minor component seems to be contributing in negative 
way. Although the results of the functional analysis of the expanded cells were different from 
that of FACS it can be suggested that mixed matrices MX5c and MX6c expanded the cell 
lineages similar to their higher ratio matrices (MX1c for MX5c and MX2c for MX6c) only 
less efficient in comparison to the pure matrices. 
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Figure 4.7: Fold expansion of HSPCs for mixing and recoating experiments. 
(A) Represents the fold expansion of the HSPC subpopulation based on surface markers. (B) 
represents the percentage of the three HSPCs sub-populations by surface markers as 
compared to total cell expansion. (C) Represents the fold expansion of the CFUs compared to 
the fold expansion for total cells. Statistical analysis was done using One-way ANOVA (* p 
≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.005). Results are based on an average of three individual 
experiments with triplicates of each condition within an experiment. 
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4.4. DISCUSSION 
Ex vivo expansion of HSPCs on coated or uncoated inorganic substrates and ECM 
components has been reported and reviewed in the literature. These scaffolds in presence or 
absence of the specific growth factors and in the time range of 10 days to 9 weeks expanded 
UCB derived CD34+ to different levels. Reported expansion ranges from an increase of 3 fold 
on Cytomatrix system in the absence of growth factors (Ehring et al., 2003), 3.3-4.8 fold on 
bio mimetic scaffolds (Tan et al., 2010), 6.8 fold on nonwoven fibrous matrices (Li et al., 
2001) and ∼100 fold on FN-conjugated scaffold (Feng et al., 2006) for CD34+ cells. These 
reports have expanded the knowledge about the constitution of the hematopoietic niches and 
they have also provided efficient and practical methods for obtaining large numbers of HSPC 
for research and clinical use (Lund et al., 2009; Miyoshi et al., 2011). However, mimicking 
the interplay between cells and their cytokine rich, tissue-specific environments remains 
relatively rare in the field of tissue engineering (Discher et al., 2009).  
The results of this work have, for the first time, shown that it is possible to expand 
human HSPCs on decellularized biological scaffolds obtained from a BM-derived stromal 
cell line. MS-5 cells with or without exogenous cytokines have been shown earlier to support 
human  HSPC expansion as feeder layers (Kanai et al., 2000; Keller et al., 2002) but, 
expansion of human HSPC has not been achieved on decellularized matrices of either mouse 
or human stromal cells. It has been demonstrated here that stromal cells can significantly 
change the constitution of their matrix and their ability to support HSPC expansion in 
response to O2 levels and osteogenic induction.  Further, preliminary analysis of the stroma 
and has been undertaken to identify matrix components that may contribute to this functional 
difference. Stromal cell matrix proteins have been found to regulate HSPC expansion in 
laboratory conditions (Verfaillie et al., 1999). In this study, the aim was to mimic the 
functions of the endosteal and vascular niches by preparing cell free matrices from MS-5 
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cells that were grown under different O2 concentrations and with/without osteogenic signals. 
Such approach has significant advantages over other traditional method of using single ECM 
protein, as it captures the true complexity of ECM mixed surfaces (Galan et al., 2007). 
The optimized growth factor concentrations for human cord blood HSPC expansion 
ex vivo have previously been established (Broxmeyer et al., 2009; Yao and Hwang, 2007). 
However, in order to clearly identify the impact of the ECM on HSPC growth, the 
concentration of these GF’s was reduced to half of the maximally stimulating levels. 
Although HSPC expansion experiments (in Stemline II media) on all matrices were 
performed at 5% O2, increase of total viable cell number was greater on matrices prepared 
from MS-5 cells grown in 20% O2 (MX2 and MX4) compared to matrices prepared from 
MS-5 cells grown in 5% O2 (MX1 and MX3). In addition, expansion of haematopoietic 
progenitors (CD34+CD45lo and CD34+CD133+) was greater on matrices obtained from MS-5 
cells grown in 20% O2 in the presence of osteogenic factors (MX2). This was also confirmed 
by clonogenic assays, with MX2 matrix showing the greatest expansion of all colony types. 
In contrast, the expansion of cells with a more “primitive” phenotype (CD34+CD38-) was 
greatest using matrices generated at low O2 without osteogenic factors (MX3).  
This data can be interpreted in several ways for the relative assessment of the 
individual and synergistic roles of O2 and osteogenic induction in the hematopoietic niches 
for controlling HSPC expansion. The greater expansion of progenitors on matrices grown in 
higher O2 conditions is consistent with the concept that the vascular niche promotes 
expansion of committed progenitors, while the greater expansion of cells with a more 
primitive phenotype on matrices grown under low O2 conditions is consistent with the 
concept that the hypoxic endosteal niche promotes self renewal  (Jones and Wagers, 2008) 
(Mohyeldin et al., 2010). However, the synergistic effect of high O2 and OGM in promoting 
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expansion of progenitors is less easy to reconcile considering such cells in vivo grow in more 
hypoxic conditions and without osteogenic stimulus.  
The matrix modification experiments were performed to answer two major questions: will 
the recoated matrices retain their functionality, and which component of the matrix is mainly 
responsible for HSPC expansion. It still remains unclear whether the molecular composition 
or the ultra-structure of the matrix plays a greater role in determining the phenotype of the 
cells that comes in its contact (Brown et al., 2010). To understand these concepts, two sets of 
experiments were performed- the recoating and the ablation experiments. In recoating 
experiments, coated MX1 and MX2 matrices were spun in pure forms (MX1c and MX2c 
respectively) as well as by mixing MX1:MX2 in the ratio of 4:1 (MX5c) and MX2:MX1 in 
the ratio of 4:1 (MX6c). The results demonstrated that the matrices can be recoated and they 
retain their activity. Since an unmanipulated MX2 was not available in those experiments, it 
is not entirely clear whether all activity was retained, or whether there was some loss. 
Nevertheless, this observation and the fact that MX6c still looks a lot like pure MX2c (albeit 
with some loss of CFU expansion) is a strong validation of the primary data (Fig 4.7A-C). 
MS-5 cells are well known to produce GAGs (Drzeniek et al., 1997) and earlier studies 
have also suggested that GAG metabolism is important in the interaction of HSCs and 
stromal cells (Luikart et al., 1990; Mazzon et al., 2011). Aggrecan, versican, neurocan, and 
Bcan are chondroitin sulfate proteoglycans of the ECM. Their interactions with cell surface 
proteins, as well as with chemokines such as CCL8, CCL5 and lymphotactin, play important 
role in cell adhesion (Kinsella et al., 2004).To confirm this, MX2 matrices were treated with 
heparinase I, II, III and chondroitinase ABC. Heparinase and chondroitinase are heparin 
sulfate and chondroitin sulphate degrading enzymes that cleave GAGs chains (Manton et al., 
2007). The ablation results showed that MX2 activity can be largely ablated by removal of 
GAGs (MX2-GAGs) (Fig 4.6A-C) confirming the results of Cool’s lab that suggested that 
Assessment of the Ability of Cell Free Matrices to Support HSPC Expansion 
96 
 
GAGs secreted into the solution, by stromal cells, have the capacity to support hematopoietic 
cytokines in the maintenance and expansion of HSCs (Bramono et al., 2011). However, it is 
also worth mentioning that these enzymes could have affected the distribution and 
organisation of other proteins too resulting in low expansion of HSPCs. 
As it was evident from the proteomics analysis that the matrices still had cellular proteins, 
they were treated with TritonX-100 to further remove cellular components (Reing et al., 
2010). The presence of cellular debris has been earlier shown to elicit negative downstream 
effects upon remodeling (Brown et al., 2009). However, when present in sufficiently small 
quantities, they were functionally harmless in vivo (Daly et al., 2009). From the results, it is 
evident that MX2 TX showed lesser HSPC expansion as compared to untreated MX2 (Fig 
4.6A-C). However, it cannot be assumed that TritonX-100 is only removing cellular residues 
as the effect of TritonX-100 on the decellularized scaffolds has been quite controversial. 
Some studies have shown that TritonX-100 treatment retains GAGs and growth factor 
contents (Brown et al., 2009; Reing et al., 2010), while others have used it for GAGs 
solublization (Yanagishita, 2001; Yanagishita et al., 2009). MX2 TX appears to retain 
significant BFU-E activity, suggesting that this is mediated by a different mechanism, though 
GAGs removal totally ablates the BFU-E expansion. This is in accordance with Drzeniek’s 
results that GAGs expression is induced during early erythroid differentiation of multipotent 
HSCs (Drzeniek et al., 1999). The mechanism by which TritonX-100 treatment of matrices 
results in the loss of expansion therefore remains unclear. 
HSPC expansion was least in MX2 Sol condition suggesting that it is the diverse 
combination of both the structural and the functional components present within ECM 
scaffolds that accounts for their functionality. 
The in vitro results indicate expansion of progenitor populations on MS-5 derived 
extracellular matrices. This is in itself of potential clinical value, since these cells may be 
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indicative of increased short term repopulating capacity. However, it is not possible to predict 
the capability of the expanded cells to support long term repopulation of all hematopoietic 
lineages. Further, since experiments have been performed only with the MS-5 cell matrices, it 
cannot be assured that experiments done on other matrices would give similar results. Hence, 
future aspects of this work would include investigating the role of the candidate proteins 
suggested by proteomics analysis on HSPC expansion, conducting SCID mice repopulating 
cell (SRC) assays and testing the capability of matrices from other cell lines to support HSPC 
expansion. Additional studies should also explore ablation of the identified factors from these 
matrices to determine whether they were critical to HSC expansion. These matrices can also 
be added back to see if the stem cell supportive effect was due to the components of these 
matrices or it was the due to the morphological property of these scaffolds. 
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5.1 OVERVIEW 
The fundamental property of any stem cell is its ability to retain a balance between the 
two basic cell fates i.e. self-renewal vs. differentiation. The mechanisms that regulate the 
determination of these two cell fates operate from both within the stem cells and through 
signals from their external microenvironment (Ding et al., 2012). HSCs utilize similar 
mechanisms in controlling their survival and differentiation, and their microenvironment 
which is primarily composed of stromal cells, plays a significant role in it. Stromal cells are a 
heterogeneous population of cells of mesenchymal origin that includes reticular endothelial 
cells, fibroblasts, chondrocytes, adipocytes, and osteogenic precursor cells.  In combination 
with one another, stromal cells provide the stem cells with growth factors,  cell–cell  contacts 
and signaling, anchorage to matrix proteins and many other positive and negative stimuli for 
their survival, migration and differentiation (Ellis and Nilsson, 2012). A similar population of 
mixed stromal cells was replicated  in vitro when BM cells were cultured under the 
appropriate conditions and used for HSPC expansion (Hammoud et al., 2011).  In another 
approach to mimic the  stem cell microenvironment, cell free matrices were used to expand 
several cells including MSCs (Chen et al., 2007), neuronal cells (Aizman et al., 2009), 
osteogenic cells (Evans et al., 2010) and hepatic cells (Shiraki et al., 2011) derived from 
murine ESCs. 
Microarray-based analyses have been employed by a number of groups in human and 
mouse ESCs, neural stem cells (NSCs), MSCs and HSCs, leading to identification of 
commonly expressed genes, called  stem cell molecular signature (Chateauvieux et al., 2007; 
Ivanova, 2002; Phillips et al., 2000; Ramalho-Santos et al., 2002; Yashiro et al., 2009). 
However, studies by Moore et al. have for the first time created a molecular profile of a stem 
cell niche (Moore, 2004). Their biological process oriented database, Stromal Cell Database 
(StroCDB), correlates with the documented stem cell supportive properties of stromal cell 
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lines, suggesting that it may be used to predict genes that are associated with stem cell 
supportive ability that are conserved, at least between mouse and man (Charbord and Moore, 
2005). A similar strategy was used by Bhatia et al., to screen the microenvironmental 
molecular signals responsible for maintaining active and quiescent HSCs by analyzing the 
differential genes expressed in fetal liver and BM stromal cells (Martin and Bhatia, 2005).  
From earlier results of this study, the expansion of UCB derived HSPCs was 
demonstrated on decellularized MS-5 matrices that mimic the complexity of a stem cell 
niche. MS-5 cells were cultured in four conditions with varying O2 levels and osteogenecity 
for matrix preparation and were tested for HSPC support (Fig 2.1B). The expansion of 
committed HSPCs (CD34+CD45lo and CD34+CD133+) was greater on matrices obtained at 
20% O2 in the presence of OGM (MX2) Fig. 4.3A-C, where as those of primitive 
CD34+CD38- was greatest using matrices generated at low O2 without OGM (MX3). This 
result suggested that the constituents of these matrices were responsible for this differential 
regulation of lineage specific HSPC expansion. To explore this hypothesis, several 
components of these matrices were selectively ablated by treating them with heparinase and 
chondroitinase to remove GAGs and tritonX-100. The results showed that MX2 activity was 
largely ablated by removal of GAGs (MX2-GAGs) and MX2 TX showed lesser HSPC 
expansion as compared to untreated MX2 though retaining BFU-E activity (Fig 4.6A-C).  
 Proteomic characterization of MX1-4 matrices (Fig. 3.3) was performed to explain 
the reason behind the differences in this lineage specific expansion of HSPCs on all the 
matrices. Although, this proteomic study helped to identify a few proteins that were 
differentially regulated and that could be linked to the observed differences in the ability of 
those matrices to support HSC expansion, there were a few limitations. Proteins with very 
high molecular weight, like GAGs, could not be detected by this approach. Similarly, the 
detection of lower levels of proteins like cytokines and growth factors was not possible 
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(Baharvand et al., 2007; Lottspeich, 2009). Hence, to get a better understanding of the 
constituents of the matrices involved with HSPC expansion, microarray analysis of the matrix 
producing MS-5 cells was performed. MS-5 cells with or without exogenous cytokines have 
also been shown earlier to support human HSPC expansion as feeder layers (Kanai et al., 
2000; Keller et al., 2002).   
It was reasoned that molecules responsible for expanding different lineages would be 
differentially expressed in MS-5 cells grown at different conditions. Since, the prime interest 
was in the genes involved in expansion of HSPCs, the focus was more on genes that encoded 
ECM and secreted proteins. Apart from comparing the data with already known proteins from 
StroCDB, it was hypothesized that there are yet to be discovered regulators, and that the stem 
cell supportive ability of the matrices prepared from MS-5 cells comes from many interacting 
molecules. These differentially affected genes were also subjected to MetaCore for pathway 
and network analysis. 
5.2 METHODS 
5.2.1 Total RNA Isolation  
High-quality total RNA was extracted and purified from three samples (MX2, MX3 
and MX4) of MS-5 cells grown in different culture conditions of varying O2 gradient and 
osteogenecity using the RNeasy Plus Mini Kit as per the manufacturer’s protocol. In brief, 
culture dishes with MS-5 cells were washed with PBS with subsequent addition of 600 µl of 
Buffer RLT Plus (with β-mecapto ethanol). The culture dish was scraped with a rubber 
policeman and the lysate was passed 5 times through a 20-gauge needle. The lysate was then 
passed through a gDNA Eeliminator spin column. This column, in combination with the 
optimized high-salt buffer, allows efficient removal of genomic DNA. Ethanol was added to 
the flow-through to provide appropriate binding conditions for RNA, and the sample was 
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then applied to an RNeasy spin column, where total RNA binds to the membrane and 
contaminants were efficiently washed away with Buffer RW1 and RPE. High-quality RNA 
was then eluted in 50 µl of diethyl pyrocarbonate (DEPC) treated ddH2O. 
5.2.2 RNA Quality Check and Quantification 
The nucleic acid concentration of the RNA preparation was determined by measuring 
the absorbance at 260 nm using a Nanodrop spectrophotometer ND1000. 50 μg of double 
stranded DNA, 33 μg of single stranded DNA (primers for PCR) and 40 μg of single stranded 
RNA was taken to be equal to 1.0 OD260. Purity was checked by taking the ratio of the 
absorbance at 260 nm to 280 nm. The A260/A280 ratio should be close to 2.0 for pure RNA 
(ratios between 1.9 and 2.1 are acceptable). 
5.2.3 Illimina mRNA Microarray Profiling Assay 
5.2.3.1 Whole-Genome Expression Profiling 
Gene expression profiling was performed by the Australian Genome Research Facility 
(AGRF) Melbourne, Australia. Total RNA from six MS-5 cell preparations, corresponding to 
three conditions of matrix preparation each in duplicate, were labeled and hybridized to 
Illumina's MouseWG-6 v2.0 Expression BeadChips according to manufacturer's protocol 
(http://www.illumina.com/support/literature.ilmn). This chip allows the interrogation of six 
RNA samples in parallel and produces data that can be treated as coming from six 
independent microarrays. Total RNA and labeled cDNA were quantified using Bioanalyzer 
prior to hybridization. The arrays were scanned using Illumina BeadArray Reader and the 
image data was processed by BeadStudio. The raw data output (not normalized) of 
BeadStudio was used for the data processing (Fig 2.4). 
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5.2.3.2 Microarray Data Analysis  
For data extraction, analysis of the array data was performed in R environment 
(RTeam, 2008) with Bioconductor (open source R package for bioinformatics) (www.r-
project.org) (Gentleman et al., 2004). Raw intensities were normalized by the limma package 
using the neqc function, which performs normexp background correction and quantile 
normalization by using control probes, recommended for Illumina and linear models for 
statistical analysis (Ritchie et al., 2007). Probes were filtered if not detected in any sample 
(detection p value, 0.01). Annotation of the Entrez gene IDs to GO (Harris et al., 2004) and 
KEGG terms (Kanehisa et al., 2008) was obtained from “illuminaMousev2.db” library, 
available via the Bioconductor website. The annotation tools can annotate the particular 
gene’s biological function, molecular function, its cellular localization etc. The annotated 
genes of similar features are clustered together which represents their enrichment in a 
population. Gene expression profile was observed in a manner in which a cut off value was 
set as threshold and expression level above that was considered as up-regulated and 
expression level below it is considered as down-regulated. Differentially expressed genes 
were identified using moderated t-statistics with an adjusted p-value <0.05 (Fig 2.4).   
5.2.3.3 Functional Annotation and Pathway Analysis 
Functional annotation in specific gene sets was also assessed using the Database for 
Annotation Visualization and Integrated Discovery (DAVID) (Huang da et al., 2009). Within 
DAVID, the newly implemented Functional Annotation tool was utilized. Given a list of 
genes, this tool uses clustering strategies to collate information from all three Gene Ontology 
categories (Cell Component, Biological Process and Metabolic Function) as well as from 
other sources (SwissProt, BioCarta, KEGG, etc.) in order to extract the most meaningful 
functional and pathway information (Huang da et al., 2009).  
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Table 5.1: Database and Software Programs used for Microarray Analysis. 
S. 
No.  
Name Website 
For functional clustering: 
1 Gene Ontology (GO) 
2 
http://www.geneontology.org/ 
Kyoto Encyclopedia of 
Genes and Genomes 
(KEGG) 
3 
http://www.genome.jp/kegg/ 
BioCarta 
4 
http://www.biocarta.com/genes/allPathways.asp 
National Centre for 
Biotechnology Information 
(NCBI) 
5 
http://www.ncbi.nlm.nih.gov/ 
Swiss Prot 
6 
http://www.uniprot.org/uniprot/ 
Database for Annotation, 
Visualization and Integrated 
Discovery (DAVID) 
For making venn diagrams: 
http://david.abcc.ncifcrf.gov 
7 VENNY 
For identifying microenvironmental molecular signals: 
http://bioinfogp.cnb.csic.es/tools/venny/index.html 
8 Stromal Cell Database 
(StroCDB) 
For localizations, pathways and network analysis: 
http://stromalcell.princeton.edu 
9 GeneGo-MetaCore software 
For associations with ‘Hematopoiesis’ related networks: 
http://www.genego.com/metacore.php 
10 Exploratory Gene 
Association Networks 
(EGAN)  
http://akt.ucsf.edu/EGAN/ 
 
GeneGo-MetaCore software and exploratory gene association networks (EGAN) 
(Paquette and Tokuyasu, 2010) were used for understanding the involvement of the 
differentially expressed genes in a pathway and their interaction with other signaling 
molecules. These software programs enabled the visualization of gene’s presence in a 
pathway, its role and also interaction with other signaling molecules in graphical method 
which can be easily analysed and understood. Process and pathways were selected based on a 
p-value ≤ 0.05. Venn diagrams were created using VENNY software (Fig 2.4) (Oliveros, 
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2007). The list of databases and software used for microarray analysis and their purposes are 
listed in Table 5.1 
5.2.4 Validation of Microarray data 
5.2.4.1 Primer Synthesis  
Quantitative real-time PCR (QRT-PCR) was performed for eight different genes, six 
of which were differentially regulated and two (Ecm1 and Gapdh) were equally expressed in 
all the conditions (Table 5.2). All oligonucleotides used in this study were designed by using 
PRIMER 3 software available online and synthesized by BIOSERVE, Hyderabad. List of the 
primers and their sequences are provided in Table 5.2.  
       Table 5.2: Primers used for QRT PCR validation 
 Cidec For ATGGCACAATCGTGGAGACAGA 
 Cidec Rev  TGAGGGTTCAGCTTGTACAGGT 
 Mmp 13 For AGCCCTATCCCTTGATGCCATT 
 Mmp 13 Rev AGCATCCACATGGTTGGGAAGT 
 Aldh1a1 For AAGGTGGCCTTCACTGGATCAA 
Aldh1a1  Rev AGCAATGTCCAAGTCGGCATCT 
 Anxa1 For TGCCATGAAGGGACTTGGAACA 
 Anxa1 Rev AAGAGCAAGCAAGGCTTTCCGA 
 Ecm1 For TGGCCCACTTTCCTAAACCCTA 
 Ecm1 Rev GGCTTCACCTCTTTCTGGACAA 
 Socs3 For TCAGCTCCAAAAGCGAGTACCA 
 Socs3 Rev AGCTGTCGCGGATAAGAAAGGT 
 Prg4 For GCACTACAGAGCTCTCCTGCAA 
 Prg4 Rev GGTGCAGTCTTTGGAGATGGTGA 
 Gapdh For GCAAGGTCATCCCAGAGCTG 
 Gapdh Rev CCTCAGATGCCTGCTTCACC 
 
For every primer melting temperature (Tm), 3’complementarity, hairpin loop and all 
potential self-annealing sites were checked by using online software 
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(http://www.basic.northwestern.edu/biotools/oligocalc.html). The following criteria were 
taken into consideration while designing the QRT-PCR primers:  
1. Amplicon length: 150-200 bp 
2. Optimal primer length: 20 bases 
3. Tm: 58-60 oC 
4. % GC: 30-80 
5. Last 5 nt at 3’ end should contain no more than 2 (G+C) residues 
5.2.4.2. Reverse-Transcription Reaction or cDNA Synthesis 
Reverse transcription (RT) was performed with oligo dT using an RT-PCR kit as per 
the manufacturers’ instructions. RT was carried out in a final concentration of 5 mM 
magnesium chloride; 1 mM each of dNTPs; 1X PCR buffer; 1 unit RNase inhibitor; 2.5 units 
superscript IIITM and 1-2 µg total RNA. A master mix was prepared (20 µl per reaction) and 
final volume was made up with DEPC-treated water. 1-2 µg RNA and Oligo dT were 
incubated at 65°C for 5 minutes. RT was carried out in a step cycle comprising extension at 
42°C for 1 hour. Inactivation of RT enzyme was done at 75°C for 15 minutes further cDNA 
was stored at -20°C. 
5.2.4.3. Polymerase Chain Reaction (PCR) 
A conventional PCR was carried out with the heated lid option in a thermal cycler to 
check the purity and conditions for quantitative real-time PCR (QRT-PCR). For PCR 
amplification, 10 ng of MX2 cDNA template was used as template in a 50 µl reaction. PCR 
was done in a reaction mix containing 1X PCR buffer from Invitrogen (10 mM Tris-HCl, pH 
9.0; 50 mM KCl; 1.5 mM MgCl2; 0.001% w/v gelatin), 200 µM each of the dNTPs, 10 pico 
mole each of primers and 1 unit of Taq DNA polymerase (Invitrogen). 35 step cycles were 
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carried out after initial denaturation at 95°C for 10 minutes. Each step cycle consisted of 
denaturation at 95°C for 30 seconds, annealing at 58ºC for 30 seconds and extension at 72°C 
for 1 minute. A final extension was given at 72°C for 7 minutes for completion of truncated 
products. After adding appropriate amounts of DNA loading dye, the DNA samples were 
resolved on 1.0 % agarose gels made in 1X-TBE. For visualization, 0.25 μg/ml of ethidium 
bromide was added to the gel while preparing. 1X-TBE was used as running buffer. 
5.2.4.5. Quantitative Real-Time PCR 
QRT-PCR assays were performed on the ABI prism 7900 HT sequence detection 
system (ABI) as per the manufacturer’s instructions. A typical 10 µl reaction mixture 
contained 5 µl of 2x SYBR green dye (ABI), 1 pm of each primer, 1 µl of template and 2 µl 
of distilled water. All reactions were set up, in triplicate, in a 384-well optical reaction plate. 
The PCR conditions were as follows: 95 ºC for 10 minutes, 95 ºC for 15 seconds, 58ºC for 30 
seconds and 72 ºC for 30 seconds for 40 cycles. All the reactions were analyzed using the 
software (SDS 2.3) provided with the instrument.  The relative expression of the genes was 
calculated by using the formula 2-∆∆Ct using Gapdh as a normalizer. The values reported are 
the mean of three biological replicates. The standard deviation from the mean is shown as 
error bars in each group. The generation of amplification plots, standard curves and 
dissociation stage analysis was as per the manufacturer’s protocol. The calculation of the 
melting temperature of each amplicon (TM) was done directly by the software provided. 
5.3 RESULTS 
5.3.1 Venn Diagram Analysis of the Data 
Gene expression profiling of MS-5 cells was performed corresponding to three 
conditions of matrix preparation (MX2, MX3 and MX4) using Illumina's MouseWG-6 v2.0 
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Expression BeadChips. These arrays contain more than 45,000 probes which collectively 
interrogate all RefSeq annotated mouse genes (>26,000 genes) and ~ 7,000 RefSeq predicted 
genes. The purpose of this experiment was to identify candidate genes from MS-5 cells that 
may have helped in HSPC expansion when they were cultured on decellularized MS-5 
matrices (Chapter 3 and 4).  
As in the proteomic study (Chapter 3), MX3 was taken as the baseline as MS-5 cells 
were originally maintained in the lab at 5% O2. Since these cells were grown in varying 
conditions of O2 and osteogenecity, it was decided to do the whole analysis by focusing on 2 
steps (Fig 5.1): 
Step 1: MX3 vs MX4 showing the “effect of change in O2”.  
Step 2: MX3 vs MX2 showing the “effect of both, change in O2 and addition of OGM”. 
 
Figure 5.1: Graphical representation of the Venn diagram for differentially expressed 
genes in step 1 and 2. A shows the number of total affected genes whereas B and C the 
number of Up- and Down- regulated genes respectively. The numbers in red color represents 
common genes between two steps, while that in black color represents number of genes 
unique to that step. 
Analysis of Gene Expression in MS-5 Cells in Response to Changes in O2 Levels and Osteogenic Stimulus 
109 
 
The analysis by VENNY software showed that out of total 172 significantly affected 
genes (1.5 fold difference) in Step 1, 24% genes were up regulated and 76% were down 
regulated with 6 genes having more than 10 fold difference. In step 2, a total of 790 genes 
were significantly affected with more than 1.5 fold difference, out of which, 39% genes were 
upregulated and 61% were down regulated with 11 genes in former and 30 genes in later 
having more than 10 fold difference (Fig 5.1). 
5.3.2. Microarray Validation  
5.3.2.1 Validation by QRT-PCR 
In order to validate the microarray results, QRT-PCR was performed for Cidec, 
MMP13, Aldh1a1, Anxa1, Ecm1, Socs3, Prg4 and Gapdh. Two of these genes, Ecm1 and 
Gapdh were equally expressed in all the conditions (Table 5.2).  
 
Figure 5.2: Checking the conditions for RT-PCR primers. Single PCR products 
demonstrate the purity of all the primers at an annealing temperature of 57°C. 
The quality of the primers and the annealing conditions were checked by performing a 
routine PCR with MX2 cDNA. Fig 5.2 shows that the all primers gave single band product 
thus proving their purity and also that they annealed best at 57°C. For QRT-PCR, the 
reactions were performed in triplicates with Gapdh as an internal control and the fold 
difference thus calculated showed a similar pattern as that of microarray fold differences (Fig 
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5.3). The level of Ecm1 did not show any significant difference in any condition, both in 
microarray and QRT-PCR analysis.  
 
 
B. Comparison of fold differences in MA and RT values  
Validations Step 1 Step 2 
Genes MA RT MA RT 
Cidec -20.31 -68.30 -7.57 -2.85 
MMP13 -1.79 -4.61 -18.39 -39.32 
Aldh1a1 1.27 1.76 7.41 27.70 
Anxa1 1.28 1.73 2.00 8.61 
Ecm1 -1.42 -1.47 -1.11 -1.32 
Socs3 1.98 2.09 -1.66 -1.38 
Prg4 -1.75 -1.26 3.93 11.33 
 
Figure 5.3: Gene expression by QRT-PCR. (A) Shows the relative fold difference as 
compared to MX3 conditions. (B) Shows that the pattern of fold difference for microarray 
(MA) and QRT-PCR (RT) for both step 1 and 2 were same. Statistical analysis was done 
using one way anova where *** denotes p≤0.001 and * denotes p≤0.05. Error bars show the 
standard error.   
5.3.2.2 Microarray Validation against Other Databases 
Since MX2 was the best matrix for expanding committed HSPCs, the genes expressed 
in this condition were compared to the StroCDB database that compares the genes expressed 
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in HSPC supportive and non-supportive cell lines. It is worth mentioning here that these 
genes were also present in the other two matrices. The design of StroCDB is oriented toward 
the biological process of stem cell regulation by the microenvironment (Hackney et al., 
2002). The focus was more on cytoskeleton, secretory and ECM proteins, i.e., molecules that 
are likely to function in direct communication between stem cells and stroma as shown in 
Annexure Table 5.1. Network analysis of the genes that matched to StroCDB by MetaCore 
software showed the interactions among these genes and their localizations as shown in Fig 
5.4. 
Most affected MetaCore pathways in the above list were cell adhesion pathways like 
cell-matrix interactions, integrin-mediated cell-matrix adhesion, integrin priming and 
leucocyte chemotaxis which are well known to regulate HSC niche involving β-Ig-H3, 
Lamr1, Col5a3, MMP-9, Timp1, Collagen V, Adam9, Vitronectin, Nidogen-2, Fibulin-1, 
Stromelysin-1, MMP-13, Col16a1, Layilin, Adam-Ts9, Aggrecanase-1, Col5a1, Versican, 
Timp4, Ecm1, Col1a2, Collagen III, Decorin, Α-Actinin, Rhg7, Tensin, Vcam1, Ip3 
Receptor, Gro-2, Camk II, Rock, Gro-1, Icap-1, Ccl2 and Ccl13 genes (Amalinei et al., 2007; 
Guilak et al., 2009; Umemoto et al., 2012). Genes like Annexin II, C-Abl, Rock2, Alpha-
Actinin, Cortactin, Myh9, Tensin, Gelsolin, Myhc, Mylk1, Rock, Filamin, Sdf-1, Limk1, 
Profilin, Actin, α-Actinin, Rhg7, Lygdi, Vimentin, and Mlck were also involved in 
cytoskeleton remodeling pathways  (Challen et al., 2010; ter Huurne et al., 2010). 
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Figure 5.4: Network analysis of the niche regulating genes from StroCDB database that were expressed by MX2 cells. The ECM related 
and secretory genes were mainly involved in MMP-9, MMP-13, Stromelysin-1, HGF receptor and Aggrecanase-1 related pathways. Red lines 
show the activation while the green lines depict inhibition and, black line no change or unspecified. Red ovals show the presence of most 
commonly studied genes in HSC regulation. Blue and orange ovals denote the presence of different proteoglycans and growth factors/cytokines 
in our matrix producing cells. Green ovals indicate the genes that were previously identified using proteomics approach and the yellow ovals are 
the genes that are validated using QRT-PCR.  
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Developmental pathways involved in hematopoiesis, such as “regulation of 
angiogenesis” and “positive regulation of cell proliferation” were also affected by genes like 
Annexin II, Nf-Kb, Ednra, Il-15, MMP-9, Endothelin-1, Osteonectin, Ip3 receptor, VEGF-A, 
Il-6, Hgf, Pleiotrophin (Osf1), Timp1, Fgf7, Fgfr2, Glypican-1, Igf-1, Igf-1 receptor, Hgf 
receptor (Met), Tob1 and Mlck (Butler et al., 2010; Efimenko et al., 2010; Jung et al., 2011). 
Four of these genes were previously identified using proteomics approach (Chapter 3) and 
another five were validated using QRT-PCR (Fig 5.4). 
5.3.3. Functional Analysis Based on Localizations 
Fig 5.5 shows the top 15 cellular localizations of the differentially expressed genes in 
step 1 and 2 as analyzed by MetaCore. It is to be noted that top 7 groups in this analysis were 
ECM related except “cytoplasmic part” which is 5th most significant localization affected. 
This also explains the differences in the lineage specific HSPC expansion on each matrix 
prepared by decellularizing these cells. 
Upon addition of the above gene groups, ECM related genes accounted for 21% (step 
1), 16% (Step 2), 26% (commons for step 1 and 2) and 10% (unique to step 2) of the total 
genes affected as shown in Annexure Table 5.2. 
 The most significant HSC microenvironment-related genes that were upregulated 
either in step 1 or 2 were Angpt2, which supports the stemness of HSCs in the BM niche  
(Udani et al., 2005), annexin A1, which modulates monocyte-endothelial cell interaction 
(Perretti et al., 2002; Yang et al., 2009), Ctla2a, which is responsible for controlling 
embryonic erythropoiesis (Redmond et al., 2011) and endothelin 1, a ligand that has a 
physiological role in the vascular niche (Nikolova et al., 2007). Growth differentiation factor 
(Gdf15), which is a TGF-β superfamily member and is expressed in erythroid differentiation 
and Vcam1 (an adhesion molecule in HSC niche) were also upregulated in MX2 along with 
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proteases like Mcpt8 and Timp4 that has been shown to induce transition of HSCs from a 
quiescent state to an active cycling state and hence are important constituents of 
hematopoietic niches (Lambert et al., 2004; Lunderius and Hellman, 2001; Tanno et al., 
2010).  
Among the down regulated genes in step 1 or 2, some important niche related genes 
were vitronectin and collagens that are known ligands present in ECM (Alberto R and 
Alejandro, 1988; Philp et al., 2005). Matrix metalloproteinases (MMPs) like MMP3, MMP9 
and MMP13 that degrade ECMs were also down regulated in both step 1 and 2 (Amalinei et 
al., 2007). MMPs also act as shedases, cleaving the ECMs and making growth factors 
available to HSCs. MMP9 also serves a similar purpose in the niche by releasing soluble Kit-
ligand (sKitL), mobilizing HSCs from the quiescent to proliferative niche (Hattori and 
Tashiro, 2010).  
However, “a disintegrin and metalloprotease with thrombospondin motifs” (Adamts) 
like Adamts12, Adamts4, Adamts7 and Adamts9, that are inhibitors for MMPs and also 
responsible for processing membrane-bound precursor proteins such as notch, delta and Hb-
Egf, showed lower expression in step 2 (Amalinei et al., 2007; Roy et al., 2006). Adamts4 
has been shown to break down aggrecan during ossification (Djouad et al., 2007). 
Osteopontin (Spp1), required for regulation of inflammation, cell adhesion and angiogenesis 
(Pedemonte et al., 2007) and Angptl4 protein that stimulates ex vivo expansion of HSPCs, 
were also found in low quantity in MX2 (Zhang, 2006). The down regulated category in both 
step 1 and 2 also included chemokines like Cxcl1, Cxcl12 and Cxcl14 that influence 
migration and survival of HSPCs (Huang et al., 2009; Li and Wu, 2011). 
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Figure 5.5: Top 15 cellular localizations of the differentially expressed genes in step 1 
and 2. The p value (log) is shown by orange colour for step 1 and blue colour for step 2. 
5.3.4. Pathway and Network Analysis 
The ECM related genes listed in Annexure Table 5.2 were submitted to MetaCore 
for pathway analysis. The canonical pathway maps represent a set of about 650 signaling and 
metabolic maps covering human biology (signaling and metabolism) in a comprehensive 
way. All maps are drawn from scratch by GeneGo annotators and manually curated and 
edited. Upon combining the pathway maps, the most significantly affected groups were 
related to cell differentiation, calcium signaling, apoptosis, hematopoiesis, immune system 
response, inflammatory system response, mitogenic signaling, neurotransmission, oxidative 
stress regulation, tissue remodeling and wound repair and vascular development or 
angiogenesis. A list of pathways from some of these groups is shown in Annexure Table 5.3. 
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Figure 5.6: Cell adhesion ECM remodeling pathway. Experimental data from both step 1 and 2 are linked to and visualized on the map as 
thermometer-like figures. Up-ward thermometers have red color and indicate up-regulated signals and down-ward (blue) ones indicate 
down-regulated expression levels of the genes. 
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“ECM remodeling” pathway was the most significantly affected pathway related to 
cell adhesion (Fig 5.6). ECM remodeling in the HSC niche is involved in physiological 
processes, such as development, proliferation, cell motility and adhesion and angiogenesis 
(Bogaczewicz et al., 2006; Daley et al., 2008). MMPs are a family of proteolytic enzymes 
that degrade various components of the ECM in these processes. Cleavage of ECM proteins 
by MMPs also releases ECM-bound growth factors. Type I collagen degradation that is 
mediated by MMP1 (upregulated in step 2) is necessary for HSC migration (Sluijter et al., 
2006). MMP3 (stromelysin-1) and MMP13, down regulated in both step 1 and 2, degrade 
ECM proteins, e.g., Secreted protein acidic cysteine-rich (Sparc) (also known as osteonectin) 
and collagen respectively (Yu and Han, 2006).  
MMP9, which cleaves collagen, aggrecan and versican was also down regulated in 
step 2 (Hattori and Tashiro, 2010; Page-McCaw et al., 2007). Insulin-like growth factor 
binding protein 4 (Ibp4) fragments lose binding capacity to insulin-like growth factors 1 and 
2 (Igf-1 and Igf-2), thereby increasing bioavailability of Igf-1 (down regulated in step 2) and 
Igf-2 (upregulated in step 2). The latter two activate Igf receptors that are involved in the 
signaling implicated with cell growth, proliferation and survival (Rehault et al., 2001). 
Oncostatin M (OSM) is a multifunctional cytokine produced by activated T 
lymphocytes, monocytes, and microglia in BM (Tanaka and Miyajima, 2003) (Fig 5.7). It is 
structurally and functionally related to the subfamily of hematopoietic and neurotrophic 
cytokines known as the interleukin 6 (Il-6)-type cytokine family (Minehata et al., 2006). 
OSM stimulation of the JAKs/STATs signaling pathway in primary chondrocytes leads to 
induction of important element regulation of this process - e.g., MMP1 (upregulated in step 
2) and TIMP1 (down regulated in step 2).  
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Figure 5.7: Oncostatin M signaling via JAK-Stat signaling. Experimental data from both step1 and 2 are linked to and visualized on the map as 
thermometer-like figures. Up-ward thermometers have red color and indicate up-regulated signals and down-ward (blue) ones indicate down-regulated 
expression levels of the genes. 
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It also participates in induction of epithelial-to-mesenchymal transition (EMT) 
pathway (Chagraoui et al., 2003; Minehata et al., 2006).  Earlier studies have also shown the 
active involvement of EMT in the fetal liver HSC microenvironment (Chagraoui et al., 2003). 
Binding of OSM to OSM receptor (downregulated in step 2), induces the Janus kinases 
(JAK)/ signal transducer and activator of transcription (STAT) signaling pathway (Zhang et 
al., 2003). Suppressor of cytokine signaling 3 (SOCS-3), also downregulated in step 2, is an 
inhibitor of oncostatin M signals. It regulates cell growth, e.g., via vascular endothelial 
growth factor A (VEGF-A) a quintessential angiogenic signal,  which is down regulated in 
step 2 (Repovic et al., 2003). Study by Kinoshita et al demonstrates that signals exerted by 
OSM induced hepatic differentiation, which in turn terminate embryonic hematopoiesis 
(Kinoshita et al., 1999) (Fig 5.7).  
Networks affected in step 1 and 2 were further analyzed by using about 110 cellular 
and molecular processes whose content is defined and annotated by GeneGo. Each process 
represents a pre-set network of protein interactions characteristic for the process along with 
their localizations. Some of the significantly affected networks by the above mentioned genes 
are listed in Table 5.3, however, the full list of top 15 statistically significant networks is 
shown in Annexure Table 5.4.  
Table 5.3: Statistically significant ECM related networks.  
S 
No. 
Networks pValue 
Step 1; Step 2 
Ratio 
Input/Known 
1 Cell adhesion_Platelet-endothelium-
leucocyte interactions 
8.568e-2; 2.385e-6 25 175 
2 Development_Regulation of angiogenesis 4.407e-5; 6.070e-5 28 223 
3 Development_Blood  vessel morphogenesis 1.382e-3; 5.497e-4 25 228 
4 Cell adhesion_Cell-matrix interactions 1.568e-2; 1.195e-3 23 213 
5 Development_Ossification and bone 
remodeling 
3.713e-3; 2.907e-2 17 157 
6 Development_Skeletal muscle development 1.584e-1; 6.446e-3 16 144 
7 Proteolysis_ECM remodeling 8.640e-3; 2.847e-2 10 85 
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The genes represented in the above list were then put together to trace the most 
represented pathways along with their localizations as shown in Annexure Fig 5.1. The 
network mainly mapped to MMP-9, MMP-13, MMP-1, VEGF-A and stromelysin-1 related 
pathways. Other important affected networks included “regulation of angiogenesis” that 
increases cell proliferation, survival and potentiates the endothelial cell migration (Waugh 
and Wilson, 2008).  
The “Cell-matrix glycoconjugates” network shows the interactions between 
glycosaminoglycan (GAGs) and cell surface proteins, as well as with chemokines, which 
plays an important role in cell adhesion and motility (Beauvais and Rapraeger, 2004; 
Netelenbos et al., 2003). Most of the genes in this network, such as decorin, versican, stabilin 
etc., were down regulated in step 1 and 2, however, laynin and Prg4 were upregulated in step 
2. “Interferon signaling” activates JAK-STAT-independent pathways and also participates in 
the activation of the Socs-1 (Alexander et al., 1999). “Ossification and bone remodeling” 
network helps in regulating the bone matrix (Standal et al., 2004). 
5.3.5. Functional Analysis by EGAN 
EGAN software (Paquette and Tokuyasu, 2010) was used to get a final picture of the 
most represented genes both in up and down regulated categories in step 1 and 2. Fifty most 
represented genes were imported from MetaCore pathway, each from up and down regulated 
groups, to EGAN to relate them to their locations, pathways and networks showing their 
involvement with hematopoiesis, osteogenesis, stem cell niche and other hematopoiesis 
related networks as shown in Fig. 5.8 and Fig. 5.9. 
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Figure 5.8: Up regulated genes in step 1 and 2 and their involvement in hematopoiesis related networks. The resulting network from 
EGAN software was redrawn manually for clarity. Genes shown in orange boxes belong to step 1 where as those in yellow boxes are from step 
2. Genes that were upregulated in both step 1 and 2 are shown in yellow-orange gradient boxes. Red numbers in the green boxes indicate the 
number of genes associated with that term. 
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Figure 5.9: Down regulated genes in Step 1 and 2 and their involvement in hematopoiesis related networks. The resulting network from 
EGAN software was redrawn manually for clarity. Genes shown in orange boxes belong to step 1 where as those in yellow boxes are from step 
2. Genes that were downregulated in both step 1 and 2 are shown in yellow-orange gradient boxes. Red numbers in the green boxes indicate the 
number of genes associated with that term. 
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This network includes ECM and secretory proteins like advanced glycation end-
product receptor (Ager), layilin (Layn), angiopoetin 2 (Angpt2), annexin-1 (Anxa1), 
Col28a1, endothelin-1 (Edn1), gelsolin (Gsn), MMP-1a, mesothelin (Msln), proteoglycan 4 
(Prg4) which is a megakaryocyte stimulating factor, proliferins like Prl2c2 and Prl2c4, 
prostaglandin (Ptgds), S100a1, selenoprotein P (Sepp1), Timp4, vascular cell adhesion 
molecule 1 (Vcam1) and Wnt4 is known to be involved with hematopoiesis through different 
signaling pathways like TGF-β (Challen et al., 2010), Hedgehog (Kiuru et al., 2009), 
Calcium signaling (Calvi et al., 2003) and Wnt signaling pathways (Malhotra and Kincade, 
2009) (Fig. 5.8). 
ECM related and secretory genes down regulated in step 1 and 2 consists of Adamts4, 
Adamts9, Angpt4, Angptl4, Bmp1, Cav1, collagens (Col16a1, Col1a2, Col3a1, Col5a1, 
Col6a2), chemokines (Cxcl1, Cxcl12, Cxcl14, Dcn) and MMP-13, MMP-3, MMP-9 are 
shown to have associations with hematopoiesis in BM. These function as chemokines and 
cell adhesion molecules that help in HSC mobilization, ECM-receptor interaction, chemokine 
signaling (Han et al., 2006; Thorsteinsdottir et al., 2011), calcium signaling (Kawamori et al., 
2010; Nakamura et al., 2010), and Jak-STAT signaling pathways (Kiger et al., 2001; Lee et 
al., 2007) (Fig 5.9).  
5.4 DISCUSSION 
Both positive and negative growth regulating factors act in concert to carefully 
regulate HSC proliferation and lineage commitment in vivo (Park et al., 2012). While much is 
known about the actions of individual hematopoietic growth factors, gaps remain in the 
knowledge regarding the true nature and specific combinations of factors that are required for 
HSC self-renewal, proliferation, and differentiation. Global transcriptomic profiling can be 
used to get a snapshot of the state of the cell in a particular condition. The molecular profile 
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of the AFT024 cell line that supports the ex vivo maintenance of murine and human HSPCs 
has been already published (Hackney et al., 2002; Hackney and Moore, 2005). StroCDB was 
prepared by comparing gene expression profiling of HSC-supportive and non-supportive cell 
lines and has provided insight into the molecular players in the hematopoietic 
microenvironment. This study focused on studying the gene expression profiling of the 
matrix-producing MS-5 stromal cells that mimics the HSC niche. Since the molecular 
identity of the HSC microenvironment is yet unclear, the gene profiling was examined for 
MS-5 cells cultured at 20% O2 with OGM (MX2), 5% O2 without OGM (MX3), 20% O2 
without OGM (MX4), the acellular matrices of which differentially supported HSPC 
expansion. It was hypothesized that common transcripts between MS-5 and AFT024 might 
represent an informatically validated list of HSC regulatory molecules. Hence the public 
StroCDB database (Hackney et al., 2002) , was interrogated against the genes expressed in all 
of the matrices; however, data shown in Table 2 represents the mean intensity of MX2 matrix 
only. A total of 162 such secreted and ECM genes were expressed by these matrix producing 
cell conditions, which are known to be involved in different HSC regulation mechanisms in 
the niche, explaining their ex vivo HSPC supportive behaviour. 
The picture of HSPC regulation by the niche that emerges from this study is complex. 
A large number of interesting gene products have been identified, suggesting that HSC-fate 
choices will be controlled by multi-component molecular networks. As such, the balance of 
self-renewal and differentiation is not likely to be governed by single or few stem cell factors, 
but rather by the integration of many interacting signal inputs. The overall behaviour of HSCs 
may be a property of regulatory networks that owes its essence to the interactive architecture 
of the network rather than to its individual components. Since MX3 was the original 
condition of growing MS-5 cells, the fold change in MX4 and MX2 was calculated by taking 
MX3 as the baseline (step 1 and 2 respectively). The changes in step 1 would be due to 
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increase in O2, whereas, step 2 would depict the changes due to both increase in O2 as well as 
addition of OGM. As can be seen in Fig 5.1, not many genes were differentially affected in 
step 1; however, step 2 resulted in the changes in expression of 790 genes suggesting that the 
addition of OGM with high O2 induced many changes at genetic level.  It is also to be noted 
that 60-70% of the genes in both the steps were down regulated, showing that the O2 and 
OGM stress on the MX3 condition resulted in down regulation of most of the genes. The 
microarray data was also validated by QRT-PCR for eight differentially expressed genes 
from the three conditions.  
8430408G22Rik, also known as Depp (decidual protein induced by progesterone), 
tops the list of upregulated candidate genes in step 2, with 21.55 fold difference. Depp is a 
hypoxia related gene expressed in endothelial stromal cells, and is also up-regulated in cancer 
cells where it is involved in notch signaling (Chen et al., 2011). Depp increases the level of 
extracellular signal-regulated kinase (Erk) and regulates the production of various cytokines, 
growth factors and MMP’s (Watanabe et al., 2005). A recent study by Saulnier’ lab has 
demonstrated the regulation of HSC niches by Erk1 (Saulnier et al., 2012), thus raising the 
possibility that Depp could be one of the novel proteins responsible for HSPC expansion seen 
in MX2.  
Stromal proteases like MMP-3 (-43.74 fold), and MMP-13 (-34.34 fold) that degrade 
ECMs were among the most down regulated genes in step 2 (Amalinei et al., 2007). MMPs 
act as both positive and negative regulators for HSCs (Ortega et al., 2003). These shedases 
cleave ECMs, make growth factors available to HSCs; however, cleavage of HSC supportive 
ligands like notch ligand delta-like1 results in negative regulation of hematopoiesis (Jin et al., 
2011).  
Functional analysis based on localization shows that the most affected groups in both 
the steps were ECM related, consistent with the observed differences in the lineage specific 
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HSPC expansion on each matrix prepared from these cells. The group ‘ECM and secreted 
proteins’ i.e., genes of the matrices that would have been involved in HSPC expansion, 
accounted for a total of 175 genes. Since both of the matrices, MX3 and MX2 were 
supportive for HSPC expansion, except that the former was better for primitive CD34+CD38- 
cells and the later expanded more committed cells, there has to be a balance between the self 
renewing and differentiation factors expressed by them. Earlier studies by Nakamura’s lab 
have shown the differential expression of ECMs and growth factors/cytokines in different 
population of HSPC supporting osteoblasts (Nakamura et al., 2010). Hence, these matrices 
must have both positive as well as negative regulators of hematopoiesis to manage the 
interplay between quiescence, proliferation and differentiation. 
Most commonly known HSC niche related genes that were upregulated either in step 
1 or 2 were:  
• Angpt2, which is an angiocrine factor that controls vascular morphogenesis 
and homeostasis in the niche through the angiopoietin–Tie system (Butler et 
al., 2010; Mazzieri et al., 2011; Udani et al., 2005);  
• Vcam1 that binds to β1 integrins expressed on HSCs and plays an important 
role in adhesion of progenitor cells in the niche (Nelissen et al., 2000);  
• Chemokines, such as monocyte chemotactic protein 1 (Mcp1; also known as 
Ccl2) (Butler et al., 2010); 
• Proteases like Mcpt8, MMP-1 and Timp-4 (Lambert et al., 2004; Lunderius 
and Hellman, 2001);  
• Ager, which has been shown to elevate aldehyde dehydrogenase (Aldh) in 
HSCs (Kume et al., 2005);  
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• Layilin, which is a receptor for hyaluronan (HA) (Bono et al., 2001) and 
mesothelin that promotes anchorage-independent growth prevents anoikis via 
ERK signaling pathway (Uehara et al., 2008);  
• Proteoglycans like glypican 3, which inhibits chondrocyte differentiation 
(Coller et al., 2006) and Prg-4, an immunomodulatory factor, regulates 
parathyroid hormone actions on HSCs (Novince et al., 2011);  
• Proliferins like Prl2c2 and Prl2c4 have angiogenic effects by positively 
regulating cell motility of stem cells (Hady Felfly et al., 2011);   
• Gdf15 (Park et al., 2012; Tanno et al., 2010) that regulates cell growth, 
senescence and differentiation and is dispensable for maintaining HSCs; 
•  Annexins and S100 proteins constitute two multigenic families of Ca2+ 
modulated proteins implicated in the regulation of both intracellular and 
extracellular activities in the BM (Arcuri et al., 2002);  
• Non-canonical Wnt4 enhances murine HSPC expansion through a planar cell 
polarity-like pathway resulting in diverse consequences like cell 
differentiation, proliferation/survival, migration and adhesion (Heinonen et al., 
2011; Kim et al., 2009) and; 
• Gelsolin, which has a potential impact on the homing functions of stem cells 
(Forsberg et al., 2005). 
Some of the most important down regulated genes in step 1 or 2 with niche related 
functions included: 
• Vitronectin and collagens, well known ligands of ECM (Alberto R and 
Alejandro, 1988; Philp et al., 2005);  
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• Angptl4 protein, which has been shown to stimulate ex vivo expansion of 
HSPCs (Zhang, 2006); 
• Chemokines like Cxcl1, Cxcl12 and Cxcl14 that influence migration, survival, 
and other actions of HSPCs  (Huang et al., 2009);  
• Osteopontin, a highly acidic phosphoprotein with pleiotropic effects, including 
regulation of inflammation, cell adhesion and angiogenesis (Pedemonte et al., 
2007);  
• Small leucine-rich proteoglycan, decorin which is an extracellular modifier of 
Tgf-β/Bmp signaling (Kinsella et al., 2004); 
•  MMP-9, which is important for the recruitment of and mobilization of HSPCs 
from the quiescent BM niche to the proliferative niche. The action of MMPs is 
not restricted to degradation of the ECM; these proteases can modify many non-
matrix substrates, such as cytokines and chemokines (Ortega et al., 2003).  
• Other proteases like MMP-3, and MMP-13 (Amalinei et al., 2007) and their 
inhibitors like Adamts12, Adamts4, Adamts7 and Adamts9 (Roy et al., 2006), 
whose activity must be highly regulated since inappropriate degradation of matrix 
would compromise the integrity of tissues (Huang et al., 2009). 
These genes, when subjected to pathway and network studies, fall into seven main 
categories: tissue remodeling, calcium signaling, hematopoiesis, cell differentiation, vascular 
development or angiogenesis, immune and inflammatory response and oxidative stress 
regulation. HSC related pathways like ECM remodeling, cell matrix glycoconjugates and 
OSM via Jak/Stat and MAPK signaling were down regulated in step 2. GAGs, which are 
involved in both ECM remodeling along with other MMPs and cell matrix glyco-conjugate 
interactions are involved in the establishment of the microenvironment and mediate the 
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interaction between HSCs and stromal cells (Netelenbos et al., 2003). The ablation studies 
described in Chapter 4 confirm an important role of GAGs in the ability of these ECM’s to 
support HSPC expansion.  The biological roles of GAGs in ex vivo culture environment can 
be explained by the fact that GAGs bind to growth factors and these bound factors may 
enhance activity/affinity to their specific receptors on the HSPCs providing a favourable 
environment and modulating their effects on the maintenance and expansion of HSPCs 
(Byron et al., 2010).  
Oncostatin M increases expression of SCF, (a ligand of c-Kit), Vcam-1 (a ligand of 
VLA-4), and secretion of IL-6 and promoted the hematopoietic supportive activity of marrow 
stroma (Oostendorp et al., 2008). On the other hand, Kinoshita et al have shown that signals 
exerted by OSM terminated embryonic hematopoiesis (Kinoshita et al., 1999). Another study 
by the same group demonstrated that OSM suppresses generation of lymphoid progenitors in 
fetal liver by inhibiting the hepatic niche (Kinoshita et al., 2001). However, pathways like 
Wnt signaling and endothelin-1 mediated transactivation of Egfr, which are required for 
enhanced cell cycling and increased proliferation and self-renewal of HSCs were upregulated 
in step 2 (Heinonen et al., 2011; Martin and Bhatia, 2005; Spinella et al., 2002) and could be 
responsible for expansion of more committed HSPCs in MX2 condition. 
In summary, the expression of several molecules has been demonstrated which are 
already known to be involved in HSPC maintenance and survival in vivo in the matrix 
conditions. The focus here was mainly on ECM and secreted molecules known to have 
function in HSC niches and looking for the pathways affected by those differential genes. 
The up regulation of genes involved in Wnt signaling and down regulation of growth factors 
like TGF-β in MX2 matrix was found in this study. Many of the ECM structural proteins 
were downregulated in MX2, but so too were many proteins associated with ECM 
degradation, such as metaloproteinases. One possible interpretation of these findings is that 
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this matrix favors proliferation over quiescence, perhaps by binding HSC’s less firmly, and 
thus supports expansion of committed HSPCs. The interplay between the up regulation of 
GAGs and other ECMs and cytokines like Cxcl12would have helped MX3 matrix condition 
to expand more primitive HSPCs.  
This study may assist in identifying the molecular profile of a stem cell supportive 
microenvironment, which may be of value for both tissue engineering and regenerative 
medicine. However, it is yet to be determined which of the identified proteins are critical for 
HSPC expansion, and at what specific concentrations. Since the array analysis did not 
encompass the complete mammalian genome, the number of up- and down regulated genes 
might be larger than what is described here. In future studies, the functional role of these 
proteins along with their concentration needs to be systematically analyzed. Various 
approaches including small interfering RNA, blocking function antibodies, and 
overexpression can be performed for these molecules to assess their significance in regulating 
hematopoiesis.  
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6.1 OVERVIEW 
The overall goals of this thesis were as follows- 
• To establish in vitro models that would reflect the properties of in vivo HSC niches as 
shown previously by other researchers. 
• To develop efficient methods for lineage specific HSPC expansion. 
• To identify a molecular profile of the stromal matrix that would be the signature of a 
stem cell supportive microenvironment. 
The results indicate that these objectives were achieved to a very significant level. In 
addition to meeting these goals, some further observations were made that are highlighted in 
this chapter. 
6.2. HSPC EXPANSION ON DECELLULARIZED MATRICES 
Future application of HSPCs in clinical therapies largely depends on their successful 
ex vivo expansion i.e. the generation of quality-controlled, off the shelf HSPCs, a "holy grail" 
procedure, that many researchers have been hunting for (Aggarwal et al., 2012; Zheng et al., 
2011). This is particularly true of HSPCs from cord blood, where the number that can be 
collected limits their application. However, despite the efforts put in for over half a century, 
the expansion of the cells responsible for long-term reconstitution has not been met with great 
success (Koestenbauer et al., 2009; Takizawa et al., 2011). A fundamental limitation in all 
HSPC-driven culture systems is the loss of their stem cell properties during culture as they 
undergo senescence or spontaneously commit to a particular cell lineage (Morrison and 
Spradling, 2008). Moreover, with longer incubation periods with cytokines, the cultures 
become depleted in pre-progenitors cells (Banu et al., 2001).  
In this thesis, the expansion of UCB derived HSPCs has been demonstrated on 
decellularized matrices prepared from MS-5 cells grown under varying conditions of 
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osteogenic induction and O2 tension that significantly mimics the endosteal and/or vascular 
niche-like conditions. Application of this system to human UCB cells yielded a rapid (8-day) 
upto 80-fold increase of HSPCs with multilineage ability. These results demonstrate the 
unique nature of these matrices and highlight the importance of the data presented in this 
thesis. 
6.2.1 The Role of Osteogenic Stimulus in Hematopoiesis  
 Maintenance of ex vivo HSPC pool and its differentiated progeny is regulated in an 
orchestrated fashion by a complex network of ECM components, growth factors and other 
elements of their microenvironment. Advances have been made to understand the 
mechanisms regulating in vivo quiescence and proliferation of HSPCs to develop strategies 
for ex vivo expansion. In adults, HSC niches are located in the trabecular bone. The network 
of trabeculae create multiple spaces thereby increasing the surface area where HSCs can 
come in intimate contact with osteoblasts and provide life-long hematopoiesis (Singbrant et 
al., 2011). Earlier studies have shown the presence of at least two types of niches in the BM. 
In vivo trafficking of HSCs by 3D imaging has shown that immature LTR-HSCs are found 
close to the endosteum (endosteal niche), whereas the more mature subsets reside at larger 
distances from the endosteal surface (vascular niche) (ter Huurne et al., 2010). Immature 
HSCs are maintained in a quiescent state within the endosteal niche and differentiate upon 
translocation into the proliferative vascular niche, indicating that osteoblast-specific signaling 
and secretory molecules are essential in maintenance of the immature phenotype of HSCs 
(Ding et al., 2012). From the work in this thesis, it has also been confirmed that osteogenic 
stimuli affects HSC niches.  
Since this project aimed at efficiently replicating the complexities of soluble and 
insoluble secretory components of the hematopoietic niche in vivo, two important factors 
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involved with quiescence and proliferation of HSCs in BM were considered: O2 and 
osteogenic signal. HSCs naturally reside within ECMs, which behave like a biological 
scaffolding material that consists of structural and functional molecules. Besides providing 
structural support to the cells, the ECM also generates a dynamic microenvironment that 
plays a role in modulating numerous cell functions, including cell survival, migration, 
proliferation, and differentiation (Lu et al., 2011). Two decades ago, Langer’s lab pioneered 
the strategy of engineering tissue constructs by culturing cells on or within a matrix (Langer 
and Vacanti, 1993). Since then, tremendous interest has shown in modulating matrix 
properties for tissue engineering applications, as well as understanding the role of matrices in 
the physiological environment (Huang and Li, 2011). In this study, cell free matrices were 
prepared from stromal MS-5 cells that were grown under 5% and 20% O2 concentrations with 
and without osteogenic signals. Such an approach has significant advantages over other 
traditional methods of using single ECM proteins, as it captures the true complexity of ECM 
surfaces (Galan et al., 2007). 
This research has, for the first time, shown that stromal cells can significantly change 
the constitution of their matrix and their ability to support HSPC expansion in response to O2 
levels and osteogenic induction. Although the increase in total cells was equally good on both 
matrices prepared from MS-5 cells grown in 20% O2 (MX2 and MX4), the expansion of the 
committed hematopoietic progenitors (CD34+CD45lo and CD34+CD133+) was greater on 
matrices grown in 20% O2 in the presence of osteogenic factors (MX2). This was also 
confirmed by CFU assays, with MX2 matrix showing the greatest expansion of all colony 
types. Since osteoblasts are key components of the endosteal BM, they are thought to play a 
pivotal regulatory role on HSCs. Earlier studies have also shown that osteoblasts support 
HSPCs in vitro and that co-culture of osteoblasts improves HSC maintenance (Bianco et al., 
2011). The number of osteoblasts have also been shown to correlate with the number of 
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HSCs in vivo, and that the engraftment of HSPCs was improved when osteoblasts were co-
transplanted into the donor (Levesque et al., 2010). These results support the hypothesis that 
osteogenic secretory molecules present in the matrices would have been responsible for 
expanding more HSPCs on MX2.  
6.2.2 The Role of O2 in Hematopoiesis 
The physiological environment of hematopoietic niches in the BM is often hypoxic 
(Dellatore et al., 2008; Mohyeldin et al., 2010). In vivo, the O2 tension in the BM is about 
2%-7%, with a gradient from higher O2 close to the endothelial sinusoids to very low O2 at 
the endosteal surface (Levesque et al., 2010). HSPCs located closer to sinusoids are exposed 
to higher O2 levels and various factors carried in the blood, and are more likely to undergo 
differentiation (Nodwell et al., 2005). It has been demonstrated that in vitro cultures 
maintained in atmospheric O2 (20%) have poorer growth compared to cultures grown in O2 
tensions ranging from 1%-10%. A 5% O2 tension has been demonstrated to enhance the size 
and numbers of HSPCs in semisolid media (Dao et al., 2007; Zhao et al., 2008). Hammoud et 
al. have recently demonstrated that association of co-culture and low O2 concentration 
induces sufficient expansion of committed progenitors and also ensures a better 
maintenance/expansion of HSPCs, pointing to oxygenation as a physiological regulatory 
factor but also as a cell engineering tool (Hammoud et al., 2011). 
Although much is known about the effect of O2 gradient on HSPC expansion, the 
effect of O2 on the niche factors like production of ECM and growth factors by stromal 
microenvironment is still not fully understood. This study has demonstrated that the matrices 
prepared at higher O2 (MX2 and MX4) helped in expanding more cells as compared to those 
that were prepared at low O2 (MX1 and MX3).  
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It was also noted that expansion of more committed HSPCs was achieved on MX2, 
which was stimulated for osteogenic differentiation, whereas, expansion of more primitive 
HSPCs (CD34+CD38-) was greatest on matrices generated at low O2 without osteogenic 
factors (MX3). The greater expansion of progenitors on matrices grown in higher O2 
conditions is consistent with the concept that the vascular niche promotes expansion of 
committed progenitors, while the better expansion of cells with a more primitive phenotype 
on matrices grown under low O2 conditions is consistent with the concept that the hypoxic 
endosteal niche promotes self renewal (Jones and Wagers, 2008; Mohyeldin et al., 2010). 
However, the synergistic effect of high O2 and OGM in promoting expansion of progenitors 
is less easy to reconcile considering such cells in vivo grow in more hypoxic conditions and 
without osteogenic stimulus. 
6.2.3 The Role of ECM and Secretory Factors in Hematopoiesis 
The loss of HSPC properties when cultured in vitro strongly suggests that a critical 
feature of the marrow environment responsible for the maintenance of HSPC stemness is 
missing in standard culture systems (Philp et al., 2005). Despite having ample knowledge 
about the in vivo BM HSC niche, one of the most challenging tasks for researchers today is to 
recreate in vitro niche-like conditions and hence provide more favorable ex-vivo HSPC 
expansion. However, the complexity of the niche exemplified by the various natural materials 
present within the niche may be part of the explanation as to why, so far, few artificial 
materials are in routine use to culture HSPCs or to help in the maintenance of HSPC in vitro 
(Philp et al., 2005; Williams and Nilsson, 2009). Synthetic polymers are limited by their 
biological inertness and the acidic moieties, residual catalysts, and micro-scale particulates 
that accompany degradation (Lu et al., 2011). Since the structural and chemical 
characteristics of 3D matrices offer opportunities for lineage-specific biochemical and 
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biophysical cues to enhance selective differentiation of HSPCs, the choice of material for the 
3D scaffold is very crucial (Lund et al., 2009; Miyoshi et al., 2011). Celebi et al., 
demonstrated that the mixtures of ECMs were better in expanding the HSPCs as compared to 
the coating of single ECM proteins (Celebi et al., 2011).  
To obtain scaffolds mimicking native ECM, cells were specifically removed by a 
decellularization treatment so that the intricate mixture of structural and functional proteins 
and GAGs remain to mimic the regulatory characteristics of natural ECMs and ECM-bound 
growth factors (Discher et al., 2009). Many methods have been developed for 
decellularization (Brown et al., 2011; Hoshiba et al., 2010). The results from this study have 
demonstrated that it is possible to prepare functional decellularized biological matrices from a 
BM-derived stromal cell line, MS-5. It has been shown that stromal cells can significantly 
change the constitution of their matrix and their ability to support HSPC expansion in 
response to O2 levels and osteogenic induction, and preliminary analysis of the stroma was 
undertaken to identify matrix components that might have contributed to this functional 
difference. These matrices were characterized using different biochemical and 
immunostaining methods and the results showed that the decellularization procedure removed 
almost all the cells  but  ECM components such as collagen and ECM bound GAGs, which 
are both important for haematopoiesis (Rodgers et al., 2008), were retained in the residual 
matrices. 
These scaffolds allowed the direct comparison of the effects of ECM generated from a 
single homogeneous cell type under different conditions, which enabled us to identify key 
factors involved in control of HSPC growth and differentiation by proteomic analysis. MX3 
(5% O2, without OGM) was taken as the “baseline” to identify the differentially expressed 
proteins in ECM grown under other conditions. Gelsolin, which has impact on the homing 
functions of stem cells, (Forsberg et al., 2005) was upregulated in MX2. Upregulation of 
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annexin A1 in stroma grown in the presence of OGM (MX1 and MX2) is consistent with its 
role in regulation of osteoblastic differentiation (Park et al., 2007; Zhang et al., 2007). 
Calreticulin, an ECM protein which interacts with thrombospondin and regulates ECM 
production, and vimentin, which is a marker for MSCs that decreases expression with the 
differentiation of the MSCs into osteogenic lineage, were downregulated in both MX1 and 
MX2 (Kim et al., 2005; Satyavani R, 2009). It was also noted that 17 out of 23 proteins were 
downregulated in the MX2 matrix, indicating that osteogenic induction and higher O2 levels 
reduced the expression of proteins that could be inhibitory for HSPC expansion. 
Although these proteomic studies helped to identify a few proteins that were differentially 
regulated and that could be linked to the observed differences in the ability of those matrices 
to support HSPC expansion, there were few limitations, like very high molecular weight 
proteins like GAGs could not be detected by this approach. Similarly, the detection of lower 
levels of proteins like cytokines and growth factors were also not possible (Baharvand et al., 
2007; Lottspeich, 2009). Hence, to verify their roles in HSPC expansion, matrix modification 
experiments were performed to answer two major questions: which component of the matrix 
was mainly responsible for HSPC expansion, and will the recoated matrices retain their 
functionality.  
Studies have suggested that GAGs metabolism is important in the interaction of HSCs 
and stromal cells (Mazzon et al., 2011). To confirm this, MX2 matrices were treated with 
heparinase I, II, III and chondroitinase ABC. Heparinase and chondroitinase are heparin 
sulfate and chondroitin sulphate degrading enzymes that cleave GAGs chains (Manton et al., 
2007). The ablation results showed that MX2 activity can be largely ablated by removal of 
GAGs (MX2-GAGs) confirming the results of Cool’s lab that suggested that GAGs secreted 
by stromal cells have the capacity to support hematopoietic cytokines in the maintenance and 
expansion of HSPCs (Bramono et al., 2011).  
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It was evident from proteomic analysis that the matrices still had cellular proteins, so they 
were treated with TritonX-100 to further remove cellular components (Reing et al., 2010). 
The results showed that MX2 TX showed lesser HSPC expansion as compared to untreated 
MX2, although significant BFU-E activity was retained. However, it cannot be assumed that 
TritonX-100 is only removing cellular residues, as its effect on the decellularized scaffolds 
has been quite controversial (Reing et al., 2010; Yanagishita et al., 2009). Therefore, the 
mechanism by which TritonX-100 treatment of matrices results in the loss of expansion 
remains unclear.  
It is also not yet established whether the molecular composition or the ultrastructure of 
the matrix plays a greater role in determining the phenotype of cells (Brown et al., 2010). To 
understand this, recoating experiments were performed, in which these acellular matrices 
were spun coated on to tissue culture plates. The results demonstrated that the matrices can be 
coated on different surfaces and still retain their functionality. MX6c, which was prepared by 
mixing MX1:MX2 in the ratio of 1:4, behaved a lot like pure MX2c, although with some loss 
of CFU expansion. Since an unmanipulated MX2 was not available in those experiments, it is 
not entirely clear whether all activities were retained, or there was some loss. However, 
HSPC expansion was least in MX2 Sol condition in which the solubelized matrices were 
added directly to the expansion medium, suggesting that it is the diverse combination of both 
the structural and the functional components present within ECM scaffolds that accounts for 
their functionality. 
6.3 MOLECULAR RESPONSE OF STROMAL CELLS TO O2 AND OSTEOGENIC 
STIMULUS 
This part of the work focused on identifying the stromal regulatory factors that may 
have helped in HSPC expansion when cultured on decellularized matrices and hence 
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providing the molecular definition for a stem cell supportive niche. While much is known 
about the actions of individual hematopoietic growth factors, gaps remain in the knowledge 
regarding the true nature and specific combinations of factors that are required for HSC self-
renewal, proliferation, and differentiation. Since the molecular identity of the HSC 
microenvironment is not clear yet, the gene profiles of MS-5 cells cultured at 20% O2 with 
OGM (MX2), 5% O2 without OGM (MX3), 20% O2 without OGM (MX4) were examined. 
The acellular matrices of these conditions differentially supported HSPC expansion. The 
secretory (both soluble and insoluble) molecules of MS-5 cells, that might have been present 
in the decellularized matrices upon induction with osteogenic factors and increase in O2, was 
of more interest. Hence, a 2 step analysis for the microarray data was performed. As done 
earlier in the proteomic study, MX3 was taken as the baseline as MS-5 cells were originally 
maintained in the lab at 5% O2.  
Step 1: MX3 vs MX4 showing the “effect of increase in O2”.  
Step 2: MX3 vs MX2 showing the “effect of both, increase in O2 and addition of OGM”.  
6.3.1 Response to O2 Stimulus (Step 1) 
Increase in O2 for MS-5 cells did not affect the expression of many genes. This can be 
related to the expansion results in which the expansion of HSPC on MX4 was not very 
different from that on MX3, in comparison to that on MX2 except for CD34+CD38- cells. Out 
of total 172 significantly affected genes with 1.5 fold differences in Step 1, 24% genes were 
up regulated and 76% were down regulated. Although, none of these genes had more than 3.9 
fold up regulation, but for down regulated category, 6 genes were found with more than 10 
fold difference., Cfd (-38.61 fold) and Adipoq (-13.22 fold), were among the most down 
regulated genes in step 1, which encode cytokines during adipogenesis, suggesting that 
increase in O2 suppresses differentiation of stromal cells towards adipocytes (Scheideler et 
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al., 2008). Expansion of more primitive HSPCs on MX3 could also be due to the 
upregulation of these genes as adipocytes are known to be residing in HSC niches and hence 
playing roles in HSC maintenance (Omatsu et al., 2010). Although, according to literature 
HSPCs expand better in hypoxic condition (Rehn et al., 2011), not much is known for the 
effect of O2 on other cells present in the supporting niche. The results suggest that not only 
low O2 but the presence of other factors like osteogenecity also act in concert to regulate HSC 
proliferation and lineage commitment in vivo by expressing both positive and negative 
growth regulating factors. 
6.3.2 Combined Response to O2 and Osteogenic Stimulus (Step 2) 
In step 2, a total of 790 genes were significantly affected with more than 1.5 fold 
difference, out of which, 39% genes were upregulated and 61% were down regulated with 11 
genes in former and 30 genes in later having more than 10 fold difference. It is also to be 
noted that 60-70% of the genes in both the steps were down regulated showing that the O2 
and OGM stress on the MX3 condition resulted in down regulation of most of the genes. MS-
5 and AFT024 were also interrogated for common transcripts from StroCDB database 
(Hackney et al., 2002), which is a validated list of HSC regulatory molecules. A total of 162 
such secreted and ECM genes, which are known to be involved in different HSC regulation 
mechanisms in the niche, were expressed by these matrices consistent with their ex vivo 
HSPC supportive behavior. Functional analysis based on localization showed that the most 
affected groups in both the steps were 175 ECM related genes; explaining the differences in 
the lineage specific HSPC expansion on each matrix prepared from these cells. 
Depp, a hypoxia related gene expressed in endothelial stromal cells that regulates 
HSC niches via Erk1, was the most upregulated gene in step 2 (21.55 fold) suggesting that 
Depp could be one of the novel proteins responsible for HSPC expansion in MX2 condition 
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(Saulnier et al., 2012).  However, stromal proteases like MMP-3 (-43.74 fold) and MMP-13 
(-34.34 fold) that degrade ECMs and act as both positive and negative regulators for HSCs 
were among the most down regulated genes in step 2 (Amalinei et al., 2007). These shedases 
cleave ECMs, making growth factors available to HSCs, however, cleavage of HSC 
supportive ligands like notch ligand delta-like1 results in negative regulation of 
hematopoiesis (Jin et al., 2011).  
Since both of the matrices, MX3 and MX2, were supportive for HSPC expansion, 
except that the former was better for primitive CD34+CD38- cells and the later expanded 
more committed cells, there has to be a balance between the self renewing and differentiation 
factors expressed by them. Earlier studies by Nakamura’s lab have shown the differential 
expression of ECMs and growth factors/cytokines in different population of HSPC 
supporting osteoblasts (Nakamura et al., 2010). Hence, these matrices must have both 
positive as well as negative regulators of hematopoiesis to manage the interplay between 
quiescence, proliferation and differentiation.  
Among the most commonly studied insoluble ECM proteins in HSC niches, 
vitronectin and collagens were downregulated in step 2. MMP-9, which is the most important 
protease for the recruitment and mobilization of HSCs from the quiescent BM niche to the 
proliferative niche, was also downregulated in MX2. MMP-3, and MMP-13 (Amalinei et al., 
2007) and  their inhibitors like Adamts12, Adamts4, Adamts7 and Adamts9 (Roy et al., 
2006) were also expressed in lower quantities in MX2. The activity of the MMP’s must be 
highly regulated, as inappropriate degradation of matrix would compromise the integrity of 
tissues (Huang et al., 2009). Hence, some of these shedases like MMP-1 and Timp-4 were 
upregulated in step 2. Annexin1 and S100 proteins that constitute two multigenic families of 
Ca2+ modulated proteins implicated in the regulation of both intracellular and extracellular 
activities in the BM (Arcuri et al., 2002) were also upregulated in MX2.  
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Differential regulation of proteoglycans and GAGs in both of these matrices also 
suggested their role in orchestrating the expansion of different HSPC lineages when co-
cultured on them. Layilin, which is a receptor for hyaluronan (HA) (Bono et al., 2001); Prg-4, 
an immunomodulatory factor that regulates PTH actions on HSCs (Novince et al., 2011); and 
glypican 3, which inhibits chondrocyte differentiation (Coller et al., 2006) were all 
upregulated in MX2. However, decorin, which is an extracellular modifier of Tgf-β/Bmp 
signaling, was down regulated in both step 1 and 2 (Kinsella et al., 2004). The biological 
roles of GAGs in ex vivo culture environment can be explained by the fact that GAGs bind to 
growth factors and these bound factors may enhance activity/affinity to their specific 
receptors on the HSPCs providing a favorable environment and modulating their effects on 
the maintenance and expansion of HSPCs. Among various pathways, the CD44/HA 
interaction has been specifically implicated in the regulation of hematopoiesis (Byron et al., 
2010). While HA does not stimulate proliferation of HSPCs directly, it does interact with the 
cell surface of BM macrophages and triggers their activation (Ellis et al., 2011).  
Several known soluble factors in HSC niche were also differentially regulated in MX2 
and MX3. Angptl4 protein, which have been shown earlier to stimulate ex vivo expansion of 
HSPCs (Zhang, 2006); chemokines like Cxcl1, Cxcl12 and Cxcl14 that influence migration, 
survival, and other actions of HSPCs (Huang et al., 2009; Li and Wu, 2011); and osteopontin, 
a highly acidic phosphoprotein with pleiotropic effects, including regulation of inflammation, 
cell adhesion and angiogenesis (Pedemonte et al., 2007) were downregulated in step 2. 
However, Vcam1, which binds to β1 integrin expressed on HSCs and plays an important role 
in adhesion of progenitor cells in the niche (Nelissen et al., 2000); chemokines and growth 
factors, such as Ccl2 (Butler et al., 2010) and Gdf15 (Park et al., 2012; Tanno et al., 2010) 
that regulates cell growth, senescence and differentiation and is dispensable for maintaining 
HSCs, were upregulated in step 2. Proliferins like Prl2c2 and Prl2c4, which have angiogenic 
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effects by positively regulating cell motility of stem cells (Hady Felfly et al., 2011), were also 
upregulated in MX2 suggesting a mechanism that makes this matrix more proliferative for 
committed progenitors. 
These genes, when subjected to pathway and network studies, fall into seven main 
categories: tissue remodeling, calcium signaling, hematopoiesis, cell differentiation, vascular 
development or angiogenesis, immune and inflammatory response and oxidative stress 
regulation. Genes known to be involved in signaling pathways related to hematopoiesis were 
also differentially regulated among MX2 and MX3. Non-canonical Wnt4 enhances murine 
HSPC expansion through a planar cell polarity-like pathway resulting in diverse 
consequences like cell differentiation, proliferation/survival, migration and adhesion 
(Heinonen et al., 2011; Kim et al., 2009) and Angpt2, which is an angiocrine factor that 
controls vascular morphogenesis and homeostasis in the niche through the ang–tie system 
(Butler et al., 2010; Mazzieri et al., 2011) were upregulated in MX2 cells. However, HSC 
related pathways like ECM remodeling, cell matrix glycoconjugates and oncostatin M via 
Jak/Stat and MAPK signaling were down regulated in step 2 (Netelenbos et al., 2003; 
Oostendorp et al., 2008).  
With the developments in different techniques in visualization, monitoring, and 
manipulating cells and tissues, concepts of stem cells and their behaviour have been 
undergoing significant modifications in recent years, with evidence  that the detailed 
mechanisms underlying stem cell niche functions are extremely variable (Lander et al., 
2012). The work presented in this thesis supports this concept, and points to O2 and 
osteogenic factors as significant variables in helping to define and alter the biological 
functions of niche ECM (Fig 6.1).  
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Figure 6.1: Replication of Hematopoietic Stem Cell Niche. (A) The acellular matrices prepared from MS-5 cells at low O2 (MX3) were closer 
to endosteal niche like conditions as depicted in (B) and hence expanded more primitive CD34+CD38- HSPCs. MX2 matrix, which was 
prepared at higher O2 with osteogenic induction resembled (C) vascular niche like conditions and  hence expanded more committed 
CD34+CD45+ and CD34+CD133+ HSPCs. Hematopoietic Stem Cells (HSC); Multipotent Progenitor Cells (MPP); Differentiated Cells (DC); 
Common Myeloid Progenitor Cells (CMP); Erythroid Cells (EC). 
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• These scaffolds were made up of decellularized ECMs from BM stromal cell line, 
which are already known to be a major component of in vivo BM niches.  
• These matrices were prepared under varying conditions of physiological factors like O2 
and osteogenecity, as have been established in the two BM niches. 
• MX3 condition was closer to endosteal niche like conditions and hence expanded more 
primitive CD34+CD38- HSPCs.  
• MX2 matrix, which was prepared at higher O2 with osteogenic induction resembled 
vascular niche like conditions and hence expanded more committed CD34+CD45+ and 
CD34+CD133+ HSPCs. 
• The tests also found the differential regulation of several ECM and secretory factors 
associated with HSC microenvironment and their relative expression in both MX3 and 
MX2 matrices.  
• Ang-2 which has similar functions like Ang-1, a ligand for Tie-2, was upregulated in 
MX2 condition, whereas Cxcl-12, which is a secreted ligand for CXCR-4, was 
upregulated in MX3 condition.  
• Genes regulating hematopoiesis related signaling pathways like Wnt and Jak/Stat were 
also differentially regulated in MX3 vs MX2. 
• Differential regulation of several proteoglycans and GAGs were also seen in MX2 and 
MX3, thus explaining the loss in their HSPC supportive behavior on treatment with 
Heparinase and chondroitinase and hence the importance of GAGs in the ability of 
these ECM proteins to support HSPC expansion. Dcn was upregulated in MX3, 
whereas Gpc-3 and Prg-4 were upregulated in MX2 condition.  
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6.4. APPLICATIONS OF EX VIVO EXPANDED HSPCS 
Lineage specific expansion of HSPCs from UCB is desirable because of their several 
applications in translational medicine e.g. treatment of cancer, BM failure and 
immunodeficiencies (Tiwari et al., 2012). For over half a century, HSC transplantation (HSCT) 
is being performed by simple infusion into the venous system due to the fluid nature of 
hematopoietic system and the characteristic of HSPCs to home to their BM niches (Zheng et 
al., 2011). UCB is highly enriched in migrating HSPCs and the recent statistics shows that 
about 500,000 cord blood samples were stored worldwide and so far about 20,000 transplants 
have been performed in 2011 (Gluckman, 2011). A list of autologous and allogenic diseases 
that can be treated with HSCT is shown in Table 6.1.  
Table 6.1: List of autologous and allogenic diseases that can be treated with HSCT 
Autologous transplantation Allogeneic transplantation 
Cancers Cancers 
Multiple myeloma Acute myoblastic leukemia 
Non-Hodgkin’s lymphoma Acute lymphoblastic leukemia 
Hodgkin’s disease Chronic myeloid leukemia 
Acute myeloid leukemia Myelodysplastic syndromes 
Neuroblastoma Myeloproliferative disorders 
Ovarian cancer Non-Hodgkin’s lymphoma 
Germ-cell tumors Hodgkin’s disease 
 Chronic lymphoblastic leukemia 
 Multiple myeloma 
 Pure red cell aplasia 
 Juvenile chronic myeloid leukemia 
Other diseases Other diseases 
Autoimmune disorders Aplastic anemia 
Systemic sclerosis Paroxysmal nocturnal hemoglobinuria 
Systemic lupus erythematosus (SLE)  Lesch Nyhan syndrome 
Amyloidosis Fanconi’s anemia 
 Anemiagloboid cell leukodystrophy 
 Blackfan-Diamond anemia 
 Thalassemia major 
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 Sickle cell anemia 
 X-linked lymphoproliferative syndrome 
 Severe combined immunodeficiency 
 Wiscott-Aldrich syndrome 
 Inborn errors of metabolism 
However, UCB derived HSCT is restricted by the low cell number from a single UCB 
unit thereby limiting their use for treatment of pediatric or young adult patients only. The 
toxicity of the HSCT can also be reduced by increasing HSC numbers in transplants, which can 
be done by generating quality-controlled, off the shelf HSPC products via ex vivo HSPC 
expansion (Takizawa et al., 2011). A recent study by Zheng et al., showed that the ex vivo 
expanded HSPCs can overcome the MHC barrier in allogeneic transplantations by modulating 
their immune privilege (Zheng et al., 2011). Similarly, another clinical trial by Zhao et al., 
demonstrated the reversal of type 1 diabetes following immune modulation by UCB derived 
HSPCs (Zhao et al., 2012). Hence, HSCT can be regarded as one of the most important 
medical advances of the 20th century with continuous increase of 10-20% transplantations each 
year (Takizawa et al., 2011), and a greater understanding of the haemopoietic niche is a critical 
step in continuing progress in this field.  
6.5. CONCLUSIONS AND FUTURE RESEARCH 
The picture of HSPC regulation by the niche that emerges from this study is complex. 
A large number of interesting gene products have been identified, suggesting that HSC-fate 
choices are controlled by multicomponent molecular networks. As such, the balance of self-
renewal and differentiation is not likely to be governed by a single or few stem cell factors, but 
rather by the integration of many interacting inputs signal. The overall behaviour of HSCs may 
be a property of regulatory networks that owes its essence to the interactive architecture of the 
network rather than to its individual components.  
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6.5.1. Concluding Results 
1. Decellularized stromal cell matrices can mimic hematopoietic niche like conditions in 
vitro. 
2. Human HSPCs can be expanded on heterologous matrices derived from mouse BM 
stromal cells.  
3. MX2 matrices (20% O2 with OGM) were closer to vascular niche like conditions and 
hence best suited for expanding more committed hematopoietic progenitors (upto 80 
fold). 
4. MX3 matrices (5% O2 without OGM) were closer to endosteal niche like conditions 
and hence best suited for expanding more primitive progenitors (upto 32 fold).  
5. GAGs play an important role in HSPC expansion. 
6.5.2 Suggestive Results 
6. The comparative proteomic analysis of the matrices indicated differential expression 
of proteins, such as Aldh1a1 and Gsn, which have previously been identified as 
playing a role in HSPC maintenance and expansion 
7. Comparative molecular profiling of the stromal cells has revealed the differential 
expression of genes like Wnt, Vcam-1, Cxcl-12, IL-6 etc., known to play roles in 
regulation of HSC niche and a balance of which would have supported the lineage 
specific expansion of HSPCs on their matrices.  
6.5.3 Future Prospects 
The results in this thesis provide a new methodology for the ex vivo expansion of human 
CD34+ cells on heterologous cell free biological scaffolds. They also suggest a model for 
investigating a more specific role of O2 tension and osteogenic signals in regulating HSPC 
differentiation through indirect effects of these factors on the niche stromal cells and ECM. The 
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proteomic and the transcriptomic studies of stromal cells helped to pick up a few candidate 
proteins which were differentially expressed in the matrices. Thus, these findings could be 
helpful in understanding the biochemical organization of hematopoietic niches and in designing 
bioactive and biomimetic scaffolds that could be used for hematopoietic stem-cell based tissue 
engineering, thereby, increasing the availability of more transplantable HSPCs.  
The results also open the doors to many future projects in the fields of tissue engineering, 
ex vivo HSPC expansion and understanding the molecular signatures of the in vivo BM niche. 
Some of these are indicated below:  
• The in vitro results indicate expansion of progenitor populations on MS-5 derived 
ECMs. This is in itself of potential clinical value, since these cells may be indicative of 
increased short term repopulating capacity. However, the results did not assure the 
capability of the expanded cells to support long term repopulation of all hematopoietic 
lineages. Hence, future aspects of this work would include investigating in vivo 
NOD/SCID mice repopulation assays to measure the repopulating capacity of these 
expanded HSPCs on different matrices by transplanting them to lethally irradiated 
mice. Although maximum expansion of committed progenitors was achieved on MX2 
matrix, which resembles the vascular niche like conditions, the in vivo assay might 
indicate MX3 as the best matrix as they expanded more primitive HSPCs and have 
closer resemblance to endosteal niche. 
• Further, since the experiments were performed only with MS-5 cell matrices, it cannot 
be assured that these finding would apply to matrices produced by other stromal cells. 
The HSPC supportive capabilities of acellular matrices from other cell lines need to be 
assessed. 
• The proteomic and transcriptomic studies showed the differential regulation of several 
molecules that are already known to be involved in HSPC maintenance and survival in 
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vivo. Since the gene chip could not encompass the complete mammalian genome, the 
number of up- and down- regulated genes might be larger than what is described here. 
A deeper study in this direction will help to identify a complete molecular profile that 
would be the signature of a stem cell supportive microenvironment.  
• It is yet to be determined what specific concentrations of these molecules affect HSC 
growth in vivo. In future, the functional role of these proteins along with their 
concentration needs to be systematically analyzed. Various approaches including small 
interfering RNA, blocking function antibodies, and overexpression can be performed 
for these molecules to assess their significance in regulating hematopoiesis. 
• Some of these relevant candidate genes, as suggested by both proteomic and microarray 
analysis, can also be used by direct addition to the liquid cultures for HSPC expansion.  
• As it has been demonstrated, these matrices can be coated on to different materials, and 
still retain their functionality. Hence, expansion experiments must be done by coating 
them on 3D scaffolds that are previously known to support HSPC expansion. This 
combination (3D scaffolds with coated matrices) will then have closer biomimetic 
composition and complexity of in vivo HSC niches. 
• The critical role of GAGs was highlighted by the ablation studies. Further studies in this 
area, in particular the identification of specific GAGs moieties or components that 
mediate these effects, may be of significant value. 
• The relevant ECM components from this study can also be biotinylated, and bound to 
neutravidin coated 3D scaffolds to test their ability to support HSPC expansion. 
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Annexure Table 3.1: Summary of proteins up- and down-regulated in MX1, MX2 and 
MX4 conditions as compared to MX3 matrix. 
Sl. 
No. 
Spot 
No. 
Mascot 
Score 
Mw/pI Acc. No. Matrix 
condition 
Protein Name 
Cytoskeletal proteins 
Present / Up-regulated 
1 1 95 81/5.52 IPI00759948 MX1 - Present Isoform 2 of Gelsolin 
2 3 119 42/5.98 IPI00153990 MX4 - Present Beta-centractin 
3 4 130 43/6.19 IPI00113895 MX4 Alpha-centractin 
4 15 144 81/5.52 IPI00759948 MX1 and MX2 Isoform 2 of Gelsolin 
5 16 99 81/5.52 IPI00759948 MX2 Isoform 2 of Gelsolin 
6 18 100 81/5.52 IPI00759948 MX1, MX2 and 
MX4 
Isoform 2 of Gelsolin 
7 29 128 43/6.19 IPI00113895 MX2 Alpha-centractin 
Absent / Downregulated 
8 6 134 42/5.23 IPI00110850 MX2 - Absent Actin, cytoplasmic 1 
9 33 131 33/4.69 IPI00123316 MX2 and MX4 Isoform 1 of Tropomyosin 
alpha-1 chain 
10 42 90 44/5.14 IPI00116112 MX2 Dynactin subunit 2 
11 50 143 42/5.31 IPI00874482 MX2 Actin, cytoplasmic 2 
12 53 107 60/5.72 IPI00116279 MX2 T-complex protein 1 
subunit epsilon 
13 62 82 56/6.02 IPI00845611 MX1 Isoform 2 of T-complex 
protein 1 subunit alpha B 
Mitochondrial proteins 
Present / Up-regulated 
14 2 67 37/5.70 IPI00229510 MX2 and MX4 
- Present 
L-lactate dehydrogenase B 
chain 
15 11 284 56/5.19 IPI00468481 MX2 and MX4 ATP synthase subunit 
beta, mitochondrial 
16 13 86 21/5.53 IPI00230145 MX1 Ferritin heavy chain 
17 21 100 57/7.53 IPI00111218 MX2 and MX4 Aldehyde dehydrogenase, 
mitochondrial 
18 25 149 57/7.53 IPI00111218 MX4 Aldehyde dehydrogenase, 
mitochondrial 
19 26 175 57/7.53 IPI00111218 MX4 Aldehyde dehydrogenase, 
mitochondrial 
20 27 87 59/6.06 IPI00228385 MX4 Glucose-6-phosphate 1-
dehydrogenase X 
21 28 156 62/5.95 IPI00114375 MX4 Dihydropyrimidinase-
related protein 2 
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22 30 105 59/6.06 IPI00228385 MX4 Glucose-6-phosphate 1-
dehydrogenase X 
Absent / Downregulated 
23 60 76 49/6.19 IPI00129178 MX1 Ornithine 
aminotransferase, 
mitochondrial 
Plasma Membrane proteins 
Absent / Downregulated 
24 34 82 57/4.79 IPI00133522 MX1 and MX2 Protein disulfide-
isomerase 
25 35 85 36/4.83 IPI00317309 MX2 Annexin A5 
26 51 105 50/5.91 IPI00114017 MX2 annexin A7 
27 61 62 47/6.37 IPI00462072 MX1 Alpha-enolase 
28 64 155 47/6.37 IPI00462072 MX1 Alpha-enolase 
ER proteins 
Absent / Downregulated 
29 38 124 93/4.74 IPI00129526 MX1, MX2 and 
MX4 
Endoplasmin 
30 52 233 57/5.88 IPI00230108 MX1 and MX2 Protein disulfide-
isomerase A3 
31 54 158 57/5.88 IPI00230108 MX2 Protein disulfide-
isomerase A3 
32 55 64 57/5.88 IPI00230108 MX1 Protein disulfide-
isomerase A3 
33 63 80 57/5.88 IPI00230108 MX1 Protein disulfide-
isomerase A3 
Cytoplasmic proteins 
Present / Up-regulated 
34 14 64 43/5.53 IPI00121471 MX4 Serpin B6 
35 17 75 43/5.53 IPI00121471 MX4 Serpin B6 
36 23 217 39/6.97 IPI00230395 MX1 and MX2 Annexin A1 
37 24 108 39/6.97 IPI00230395 MX1 Annexin A1 
Absent / Downregulated 
38 5 74 49/5.69 IPI00890005 MX2 - Absent Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein K 
39 9 71 25/5.7 IPI00555059 MX2 - Absent Peroxiredoxin-6 
Extracellular Proteins 
Present / Up-regulated 
40 19 137 16/6.02 IPI00130589 MX4 Superoxide dismutase [Cu-
Zn] 
Absent / Downregulated 
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41 31 107 48/4.33 IPI00123639 MX1 and MX2 Calreticulin 
42 44 220 72/5.07 IPI00319992 MX2 78 kDa glucose-regulated 
protein 
Intermediate Filament proteins 
Absent / Downregulated 
43 37 66 54/5.06 IPI00227299 MX2 Vimentin 
44 39 309 54/5.06 IPI00227299 MX2 Vimentin 
45 41 321 54/5.06 IPI00227299 MX1 and MX2 Vimentin 
45 41 74 54/5.06 IPI00403810 MX1 and MX2 Tubulin alpha-1C chain 
Others 
Present / Up-regulated 
46 12 255 50/4.78 IPI00338039 MX4 Tubulin beta-2A chain 
47 20 94 49/5.89 IPI00108143 MX4 Heterogeneous nuclear 
Ribonucleoprotein H2 
Absent / Downregulated 
48 8 125 20/5.66 IPI00608020 MX2 - Absent Ferritin light chain 1 
49 36 72 30/4.45 IPI00515155 MX2 and MX4 Nucleophosmin 1 
50 46 137 51/5.36 IPI00469987 MX1 and MX2 Guanine deaminase 
51 48 72 21/5.66 IPI00608020 MX1 and MX4 Ferritin light chain 1 
52 49 87 21/5.66 IPI00762203 MX4 Ferritin light chain 1 
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Annexure Table 4.1: Fold expansion of HSPCs based on surface markers (n=3). 
Condition Total viable cells CD45+CD34+ 
7AAD- cells 
CD34+CD38- 
7AAD- cells 
CD34+CD133+ 
7AAD- cells 
C1 33.9 ± 3.78 2.82 ± 0.73 4.05 ± 1.08 2.80 ± 0.74 
MX1 46.08 ± 10.13 5.64 ± 1.18 12.84 ± 2.44 7.13 ± 1.28 
MX2 77.53 ± 13.05 18.01 ± 1.00 7.94 ± 1.66 19.71 ± 3.45 
C2 35.79 ± 3.00 3.42 ± 0.6 6.51 ± 2.54 3.27 ± 0.55 
MX3 56.00 ± 11.41 7.42 ± 1.60 20.34 ± 5.18 8.13 ± 0.83 
MX4 83.29 ± 16.46 11.36 ± 2.96 12.11 ± 0.51 10.56 ± 1.51 
C3 53.23 ± 4.07 8.12 ± 1.89 10.96 ± 0.65 10.79 ± 2.03 
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Annexure Table 4.2: Fold expansion of cell populations by colony forming assay (n=3). 
Condition BFU-E CFU-GM CFU-GEMM Total colonies 
C1 20.72 ± 2.38 11.35 ± 0.99 5.27 ± 1.95 25.89 ± 4.47 
MX1 30.84 ± 0.81 15.67 ± 2.64 10.09 ± 2.17 33.41 ± 3.53 
MX2 77.23 ± 4.28 54.18 ± 3.06 50.38 ± 14.70 65.73 ± 7.05 
C2 22.11 ± 1.53 11.84 ± 0.97 4.16 ± 0.35 27.43 ± 3.36 
MX3 27.95 ± 3.29 23.62 ± 2.84 5.64 ± 0.67 41.45 ± 5.52 
MX4 41.33 ± 5.61 27.68 ± 3.23 8.37 ± 0.66 56.60 ± 6.41 
C3 38.09 ± 5.08 24.79 ± 1.19 20.60 ± 2.52 41.33 ± 4.30 
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Annexure Table 5.1: Expression of niche regulating genes from StroCDB database in 
MX2 cells.  
S. 
No. 
Probe 
Set_ID 
Gene 
Symbol 
Gene Name MX2 
Mean 
Intensity 
P value 
1 430068 Acta2 actin, alpha 2, smooth muscle, aorta 20957.79 4.02E-02 
2 20088 Cxcl12 chemokine (C-X-C motif) ligand 12 17227.45 2.17E-02 
3 3460296 Anxa2 annexin A2 14937.61 1.52E-02 
4 5050653 Igf2 insulin-like growth factor 2 14424.10 5.85E-03 
5 3360608 Cfd complement factor D (adipsin) 13662.12 4.61E-07 
6 7160603 Sepp1 selenoprotein P, plasma, 1 12648.02 6.62E-04 
7 2370520 Ahnak AHNAK nucleoprotein 
(desmoyokin) 
12225.46 3.41E-03 
8 1690091 Vim vimentin 11362.10 5.08E-02 
9 730706 Serpinh1 serine (or cysteine) peptidase 
inhibitor, clade H, member 1 
10565.81 2.23E-03 
10 840044 Hp haptoglobin 10289.75 6.60E-04 
11 3990674 Cd9 CD9 antigen 10057.91 7.90E-04 
12 4200341 Lbp lipopolysaccharide binding protein 9655.81 3.05E-05 
13 1710242 Ecm1 extracellular matrix protein 1 9558.10 3.43E-02 
14 940338 S100a1 S100 calcium binding protein A1 9468.62 5.45E-05 
15 4210327 Klf9 Kruppel-like factor 9 8358.75 1.49E-05 
16 5810470 Aldh1a1 aldehyde dehydrogenase family 1, 
subfamily A1 
8254.80 4.45E-06 
17 5130148 Sparc secreted acidic cysteine rich 
glycoprotein; similar to Secreted 
acidic cysteine rich glycoprotein 
8241.09 1.14E-02 
18 4590136 Actn1 actinin, alpha 1 8190.06 5.92E-03 
19 2000373 Serping1 serine (or cysteine) peptidase 
inhibitor, clade G, member 1 
7156.76 4.96E-04 
20 4150541 Myh9 myosin, heavy polypeptide 9, non-
muscle 
6754.43 3.74E-02 
21 1710239 Itpr1 inositol 1,4,5-triphosphate receptor 1 6522.05 9.63E-04 
22 50048 Mylk myosin, light polypeptide kinase 6154.95 8.64E-05 
23 1660220 Tns1 tensin 1 5649.32 2.68E-06 
24 1740112 Loxl1 lysyl oxidase-like 1 5442.70 5.85E-03 
25 3610082 Cxcl1 chemokine (C-X-C motif) ligand 1 5216.24 2.71E-05 
26 5690341 Pgk1 phosphoglycerate kinase 1; predicted 
gene, EG668435 
5202.73 9.35E-05 
27 2850575 Vcam1 vascular cell adhesion molecule 1 5016.12 3.70E-03 
28 670240 Anxa1 annexin A1 4843.00 2.42E-04 
29 4490475 Flna filamin, alpha 4792.32 1.16E-02 
30 5810598 Col6a3 collagen, type VI, alpha 3 4677.75 5.65E-03 
31 6450372 Fgf7 fibroblast growth factor 7 3609.29 7.51E-05 
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32 5050731 Pik3r1 phosphatidylinositol 3-kinase, 
regulatory subunit, polypeptide 1  
3595.16 4.28E-02 
33 650524 Gdf15 growth differentiation factor 15 3571.00 2.76E-05 
34 3140400 Aoc3 amine oxidase, copper containing 3 3559.55 3.43E-02 
35 5490477 Col8a1 collagen, type VIII, alpha 1 3554.75 2.44E-05 
36 7380524 Prelp proline arginine-rich end leucine-rich 
repeat 
3387.06 1.38E-05 
37 6060452 Fgfr2 fibroblast growth factor receptor 2 3349.60 9.03E-05 
38 3830706 Col16a1 collagen, type XVI, alpha 1 3327.31 1.57E-03 
39 2760349 Bcap29 B-cell receptor-associated protein 29 3302.20 2.21E-04 
40 5890064 Rras Harvey rat sarcoma oncogene, 
subgroup R 
3185.00 3.08E-02 
41 5310598 Cryab crystallin, alpha B 3172.29 9.00E-05 
42 4760110 Itgb1bp1 integrin beta 1 binding protein 1 3051.02 1.05E-02 
43 2320402 Pparg peroxisome proliferator activated 
receptor gamma 
3042.87 1.04E-03 
44 1470328 Fibp fibroblast growth factor binding 
protein 1  
3041.27 4.09E-03 
45 6940278 Bmp1 bone morphogenetic protein 1 2803.99 7.37E-03 
46 7400725 Mgp matrix Gla protein 2779.39 3.30E-06 
47 6060561 Adam9 a disintegrin and metallopeptidase 
domain 9 (meltrin gamma) 
2732.03 3.71E-02 
48 160332 Timp1 tissue inhibitor of metalloproteinase 
1 
2706.38 9.36E-06 
49 5670132 Gsn gelsolin 2613.20 1.93E-04 
50 4480167 Capn2 calpain 2 2381.67 2.09E-03 
51 1770541 Tnfrsf12a tumor necrosis factor receptor 
superfamily, member 12a 
2205.60 8.28E-03 
52 4150386 Col5a1 collagen, type V, alpha 1 2176.32 2.90E-04 
53 4570184 Igf2bp2 insulin-like growth factor 2 mRNA 
binding protein 2 
2173.40 1.09E-02 
54 1690164 Fbln1 fibulin 1 2147.34 1.74E-03 
55 1710215 Angptl4 angiopoietin-like 4 2118.03 1.39E-04 
56 4860041 Gcap27 granule cell antiserum positive 27 2049.82 1.67E-02 
57 1510020 Rgl1 ral guanine nucleotide dissociation 
stimulator,-like 1 
2036.77 3.89E-02 
58 5810767 Sdc1 syndecan 1 2025.53 7.45E-03 
59 870309 Serpine2 serine (or cysteine) peptidase 
inhibitor, clade E, member 2 
1809.71 2.89E-03 
60 3130066 Nox4 NADPH oxidase 4 1792.23 7.30E-04 
61 7380603 Igfbp6 insulin-like growth factor binding 
protein 6 
1765.44 2.77E-02 
62 2000647 Igf1 insulin-like growth factor 1 1727.75 2.31E-04 
63 5690131 MMP13 matrix metallopeptidase 13 1703.76 1.39E-07 
64 3180682 Dkk3 dickkopf homolog 3 (Xenopus 1640.13 1.25E-04 
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laevis) 
65 1440189 Col6a2 collagen, type VI, alpha 2 1638.25 1.78E-02 
66 6400672 Kif1b kinesin family member 1B 1562.35 6.59E-03 
67 5700093 Flnb filamin, beta 1539.90 3.64E-04 
68 4670487 Kif3c kinesin family member 3C 1329.60 5.02E-04 
69 3710594 Pkp2 plakophilin 2 1319.33 5.98E-04 
70 1030270 Pld1 phospholipase D1 1273.70 9.62E-06 
71 5090543 Rgl2 ral guanine nucleotide dissociation 
stimulator-like 2 
1263.33 4.65E-03 
72 6960678 Igf1r insulin-like growth factor I receptor 1245.61 2.34E-02 
73 110112 Ccl2 chemokine (C-C motif) ligand 2 1210.62 1.17E-06 
74 5910220 Osmr oncostatin M receptor 1169.78 1.16E-05 
75 1430368 St6gal1 beta galactoside alpha 2,6 
sialyltransferase 1 
1155.74 6.57E-05 
76 6650438 Optn optineurin 1020.91 2.67E-02 
77 3710167 Hs6st2 heparan sulfate 6-O-sulfotransferase 
2 
1009.89 1.86E-02 
78 5890221 Fas Fas (TNF receptor superfamily 
member 6) 
1009.72 1.00E-04 
79 290672 Pfn2 profilin 2 975.17 9.85E-04 
80 3890465 Plod2 procollagen lysine, 2-oxoglutarate 5-
dioxygenase 2 
960.41 4.46E-05 
81 6760762 Sdc3 syndecan 3 869.57 8.88E-04 
82 4230142 Rras2 related RAS viral (r-ras) oncogene 
homolog 2 
789.14 4.51E-03 
83 5860358 VEGFa vascular endothelial growth factor A 784.99 1.89E-05 
84 4250131 Tob1 transducer of ErbB-2.1 710.22 4.96E-03 
85 6270521 Ncam1 neural cell adhesion molecule 1 702.08 4.49E-04 
86 3850192 Lrp6 similar to LDL receptor-related 
protein 6; low density lipoprotein 
receptor-related protein 6 
662.11 4.53E-02 
87 4890563 Sema3a sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3A; 
hypothetical protein LOC100044161 
594.73 3.34E-04 
88 3400630 Angptl2 angiopoietin-like 2 562.55 2.08E-02 
89 5720064 Adamts4 a disintegrin-like and 
metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 4 
561.57 1.07E-03 
90 1240039 Plcd3 phospholipase C, delta 3 535.77 2.89E-04 
91 3190468 Camk2d calcium/calmodulin-dependent 
protein kinase II, delta 
534.20 6.82E-04 
92 1570594 Socs3 suppressor of cytokine signaling 3 477.47 6.86E-04 
93 3400747 Igfbp4 insulin-like growth factor binding 
protein 4 
454.60 1.13E-02 
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94 830427 Gnb5 guanine nucleotide binding protein 
(G protein), beta 5 
421.63 3.89E-03 
95 4610110 Fst follistatin 408.66 5.32E-05 
96 4610072 Cav1 caveolin 1, caveolae protein 405.93 1.06E-03 
97 1710746 Cttn cortactin; predicted gene 8786 397.57 2.24E-02 
98 6350132 Ctsl cathepsin L 388.60 1.05E-02 
99 6560341 Cd68 CD68 antigen 369.21 1.19E-03 
100 5050735 Ager advanced glycosylation end product-
specific receptor 
356.58 1.45E-04 
101 10121 Il6ra interleukin 6 receptor, alpha 350.27 4.81E-02 
102 2510082 Fstl frizzled homolog 1 (Drosophila) 341.37 1.40E-03 
103 6940402 Il15 interleukin 15 336.20 9.41E-04 
104 1090180 Arhgdib Rho, GDP dissociation inhibitor 
(GDI) beta 
330.91 1.61E-02 
105 3370482 Rapsn receptor-associated protein of the 
synapse 
326.84 2.64E-03 
106 6900706 Gria3 glutamate receptor, ionotropic, 
AMPA3 (alpha 3) 
320.85 2.04E-03 
107 2650156 Limk1 LIM-domain containing, protein 
kinase 
310.79 7.44E-03 
108 3990324 Pdk1 pyruvate dehydrogenase kinase, 
isoenzyme 1 
297.13 9.30E-06 
109 5570672 Ptgds prostaglandin D2 synthase (brain) 294.43 3.31E-05 
110 60431 Layn layilin 293.97 2.08E-04 
111 4640711 Edn1 endothelin 1 290.09 2.13E-04 
112 5390328 Dcn decorin 264.23 3.46E-06 
113 5390382 Tprgl transformation related protein 63 
regulated like 
254.55 2.21E-03 
114 3170592 Nlgn2 neuroligin 2 253.63 2.11E-02 
115 2370575 Rock2 Rho-associated coiled-coil 
containing protein kinase 2 
224.04 1.71E-03 
116 5570079 Hgf hepatocyte growth factor 211.78 1.31E-06 
117 4540445 Matn2 matrilin 2 199.65 2.34E-02 
118 5560400 Islr immunoglobulin superfamily 
containing leucine-rich repeat 
199.57 4.72E-03 
119 2070014 Nfkb2 nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
2, p49/p100 
196.33 8.68E-03 
120 7210039 Gpc1 glypican 1 196.10 1.35E-03 
121 630274 Cxcl16 chemokine (C-X-C motif) ligand 16 195.94 1.62E-05 
122 3450040 Add3 adducin 3 (gamma) 186.00 8.33E-05 
123 2470608 Timp4 tissue inhibitor of metalloproteinase 
4 
177.26 3.58E-06 
124 6370035 Nid2 nidogen 2 175.31 6.87E-05 
125 3060647 Relb avian reticuloendotheliosis viral (v- 167.29 2.63E-05 
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rel) oncogene related B 
126 1660242 Angpt4 angiopoietin 4 165.30 2.92E-04 
127 110678 Ptpn14 protein tyrosine phosphatase, non-
receptor type 14 
164.67 3.00E-02 
128 3290209 Col7a1 collagen, type VII, alpha 1 146.49 1.45E-02 
129 4760477 Prl2c2 prolactin family 2, subfamily c, 
member 2 
140.17 6.04E-04 
130 3460379 Arhgef2 rho/rac guanine nucleotide exchange 
factor (GEF) 2 
136.68 4.81E-02 
131 2230544 Col3a1 collagen, type III, alpha 1 133.31 2.98E-05 
132 5090600 Bmp2k predicted gene 4521; BMP2 
inducible kinase 
127.16 2.80E-04 
133 360445 Cd109 CD109 antigen 118.60 3.56E-04 
134 4540725 Fetub fetuin beta 115.63 2.71E-05 
135 2690619 Col1a2 collagen, type I, alpha 2 115.04 5.24E-04 
136 270341 Emb embigin 110.17 1.26E-03 
137 5220324 Tnfrsf11b tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 
106.12 6.06E-04 
138 2760427 Il16 interleukin 16 105.43 9.46E-06 
139 5670451 Sox9 SRY-box containing gene 9 89.82 1.44E-04 
140 4040189 Ednra endothelin receptor type A 88.35 6.71E-05 
141 380554 Adamts9 a disintegrin-like and 
metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 9 
85.00 1.61E-04 
142 6130398 Col5a3 collagen, type V, alpha 3 84.87 2.77E-03 
143 7610477 Tm4sf1 transmembrane 4 superfamily 
member 1 
84.63 8.11E-04 
144 2490039 Nrg1 neuregulin 1 82.01 5.56E-04 
145 150746 Cxcl14 chemokine (C-X-C motif) ligand 14 74.18 6.72E-05 
146 1740332 P2rx5 purinergic receptor P2X, ligand-
gated ion channel, 5 
72.45 5.10E-04 
147 4230446 Sfrp2 secreted frizzled-related protein 2 57.50 4.13E-04 
148 1770324 Wnt4 wingless-related MMTV integration 
site 4 
54.29 1.18E-04 
149 2190128 Fap fibroblast activation protein 47.38 1.35E-05 
150 1570551 MMP9 matrix metallopeptidase 9 43.71 4.43E-05 
151 2570148 Vcan versican 41.37 7.45E-07 
152 830397 Ptn pleiotrophin 37.65 6.95E-06 
153 2750326 Egln3 EGL nine homolog 3 (C. elegans) 36.74 4.06E-05 
154 6770671 Vtn vitronectin 34.05 5.47E-06 
155 450133 Tgfbi transforming growth factor, beta 
induced 
33.39 8.69E-05 
156 2650056 Cma1 chymase 1, mast cell 32.18 4.91E-04 
157 3830470 Dpt dermatopontin 31.51 8.37E-07 
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158 270201 Col28a1 collagen, type XXVIII, alpha 1 31.51 6.23E-05 
159 4670328 Abl1 c-abl oncogene 1, receptor tyrosine 
kinase 
30.14 7.09E-03 
160 4920300 Msln mesothelin 28.17 1.67E-04 
161 1510750 MMP3 matrix metallopeptidase 3 27.18 2.41E-07 
162 5670731 Il6 interleukin 6 26.63 2.56E-02 
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Annexure Table 5.2: List of ECM related genes differentially expressed in step 1 and 2 
and their fold change (FC) in comparison to MX3. 
S 
No. 
Gene IDs Gene Name FC 
(Step1) 
FC    
(Step 2) 
1 1100001G20Rik RIKEN cDNA 1100001G20 gene -11.839 -13.619 
2 4930486L24Rik RIKEN cDNA 4930486L24 gene  3.1914 
3 5430419D17Rik RIKEN cDNA 5430419D17 gene  -3.7122 
4 9030224M15Rik RIKEN cDNA 9030224M15 gene -2.8859 -3.2284 
5 9030425E11Rik RIKEN cDNA 9030425E11 gene  -1.7351 
6 Acp5 acid phosphatase 5, tartrate resistant  -1.6132 
7 C130099A20Rik acid phosphatase-like 2  -2.7857 
8 Adamts12 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 motif, 12 
 -1.9985 
9 Adamts4 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 motif, 4 
-1.7856  
10 Adamts7 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 motif, 7 
 -2.771 
11 Adamts9 a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 motif, 9 
 -2.2331 
12 Adipoq adiponectin, C1Q and collagen domain 
containing 
-13.224 -6.2983 
13 Ager advanced glycosylation end product-
specific receptor 
 4.7325 
14 Akp2 alkaline phosphatase, liver/bone/kidney -2.2072  
15 Angpt2 angiopoietin 2  1.9482 
16 Angpt4 angiopoietin 4  -1.9422 
17 Angptl4 angiopoietin-like 4 -1.8673 -2.6075 
18 Anxa1 annexin A1  2.0009 
19 Apob apolipoprotein B  -2.5145 
20 Apoc1 apolipoprotein C-I  -3.765 
21 Aqp1 aquaporin 1  -2.8826 
22 Bmp1 bone morphogenetic protein 1  -2.0406 
23 Bmper BMP-binding endothelial regulator  -5.4121 
24 Calu calumenin  -1.8206 
25 Camp cathelicidin antimicrobial peptide -2.0961 -10.138 
26 Ccdc3 coiled-coil domain containing 3  3.5129 
27 Ccdc80 coiled-coil domain containing 80  -2.0505 
28 Ccl2 chemokine (C-C motif) ligand 12  -4.9783 
29 Ccl2 chemokine (C-C motif) ligand 2  -4.9783 
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30 Cd109 CD109 antigen  1.9406 
31 Fap carboxyl ester lipase -2.4267 -9.1509 
32 Cfb complement factor B  -3.6377 
33 Cfd complement factor D (adipsin) -38.614  
34 Tna;Clec3b C-type lectin domain family 3, member b  -3.1921 
35 Cma1 chymase 1, mast cell 2.3672  
36 Cml3 camello-like 3  -1.9007 
37 Col16a1 collagen, type XVI, alpha 1  -1.7936 
38 Col1a2 collagen, type I, alpha 2  -2.6495 
39 Col28a1 collagen, type XXVIII, alpha 1 1.9029  
40 Col3a1 collagen, type III, alpha 1  -5.1442 
41 Col5a1 collagen, type V, alpha 1  -2.138 
42 Col5a2 collagen, type V, alpha 2  -3.1669 
43 Col6a2 collagen, type VI, alpha 2  -2.9376 
44 Col6a3 collagen, type VI, alpha 3  -3.2754 
45 Col8a1 collagen, type VIII, alpha 1  -2.5865 
46 Colec10 collectin sub-family member 10  -3.0225 
47 Creg1 cellular repressor of E1A-stimulated genes 
1 
 1.5715 
48 Ctla2a cytotoxic T lymphocyte-associated protein 
2 alpha 
 4.8841 
49 Cxcl1;Cxcl2 chemokine (C-X-C motif) ligand 1  -2.9 
50 Cxcl12 chemokine (C-X-C motif) ligand 12  -2.8228 
51 Cxcl14 chemokine (C-X-C motif) ligand 14  -6.0245 
52 Zmynd15;Cxcl16 chemokine (C-X-C motif) ligand 16  -4.3483 
53 Cxcl2 chemokine (C-X-C motif) ligand 2  -1.6807 
54 Cxcl1 chemokine (C-X-C motif) ligand 3  -2.910 
55 Dcn decorin -6.1048 -12.857 
56 Dkk3 dickkopf homolog 3 (Xenopus laevis) -2.007  
57 Dpt dermatopontin -2.8247 -15.829 
58 Dpysl3 dihydropyrimidinase-like 3  -4.7569 
59 Edn1 endothelin 1  3.0253 
60 Endod1 endonuclease domain containing 1 -1.5923  
61 Enpp1 ectonucleotide 
pyrophosphatase/phosphodiesterase 1 
 -2.9094 
62 Enpp2 ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
-1.8782  
63 Enpp3 ectonucleotide 
pyrophosphatase/phosphodiesterase 3 
 -3.4383 
64 Epdr1 ependymin related protein 1 (zebrafish)  -2.0888 
65 Erap1 endoplasmic reticulum aminopeptidase 1  -1.757 
66 Esm1 endothelial cell-specific molecule 1 -1.89 -13.513 
67 F13a1 coagulation factor XIII, A1 subunit -4.7944 -29.179 
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68 F8 coagulation factor VIII  2.3108 
69 Fas Fas (TNF receptor superfamily member 6)  -2.2147 
70 Fetub fetuin beta  4.0025 
71 Fgf7 fibroblast growth factor 7  -1.8952 
72 Fgfr2 fibroblast growth factor receptor 2  2.6829 
73 Fgl1 fibrinogen-like protein 1  -3.9173 
74 Fst follistatin  2.9435 
75 Fxyd5 FXYD domain-containing ion transport 
regulator 5 
-1.9048 -2.8009 
76 Gbp1 guanylate binding protein 1  -2.8321 
77 Gbp2 guanylate binding protein 2  -2.2818 
78 Dbp group specific component  -2.0841 
79 Gdf15 growth differentiation factor 15  4.8264 
80 Gpc1 glypican 1  -5.5069 
81 Gpi1 glucose phosphate isomerase 1  -2.0234 
82 Grem1 gremlin 1  -2.1274 
83 Gria3 glutamate receptor, ionotropic, AMPA3  1.6481 
84 Gsn gelsolin -4.1321 3.2729 
85 Gstm1;Gsta3 glutathione S-transferase, mu 1  6.1158 
86 Hgf hepatocyte growth factor  -5.9014 
87 Hp haptoglobin  -1.7199 
88 Hsd17b11 hydroxysteroid (17-β) dehydrogenase 11  2.9423 
89 Htra1 HtrA serine peptidase 1  -1.6745 
90 Igf1 insulin-like growth factor 1  -1.8976 
91 Igfbp4 insulin-like growth factor binding protein 4 -3.5146  
92 Il13ra2 interleukin 13 receptor, α 2  -1.7713 
93 Il15 interleukin 15 -1.7454  
94 Il16 interleukin 16  -4.2025 
95 Il1rl1 interleukin 1 receptor-like 1  -1.9204 
96 Il33 interleukin 33  -2.951 
97 Il4ra interleukin 4 receptor, α  -2.1844 
98 Hgf interleukin 6  -5.9014 
99 Il7 interleukin 7  -4.6948 
100 Insl3 insulin-like 3 -2.3022 -2.2062 
101 Itgbl1 integrin, beta-like 1 -2.591 -3.1682 
102 Kng1 kininogen 1  -2.745 
103 Lbp lipopolysaccharide binding protein  3.2792 
104 Lefty1 left right determination factor 1  -1.6338 
105 Lepre1 leprecan 1  -1.6405 
106 Lrg1 leucine-rich alpha-2-glycoprotein 1  -4.6728 
107 Mcpt8 mast cell protease 8 2.9043  
108 Hgf met proto-oncogene  -5.9014 
109 Mfap5 microfibrillar associated protein 5  -2.189 
110 Mgp matrix Gla protein (glypican 3)  4.2015 
111 MMP13 matrix metallopeptidase 13 -1.7855 -11.849 
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112 MMP3 matrix metallopeptidase 3 -3.3833 -17.747 
113 MMP9 matrix metallopeptidase 9  -5.0587 
114 Msln mesothelin 1.6651  
115 Nid2 nidogen 2  -2.6617 
116 Olfml3 olfactomedin-like 3  -6.1867 
117 Orm1;Orm2 orosomucoid 1 -5.2841  
118 Orm1;Orm2 orosomucoid 2 -5.2841  
119 Orm1;Orm2 orosomucoid 3 -5.2841  
120 Pla1a phospholipase A1 member A  1.7027 
121 Prelp proline arginine-rich end leucine-rich 
repeat 
 3.2311 
122 Prg4 proteoglycan 4   3.9319 
123 Prl2c2 prolactin family 2, subfamily c, member 2 3.1404 3.4205 
124 Prl2c4 prolactin family 2, subfamily c, member 3 2.7615 3.0803 
125 Prl2c4 prolactin family 2, subfamily c, member 4 2.7615 3.0803 
126 Prrg2 proline-rich Gla (G-carboxyglutamic acid) 
polypeptide 2 
 -1.6326 
127 Prss23 protease, serine, 23  -2.4939 
128 Ptgds prostaglandin D2 synthase (brain)  5.6525 
129 Ptn pleiotrophin 1.7609 -2.0464 
130 Tns1 PYD and CARD domain containing  6.0674 
131 Lbp ribosomal protein SA  3.2792 
132 S100a1 S100 calcium binding protein A13  2.0034 
133 S100a8 S100 calcium binding protein A8 
(calgranulin A) 
-3.5527 -3.6393 
134 Saa1 serum amyloid A 1  -8.4299 
135 Saa1 serum amyloid A 2  -8.4299 
136 Saa3;Saa1 serum amyloid A 3  -35.708 
137 Scgn secretagogin, EF-hand calcium binding 
protein 
 2.0983 
138 Selp selectin, platelet -2.0813 -2.1803 
139 Sema3a sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3A 
 -2.0095 
140 Sema3c sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3C 
 -2.9553 
141 Sema3e sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3E 
 2.9479 
142 Sepp1;Selp selenoprotein P, plasma, 1 -2.0813 3.3669 
143 Serpina3f serine (or cysteine) peptidase inhibitor, 
clade A, member 3F 
 -1.7811 
144 Serpina3g serine (or cysteine) peptidase inhibitor, 
clade A, member 3G 
 -4.1345 
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145 Serpinb1a serine (or cysteine) peptidase inhibitor, 
clade B, member 1a 
 -36.861 
146 Serpine2 serine (or cysteine) peptidase inhibitor, 
clade E, member 2 
 -1.9456 
147 Serping1 serine (or cysteine) peptidase inhibitor, 
clade G, member 1 
 -1.786 
148 Sfrp1 secreted frizzled-related protein 1  -1.9697 
149 Sfrp2 secreted frizzled-related protein 2  -3.2157 
150 Slc1a3 solute carrier family 1 (glial high affinity 
glutamate transporter), member 3 
 -1.7185 
151 Slpi secretory leukocyte peptidase inhibitor  -12.206 
152 Sparc secreted acidic cysteine rich glycoprotein -1.6497 -2.3295 
153 St6gal1 beta galactoside alpha 2,6 sialyltransferase 
1 
 1.6493 
154 Stc1 stanniocalcin 1  -13.677 
155 Sulf1 sulfatase 1  -1.8901 
156 Tfrc transferrin receptor  -2.1891 
157 Tgfbi transforming growth factor, beta induced -2.1783 -3.8837 
158 Thbd thrombomodulin  -3.1583 
159 Timp1 tissue inhibitor of metalloproteinase1  -3.0244 
160 Timp4 tissue inhibitor of metalloproteinase4  5.6433 
161 Tinagl tubulointerstitial nephritis antigen-like 1  3.2907 
162 Tnfrsf11b tumor necrosis factor receptor superfamily, 
member 11b (osteoprotegerin) 
-3.0351 -2.5493 
163 Tnfsf13b tumor necrosis factor (ligand) superfamily, 
member 13b 
 -1.6894 
164 Tnxb tenascin XB  -2.1409 
165 Tpsab1 tryptase alpha/beta 1 -5.5514 -13.068 
166 Tpsab1 tryptase beta 2 -5.5514 -13.068 
167 Trem2 triggering receptor expressed on myeloid 
cells 2 
 -2.1177 
168 Hp transferrin  -1.7199 
169 Vcam1 vascular cell adhesion molecule 1  1.6674 
170 Vcan versican  -2.7587 
171 VEGFa vascular endothelial growth factor A -2.3108 -3.7255 
172 Vnn3 vanin 3 -1.9471 -2.049 
173 Vtn vitronectin  -3.3449 
174 Wfdc12 WAP four-disulfide core domain 12 -3.2524 -4.1203 
175 Wnt4 wingless-related MMTV integration site 4  1.9837 
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Annexure Table 5.3: Most affected pathway groups in step 1 and 2. 
S. No. Maps Input genes 
 Tissue remodeling  
1 ECM remodeling 12 
2 TGF, WNT and cytoskeletal remodeling 11 
3 Cytoskeleton remodeling 9 
4 Cell adhesion_PLAU signaling 6 
5 Cell-matrix glycoconjugates 5 
6 HGF signaling pathway 5 
7 FGF-family signaling 5 
8 EGFR signaling pathway 4 
9 Cadherin-mediated cell adhesion 3 
10 Cell adhesion_Plasmin signaling 3 
  Calcium signaling   
1 IL-13 signaling via PI3K-ERK 5 
2 Signal transduction_IP3 signaling 4 
3 NF-AT signaling and leukocyte interactions 3 
4 Oxytocin receptor signaling 2 
5 Calcium signaling 2 
6 Signal transduction_PKA signaling 2 
7 NFAT in immune response 2 
8 Role of HDAC and calcium/calmodulin-dependent kinase 
(CaMK) in control of skeletal myogenesis 
2 
  Hematopoiesis   
1 IL-3 activation and signaling pathway 3 
2 Thrombopoietin-regulated cell processes 3 
3 Transcription regulation of granulocyte development 3 
4 EPO-induced Jak-STAT pathway 2 
5 Delta-type opioid receptor signaling via G-protein alpha-14 2 
6 EPO-induced PI3K/AKT pathway and Ca(2+) influx 2 
7 Flt3 signaling 2 
8 EPO-induced MAPK pathway 2 
9 Heme metabolism 2 
10 Thrombopoetin signaling via JAK-STAT pathway 1 
  Cell differentiation   
1 Regulation of epithelial-to-mesenchymal transition (EMT) 9 
2 IL-13 signaling via JAK-STAT 5 
3 HGF-dependent inhibition of TGF-beta-induced EMT 3 
4 Angiotensin activation of ERK 3 
5 Hedgehog signaling 3 
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6 TGF-beta-dependent induction of EMT via RhoA, PI3K and 
ILK. 
3 
7 Hedgehog and PTH signaling pathways in bone and cartilage 
development 
2 
8 BMP signaling 2 
9 TGF-beta-dependent induction of EMT via SMADs 2 
10 EPO-induced PI3K/AKT pathway and Ca(2+) influx 2 
11 GM-CSF signaling 2 
  Vascular development (angiogenesis)   
1 Role of IL-8 in angiogenesis 9 
2 VEGF signaling via VEGFR2 - generic cascades 7 
3 EDNRB signaling 6 
4 Role of Akt in hypoxia induced HIF1 activation 6 
5 FGF-family signaling 5 
6 Inhibition of angiogenesis by PEDF 4 
7 Angiopoietin - Tie2 signaling 4 
8 Receptor-mediated HIF regulation 4 
9 VEGF-family signaling 4 
10 Thrombospondin-1 signaling 2 
  Immune and inflammatory response   
1 Chemokines and adhesion 9 
2 Oncostatin M signaling via MAPK signaling 7 
3 Oncostatin M signaling via JAK-Stat signaling 7 
4 Histamine H1 receptor signaling in immune response 7 
5 Leukocyte chemotaxis 7 
6 CD40 signaling 7 
7 Gastrin in inflammatory response 6 
8 CCR3 signaling in eosinophils 6 
9 Role of HMGB1 in dendritic cell maturation and migration 5 
10 Transcription regulation of granulocyte development 3 
11 IFN alpha/beta signaling pathway 3 
12 Lectin induced complement pathway 3 
13 IL-6 signaling pathway 2 
  Oxidative stress regulation   
1 Plasmalogen biosynthesis 5 
2 IL-13 signaling via PI3K-ERK 5 
3 Dopamine D2 receptor transactivation of EGFR 3 
4 NO synthesis and signaling 3 
5 Angiotensin II-induced production of ROS 2 
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Annexure Table 5.4: Top 15 ECM related networks 
S 
No. 
Networks pValue 
Step 1; Step 2 
Ratio 
Input/Known 
1 Cell adhesion_Platelet-endothelium-
leucocyte interactions 
8.568e-2; 2.385e-6 25 175 
2 Development_Regulation of angiogenesis 4.407e-5; 6.070e-5 28 223 
3 Development_Blood  vessel morphogenesis 1.382e-3; 5.497e-4 25 228 
4 Cell adhesion_Cell-matrix interactions 1.568e-2; 1.195e-3 23 213 
5 Development_Ossification and bone 
remodeling 
3.713e-3; 2.907e-2 17 157 
6 Development_Skeletal muscle development 1.584e-1; 6.446e-3 16 144 
7 Proteolysis_ECM remodeling 8.640e-3; 2.847e-2 10 85 
8 Signal transduction_ESR2 pathway 3.695e-2; 1.589e-2 9 77 
9 Cell adhesion_Leucocyte chemotaxis 8.643e-1; 1.677e-2 18 205 
10 Development_Cartilage development 1.309e-1; 1.831e-2 9 66 
11 Inflammation_Interferon signaling 2.064e-2; 5.340e-2 11 110 
12 Cell adhesion_Glycoconjugates 2.080e-2; 8.096e-2 13 166 
13 Cytoskeleton_Regulation of cytoskeleton 
rearrangement 
5.257e-1; 2.419e-2 17 183 
14 Inflammation_IL-6 signaling 2.664e-2; 8.158e-2 13 119 
15 Proteolysis_Connective tissue degradation 2.664e-2; 3.982e-2 13 119 
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Annexure Figure 2.1: Ethical Clearance for collection of cord blood for use in research of 
HSPC expansion at Deakin University, Geelong, Australia. 
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. 
Annexure Figure 2.2: Ethical Clearance for collection of cord blood for use in research of 
HSPC expansion at CCMB, Hyderabad, India.
Annexure 
174 
 
 
Annexure 
175 
 
Annexure Figure 5.1: ECM related networks with their localizations. The ECM related and secretory genes are mainly involved in MMP-9, 
MMP-13, MMP-1, VEGF-A and stromelysin-1 related pathways. Experimental data is mapped on the processes and shown as red 
(up-regulation) and blue (down-regulation) circles of different intensity. Relative intensity corresponds to the expression value. Red lines show 
the activation while the green lines depict inhibition and, black line no change or unspecified. 
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